Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Chronic Heart Failure

  Free Subscription


Articles published in Eur J Heart Fail

Retrieve available abstracts of 1259 articles:
HTML format



Single Articles


    July 2021
  1. SKAARUP KG, Lassen MCH, Johansen ND, Sengelov M, et al
    Layer-Specific Global Longitudinal Strain and the Risk of Heart Failure and Cardiovascular Mortality in the General Population: The Copenhagen City Heart Study.
    Eur J Heart Fail. 2021 Jul 29. doi: 10.1002/ejhf.2315.
    PubMed     Abstract available


  2. PANDEY A, Butler J
    Improving Exercise Tolerance & Quality of Life in Heart Failure with Preserved Ejection Fraction Time to Think Outside the Heart.
    Eur J Heart Fail. 2021 Jul 22. doi: 10.1002/ejhf.2313.
    PubMed    


  3. KHAN MS, Butler J, Greene SJ
    Simultaneous or Rapid Sequence Initiation of Medical Therapies for Heart Failure: Seeking to Avoid the Case of "Too Little, Too Late".
    Eur J Heart Fail. 2021 Jul 19. doi: 10.1002/ejhf.2311.
    PubMed    


  4. SWEDBERG K
    The clinical practise of treating patients with chronic heart failure needs to be improved.
    Eur J Heart Fail. 2021 Jul 17. doi: 10.1002/ejhf.2309.
    PubMed    


  5. ADAMSON C, Jhund PS, Docherty KF, Belohlavek J, et al
    Efficacy of dapagliflozin in heart failure with reduced ejection fraction according to body mass index.
    Eur J Heart Fail. 2021 Jul 16. doi: 10.1002/ejhf.2308.
    PubMed     Abstract available


  6. MILLER RJ, Howlett JG
    Untying the Gordian Knot of Sex and Heart Failure Therapy.
    Eur J Heart Fail. 2021 Jul 15. doi: 10.1002/ejhf.2299.
    PubMed    


  7. SAVARESE G, Merlo M, Coats AJ, Metra M, et al
    Best of European Journal of Heart Failure at the ESC/HFA Heart Failure Congress 2021.
    Eur J Heart Fail. 2021 Jul 15. doi: 10.1002/ejhf.2306.
    PubMed    


  8. ANKER MS, Tschope C
    Reply to 'Heart failure with preserved ejection fraction and COVID-19: which comes first, the chicken or the egg?'
    Eur J Heart Fail. 2021 Jul 15. doi: 10.1002/ejhf.2305.
    PubMed    


  9. GRAHAM FJ, Pellicori P, Cleland JGF, Clark AL, et al
    REPLY to a letter regarding the article "Natural history and prognostic significance of iron deficiency and anaemia in ambulatory patients with chronic heart failure".
    Eur J Heart Fail. 2021 Jul 14. doi: 10.1002/ejhf.2304.
    PubMed    


  10. GREENE SJ, Butler J, Metra M
    Another Reason to Embrace Quadruple Medical Therapy for Heart Failure: Medications Enabling Tolerance of the Others.
    Eur J Heart Fail. 2021 Jul 14. doi: 10.1002/ejhf.2301.
    PubMed    


  11. NUNEZ J, de la Espriella R, Minana G, Santas E, et al
    Antigen Carbohydrate 125 as a Biomarker in Heart Failure: a Narrative Review.
    Eur J Heart Fail. 2021 Jul 9. doi: 10.1002/ejhf.2295.
    PubMed     Abstract available


  12. KRESOJA KP, Rommel KP, Wachter R, Henger S, et al
    Proteomics to Improve Phenotyping in Obese Patients with Heart Failure with Preserved Ejection Fraction.
    Eur J Heart Fail. 2021 Jul 7. doi: 10.1002/ejhf.2291.
    PubMed     Abstract available


  13. BAYES-GENIS A, Januzzi JL, Richards AM, Arfsten H, et al
    The "Peptide for Life" Initiative: A Call for Action to Provide Equal Access for the Use of Natriuretic Peptides in the Diagnosis of Acute Heart Failure across Europe.
    Eur J Heart Fail. 2021 Jul 7. doi: 10.1002/ejhf.2293.
    PubMed    


  14. BISSON A, Ding WY, Bodin A, Lip GYH, et al
    Clinical outcomes with digoxin vs beta-blocker for heart rate control in permanent atrial fibrillation with heart failure.
    Eur J Heart Fail. 2021 Jul 7. doi: 10.1002/ejhf.2292.
    PubMed    


  15. CARAVITA S, Iacovoni A, Senni M
    The right side of the circulation in not secondary heart failure with preserved ejection fraction: an elephant in the room?
    Eur J Heart Fail. 2021 Jul 7. doi: 10.1002/ejhf.2294.
    PubMed    


    June 2021
  16. PONIKOWSKI P, Alemayehu W, Oto A, Bahit MC, et al
    Vericiguat in Patients with Atrial Fibrillation and Heart Failure with Reduced Ejection Fraction: Insights from the VICTORIA trial.
    Eur J Heart Fail. 2021 Jun 30. doi: 10.1002/ejhf.2285.
    PubMed     Abstract available


  17. MCEWAN P, Ponikowski P, Davis JA, Rosano G, et al
    Ferric carboxymaltose for the treatment of iron deficiency in heart failure: a multinational cost-effectiveness analysis utilising AFFIRM-AHF.
    Eur J Heart Fail. 2021 Jun 30. doi: 10.1002/ejhf.2270.
    PubMed     Abstract available


  18. YAFASOVA A, Butt JH, Rorth R
    Troponin - An important prognostic biomarker in patients with heart failure and reduced ejection fraction?
    Eur J Heart Fail. 2021 Jun 29. doi: 10.1002/ejhf.2282.
    PubMed    


  19. GREENE SJ, Fonarow GC
    Clinical Inertia and Medical Therapy for Heart Failure: The Unintended Harms of "First, Do No Harm".
    Eur J Heart Fail. 2021 Jun 29. doi: 10.1002/ejhf.2283.
    PubMed    


  20. ABDIN A, Bohm M
    Renal function and vericiguat in heart failure patients: Light at the end of the tunnel!
    Eur J Heart Fail. 2021 Jun 26. doi: 10.1002/ejhf.2280.
    PubMed    


  21. KHAN MS, Khan F, Fonarow GC, Sreenivasan J, et al
    Dietary Interventions and Nutritional Supplements for Heart Failure: A Systematic Appraisal and Evidence Map.
    Eur J Heart Fail. 2021 Jun 26. doi: 10.1002/ejhf.2278.
    PubMed     Abstract available


  22. ANKER SD, Khan MS, Shahid I, Filippatos G, et al
    SGLT-2 Inhibitors in Heart Failure with Preserved Ejection Fraction Reasons for Optimism.
    Eur J Heart Fail. 2021 Jun 26. doi: 10.1002/ejhf.2279.
    PubMed    


  23. SHAH SJ, Cowie MR, Wachter R, Szecsody P, et al
    Baseline Characteristics of Patients in the PARALLAX Trial: Insights into Quality of Life and Exercise Capacity in Heart Failure with Preserved Ejection Fraction.
    Eur J Heart Fail. 2021 Jun 25. doi: 10.1002/ejhf.2277.
    PubMed     Abstract available


  24. PAGNESI M, Adamo M, Sama IE, Anker SD, et al
    Impact of mitral regurgitation in patients with worsening heart failure: Insights from BIOSTAT-CHF.
    Eur J Heart Fail. 2021 Jun 23. doi: 10.1002/ejhf.2276.
    PubMed     Abstract available


  25. BARATTO C, Caravita S, Parati G
    HFpEF and COVID-19: which comes first, the chicken or the egg? Letter regarding the article "Heart Failure with preserved ejection fraction according to the HFA-PEFF score in COVID-19 patients: clinical correlates and echocardiographic findings".
    Eur J Heart Fail. 2021 Jun 17. doi: 10.1002/ejhf.2273.
    PubMed    


  26. SAVARESE G, Bodegard J, Norhammar A, Sartipy P, et al
    Heart failure drug titration, discontinuation, mortality and heart failure hospitalization risk: a multinational observational study (US, UK and Sweden).
    Eur J Heart Fail. 2021 Jun 15. doi: 10.1002/ejhf.2271.
    PubMed     Abstract available


  27. RICHARDS AM, Pemberton CJ
    Urinary Peptides in Heart Failure - the need for care with pees and cues.
    Eur J Heart Fail. 2021 Jun 12. doi: 10.1002/ejhf.2269.
    PubMed    


  28. PATEL RB, Shah SJ
    The Splanchnic Reservoir: An Oasis for Blood Volume in Heart Failure with Preserved Ejection Fraction?
    Eur J Heart Fail. 2021 Jun 12. doi: 10.1002/ejhf.2268.
    PubMed    


  29. STOLFO D, Savarese G
    Association Between Heart Failure and Cancer: Is Gender the Answer?
    Eur J Heart Fail. 2021 Jun 11. doi: 10.1002/ejhf.2261.
    PubMed    


  30. BHATT AS, Vaduganathan M, Claggett BL, Liu J, et al
    Effect of Sacubitril/Valsartan versus Enalapril on Changes in Heart Failure Therapies Over Time: The PARADIGM-HF Trial.
    Eur J Heart Fail. 2021 Jun 7. doi: 10.1002/ejhf.2259.
    PubMed     Abstract available


    May 2021
  31. PACKER M, Januzzi JL Jr, Ferreira JP, Anker SD, et al
    Concentration-Dependent Clinical and Prognostic Importance of High-Sensitivity Cardiac Troponin T in Heart Failure and a Reduced Ejection Fraction and the Influence of Empagliflozin: the EMPEROR-Reduced Trial.
    Eur J Heart Fail. 2021 May 30. doi: 10.1002/ejhf.2256.
    PubMed     Abstract available


  32. BUTLER J, Yang M, Sawhney B, Chakladar S, et al
    Treatment Patterns and Clinical Outcomes Among Patients <65 Years with a Worsening Heart Failure Event.
    Eur J Heart Fail. 2021 May 30. doi: 10.1002/ejhf.2252.
    PubMed     Abstract available


  33. SORIMACHI H, Burkhoff D, Verbrugge FH, Omote K, et al
    Obesity, Venous Capacitance, and Venous Compliance in Heart Failure with Preserved Ejection Fraction.
    Eur J Heart Fail. 2021 May 30. doi: 10.1002/ejhf.2254.
    PubMed     Abstract available


  34. SOLOMON SD, de Boer RA, DeMets D, Hernandez AF, et al
    Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial.
    Eur J Heart Fail. 2021 May 29. doi: 10.1002/ejhf.2249.
    PubMed     Abstract available


  35. TKACZYSZYN M, Comin-Colet J, Voors AA, van Veldhuisen DJ, et al
    Iron deficiency contributes to the resistance to endogenous erythropoietin in anaemic heart failure patients.
    Eur J Heart Fail. 2021 May 29. doi: 10.1002/ejhf.2253.
    PubMed     Abstract available


  36. GRAHAM FJ, Masini G, Pellicori P, Cleland JGF, et al
    Natural history and prognostic significance of iron deficiency and anaemia in ambulatory patients with chronic heart failure.
    Eur J Heart Fail. 2021 May 28. doi: 10.1002/ejhf.2251.
    PubMed     Abstract available


  37. FADINI GP, Avogaro A
    A simple way to spotlight hidden heart failure in type 2 diabetes?
    Eur J Heart Fail. 2021 May 28. doi: 10.1002/ejhf.2258.
    PubMed    


  38. VAN SPALL HG, Averbuch T, Damman K, Voors AA, et al
    Risk and Risk Reduction In Trials of Heart Failure with Reduced Ejection Fraction: Absolute or Relative?
    Eur J Heart Fail. 2021 May 26. doi: 10.1002/ejhf.2248.
    PubMed    


  39. SEFEROVIC PM, Tsutsui H, McNamara DM, Ristic AD, et al
    Heart Failure Association of the ESC, Heart Failure Society of America and Japanese Heart Failure Society Position statement on endomyocardial biopsy.
    Eur J Heart Fail. 2021 May 19. doi: 10.1002/ejhf.2190.
    PubMed     Abstract available


  40. VOORS AA, Mulder H, Reyes E, Cowie MR, et al
    Renal Function and the Effects of Vericiguat in Patients with Worsening Heart Failure with Reduced Ejection Fraction: Insights from VICTORIA (VerICiguaT Global Study in Subjects with HFrEF) Trial.
    Eur J Heart Fail. 2021 May 17. doi: 10.1002/ejhf.2221.
    PubMed     Abstract available


  41. BRAUNWALD E
    The War on Heart Failure.
    Eur J Heart Fail. 2021 May 16. doi: 10.1002/ejhf.2217.
    PubMed    


  42. KAPELIOS CJ, Canepa M, Savarese G, Lund LH, et al
    Use of loop diuretics in chronic heart failure: do we adhere to the Hippocratian principle "do no harm"?
    Eur J Heart Fail. 2021 May 16. doi: 10.1002/ejhf.2218.
    PubMed    


  43. BISTOLA V, Simitsis P, Parissis J, Ouwerkerk W, et al
    Association between up-titration of medical therapy and total hospitalizations and mortality in patients with recent worsening heart failure across the ejection fraction spectrum.
    Eur J Heart Fail. 2021 May 16. doi: 10.1002/ejhf.2219.
    PubMed     Abstract available


  44. KAPELIOS CJ, Canepa M, Savarese G, Lund LH, et al
    Use of loop diuretics in chronic heart failure: do we adhere to the Hippocratian principle "do no harm"?
    Eur J Heart Fail. 2021 May 8. doi: 10.1002/ejhf.2214.
    PubMed    


  45. TOCCHETTI CG, Mercurio V, Maack C
    The multifaceted mechanisms of nitroxyl in heart failure: Inodilator or "only" vasodilator?
    Eur J Heart Fail. 2021 May 2. doi: 10.1002/ejhf.2204.
    PubMed    


  46. HILL L, Lambrinou E, Antoniou S
    Optimizing evidence-based heart failure medication: Every contact counts.
    Eur J Heart Fail. 2021 May 1. doi: 10.1002/ejhf.2213.
    PubMed    


  47. ROSANO GMC, Moura B, Metra M, Bauersachs J, et al
    Patients profiling in Heart Failure for tailoring medical therapy A consensus document of the Heart Failure Association of the European Society of Cardiology.
    Eur J Heart Fail. 2021 May 1. doi: 10.1002/ejhf.2206.
    PubMed    


  48. LEEDY DJ, Reding KW, Vasbinder AL, Anderson GL, et al
    The association between heart failure and incident cancer in women: An analysis of the Women's Health Initiative.
    Eur J Heart Fail. 2021 May 1. doi: 10.1002/ejhf.2207.
    PubMed     Abstract available


  49. MALEK F, Gajewski P, Zymlinski R, Janczak D, et al
    Surgical ablation of the right greater splanchnic nerve for the treatment of heart failure with preserved ejection fraction: First-in-human clinical trial.
    Eur J Heart Fail. 2021 May 1. doi: 10.1002/ejhf.2209.
    PubMed     Abstract available


  50. MULDER BA, van Veldhuisen DJ, Rienstra M
    Sudden cardiac death in heart failure: more than meets the eye.
    Eur J Heart Fail. 2021 May 1. doi: 10.1002/ejhf.2212.
    PubMed    


  51. HADZIBEGOVIC S, Lena A, Churchill TW, Ho JE, et al
    Heart Failure with preserved ejection fraction according to the HFA-PEFF score in COVID-19 patients: clinical correlates and echocardiographic findings.
    Eur J Heart Fail. 2021 May 1. doi: 10.1002/ejhf.2210.
    PubMed     Abstract available


  52. TOMASONI D, Adamo M, Metra M
    May 2021 at a glance: focus on acute heart failure and heart failure with preserved ejection fraction.
    Eur J Heart Fail. 2021;23:691-692.
    PubMed    


  53. MULLENS W, Martens P, Witte K, Cowie MR, et al
    Reply to 'Why mechanical dyssynchrony remains relevant to cardiac resynchronization therapy'.
    Eur J Heart Fail. 2021;23:844-845.
    PubMed    


  54. TOMASONI D, Coats AJS
    The Altmetric Attention Score: how science tries to meet social media.
    Eur J Heart Fail. 2021;23:693-697.
    PubMed    


  55. SUGUMAR H, Nanayakkara S, Vizi D, Wright L, et al
    A prospective STudy using invAsive haemodynamic measurements foLLowing catheter ablation for AF and early HFpEF: STALL AF-HFpEF.
    Eur J Heart Fail. 2021;23:785-796.
    PubMed     Abstract available


  56. KHEDRAKI R, Tang WHW
    Identifying sodium non-excretors: heart failure's emerging golden ticket for risk stratification.
    Eur J Heart Fail. 2021;23:740-742.
    PubMed    


  57. VEENIS JF, Brugts JJ, Yalcin YC, Caliskan K, et al
    Reply to 'Aortic valve surgery and left ventricular assist device: lights and shadows'.
    Eur J Heart Fail. 2021;23:842-843.
    PubMed    


  58. LOARDI C, Zanobini M
    Aortic valve surgery and left ventricular assist device: lights and shadows. Letter regarding the article 'Survival following a concomitant aortic valve procedure during left ventricular assist device surgery: an ISHLT Mechanically Assisted Circulator
    Eur J Heart Fail. 2021;23:841-842.
    PubMed    


  59. BHATT AS, Yanamandala M, Konstam MA
    For vaptans, as for life, balance is better.
    Eur J Heart Fail. 2021;23:751-753.
    PubMed    


  60. SANDERS-VAN WIJK S, Barandiaran Aizpurua A, Brunner-La Rocca HP, Henkens MTHM, et al
    The HFA-PEFF and H2 FPEF scores largely disagree in classifying patients with suspected heart failure with preserved ejection fraction.
    Eur J Heart Fail. 2021;23:838-840.
    PubMed    


    April 2021
  61. FRASER AG, Tschope C, de Boer RA
    Diagnostic recommendations and phenotyping for heart failure with preserved ejection fraction - knowing more and understanding less?
    Eur J Heart Fail. 2021 Apr 30. doi: 10.1002/ejhf.2205.
    PubMed    


  62. BEUSEKAMP JC, Tromp J, Boorsma EM, Heerspink HJL, et al
    Effects of SGLT2 inhibition with Empagliflozin on Potassium Handling in Patients with Acute Heart Failure.
    Eur J Heart Fail. 2021 Apr 26. doi: 10.1002/ejhf.2197.
    PubMed    


  63. FUDIM M, Ponikowski P, Burkhoff D, Dunlap M, et al
    Splanchnic Nerve Modulation in Heart Failure: Mechanistic Overview, Initial Clinical Experience, and Safety Considerations.
    Eur J Heart Fail. 2021 Apr 22. doi: 10.1002/ejhf.2196.
    PubMed     Abstract available


  64. HE T, Mischak M, Clark AL, Campbell RT, et al
    Urinary peptides in heart failure: a link to molecular pathophysiology.
    Eur J Heart Fail. 2021 Apr 21. doi: 10.1002/ejhf.2195.
    PubMed     Abstract available


  65. FINE NM, Howlett JG
    Cautious optimism for machine learning techniques for prediction of heart failure outcomes.
    Eur J Heart Fail. 2021 Apr 20. doi: 10.1002/ejhf.2192.
    PubMed    


  66. NASSIF M, Butler J
    Moving in the Right Direction but Not There Yet. The Utility, Measurement, and Analysis of Health Status in Heart Failure Trials.
    Eur J Heart Fail. 2021 Apr 20. doi: 10.1002/ejhf.2193.
    PubMed    


  67. JERING KS, Claggett B, Pfeffer MA, Granger C, et al
    Prospective ARNI versus ACE inhibitor trial to DetermIne Superiority in reducing heart failure Events after Myocardial Infarction (PARADISE-MI): Design and Baseline Characteristics.
    Eur J Heart Fail. 2021 Apr 12. doi: 10.1002/ejhf.2191.
    PubMed     Abstract available


  68. BAYES-GENIS A, Lupon J
    Heart failure is ejection fraction in motion.
    Eur J Heart Fail. 2021 Apr 9. doi: 10.1002/ejhf.2185.
    PubMed    


  69. ABRAHAM WT
    Interatrial Shunting for the Treatment of Heart Failure: An On-Demand, Self-Regulating Left Atrial Pressure Lowering System.
    Eur J Heart Fail. 2021 Apr 8. doi: 10.1002/ejhf.2184.
    PubMed    


  70. SORENSEN TB, Minamisawa M, Liu J, Claggett B, et al
    The Effect of the Cardiac Myosin Activator, Omecamtiv Mecarbil, on Right Ventricular Structure and Function in Chronic Systolic Heart Failure (COSMIC -HF).
    Eur J Heart Fail. 2021 Apr 7. doi: 10.1002/ejhf.2181.
    PubMed    


  71. FERREIRA JP
    Cognitive function assessment for personalized heart failure disease management programmes.
    Eur J Heart Fail. 2021 Apr 7. doi: 10.1002/ejhf.2183.
    PubMed    


  72. GIRERD N, Felker GM
    The lower is not always the better: a better understanding of loop diuretics in heart failure.
    Eur J Heart Fail. 2021 Apr 7. doi: 10.1002/ejhf.2182.
    PubMed    


  73. BOLLI R, Mitrani RD, Hare JM, Pepine CJ, et al
    A Phase II Study of Autologous Mesenchymal Stromal Cells and c-kit Positive Cardiac Cells, Alone or in Combination, in Patients with Ischemic Heart Failure: The CCTRN CONCERT-HF Trial.
    Eur J Heart Fail. 2021 Apr 3. doi: 10.1002/ejhf.2178.
    PubMed     Abstract available


  74. PAGNESI M, Adamo M, Metra M
    April 2021 at a glance: focus on systolic function, quality of life and treatment in heart failure.
    Eur J Heart Fail. 2021;23:505-506.
    PubMed    


  75. BAYES-GENIS A
    The CONCERT-HF trial: a sweet and sour symphony.
    Eur J Heart Fail. 2021;23:675-676.
    PubMed    


  76. GARCIA-PAVIA P, Rapezzi C, Adler Y, Arad M, et al
    Diagnosis and treatment of cardiac amyloidosis. A position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases.
    Eur J Heart Fail. 2021;23:512-526.
    PubMed     Abstract available


  77. BOUDOULAS KD, Boudoulas H
    Time and left ventricular function: the forgotten dynamic factor.
    Eur J Heart Fail. 2021;23:552-554.
    PubMed    


  78. STRANGE G, Playford D, Scalia GM, Celermajer DS, et al
    Change in ejection fraction and long-term mortality in adults referred for echocardiography.
    Eur J Heart Fail. 2021;23:555-563.
    PubMed     Abstract available


  79. COATS AJS, Rosano G
    Treatments delayed lead to lives lost.
    Eur J Heart Fail. 2021;23:511.
    PubMed    


  80. DOCHERTY KF, Curtain JP, Anand IS, Bengtsson O, et al
    Effect of dapagliflozin on anaemia in DAPA-HF.
    Eur J Heart Fail. 2021;23:617-628.
    PubMed     Abstract available


  81. DOBNER S
    Letter regarding the article 'Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and long-term extension study'.
    Eur J Heart Fail. 2021;23:681-682.
    PubMed    


  82. HAGNAS MJ, Grasso C, Di Salvo ME, Sardone A, et al
    Effect of post-procedural evidence-based therapy on 2-year prognosis after transcatheter mitral valve repair.
    Eur J Heart Fail. 2021;23:677-679.
    PubMed    


    March 2021
  83. WETTERSTEN N, Horiuchi Y, van Veldhuisen DJ, Ix JH, et al
    Decongestion Discriminates Risk for One Year Mortality in Patients with Improving Renal Function in Acute Heart Failure.
    Eur J Heart Fail. 2021 Mar 31. doi: 10.1002/ejhf.2179.
    PubMed     Abstract available


  84. HUYNH QL, Whitmore K, Negishi K, DePasquale CG, et al
    Cognitive Impairment as a Determinant of Response to Management Plans After Heart Failure Admission.
    Eur J Heart Fail. 2021 Mar 31. doi: 10.1002/ejhf.2177.
    PubMed     Abstract available


  85. BARAKAT MF, Amin-Youseff G, Okonko DO
    Oral Sucrosomial Iron in Heart Failure with a Reduced Ejection Fraction.
    Eur J Heart Fail. 2021 Mar 31. doi: 10.1002/ejhf.2176.
    PubMed    


  86. UIJL A, Savarese G, Vaartjes I, Dahlstrom U, et al
    Identification of Distinct Phenotypic Clusters in Heart Failure with Preserved Ejection Fraction.
    Eur J Heart Fail. 2021 Mar 29. doi: 10.1002/ejhf.2169.
    PubMed     Abstract available


  87. KALOGEROPOULOS AP, Hotelling J, Skopicki HA
    Blood Counts: Targeting Anemia in Patients with Heart Failure.
    Eur J Heart Fail. 2021 Mar 29. doi: 10.1002/ejhf.2173.
    PubMed    


  88. KHAN MS, Fonarow GC, Greene SJ
    SGLT-2 Inhibitors for Heart Failure: Clinical Trial Efficacy and Clinical Practice Effectiveness.
    Eur J Heart Fail. 2021 Mar 29. doi: 10.1002/ejhf.2170.
    PubMed    


  89. WAN SH, Pandey A
    Targeting the nitrate-nitrite-nitric oxide pathway in heart failure with preserved ejection fraction: too soon to say no to nitric oxide?
    Eur J Heart Fail. 2021 Mar 29. doi: 10.1002/ejhf.2171.
    PubMed    


  90. KHAN MS, Usman MS, Butler J
    Etiology Of Heart Failure Is In The Eye Of The Beholder: Does It Even Matter?
    Eur J Heart Fail. 2021 Mar 26. doi: 10.1002/ejhf.2166.
    PubMed    


  91. PACKER M
    What Causes Exertional Dyspnea in Patients With Atrial Fibrillation? Implications for Catheter Ablation in Patients With Heart Failure.
    Eur J Heart Fail. 2021 Mar 26. doi: 10.1002/ejhf.2164.
    PubMed    


  92. BHATT AS, Varshney AS, Nekoui M, Moscone A, et al
    Virtual Optimization of Guideline-Directed Medical Therapy in Hospitalized Patients with Heart Failure with Reduced Ejection Fraction: the IMPLEMENT-HF Pilot Study.
    Eur J Heart Fail. 2021 Mar 26. doi: 10.1002/ejhf.2163.
    PubMed     Abstract available


  93. METRA M, Coats AJS
    Why we love heart failure. An introduction to the universal definition of heart failure.
    Eur J Heart Fail. 2021 Mar 26. doi: 10.1002/ejhf.2168.
    PubMed    


  94. GUPTA P, Voors AA, Patel P, Lane D, et al
    Non-adherence to heart failure medications predicts clinical outcomes: Assessment in a single spot urine sample by liquid chromatography - tandem mass spectrometry (results of a prospective multicentre study).
    Eur J Heart Fail. 2021 Mar 23. doi: 10.1002/ejhf.2160.
    PubMed    


  95. CHIONCEL O, Stewart Coats AJ
    National Heart Failure Societies Summit 2020.
    Eur J Heart Fail. 2021 Mar 21. doi: 10.1002/ejhf.2157.
    PubMed    


  96. BOORSMA EM, Ter Maaten JM, Damman K, van Veldhuisen DJ, et al
    Dipeptidyl peptidase-3, a marker of the antagonist pathway of the renin-angiotensin-aldosterone system in patients with heart failure.
    Eur J Heart Fail. 2021 Mar 20. doi: 10.1002/ejhf.2158.
    PubMed     Abstract available


  97. RAVERA A, Santema BT, Sama IE, Meyer S, et al
    Quality of life in men and women with heart failure: association with outcome, and comparison of the Kansas City Cardiomyopathy Questionnaire and the EuroQol 5 dimensions questionnaire.
    Eur J Heart Fail. 2021 Mar 16. doi: 10.1002/ejhf.2154.
    PubMed     Abstract available


  98. TROMP J, Bryant JA, Jin X, van Woerden G, et al
    Epicardial fat in heart failure with reduced versus preserved ejection fraction.
    Eur J Heart Fail. 2021 Mar 16. doi: 10.1002/ejhf.2156.
    PubMed    


  99. ZIAEIAN B, Fonarow GC
    Making heart failure count.
    Eur J Heart Fail. 2021 Mar 13. doi: 10.1002/ejhf.2148.
    PubMed    


  100. PACKER M, McMurray JJV
    Rapid Evidence-Based Sequencing of Foundational Drugs for Heart Failure and a Reduced Ejection Fraction.
    Eur J Heart Fail. 2021 Mar 11. doi: 10.1002/ejhf.2149.
    PubMed     Abstract available


  101. PUVREZ A, Duchenne J, Gorcsan J 3rd, Marwick TH, et al
    Why mechanical dyssynchrony remains relevant to cardiac resynchronization therapy. Letter regarding the article 'Optimized implementation of cardiac resynchronization therapy: a call for action for referral and optimization of care: a joint position s
    Eur J Heart Fail. 2021 Mar 11. doi: 10.1002/ejhf.2150.
    PubMed    


  102. WOLSK E, Kaye DM, Komtebedde J, Shah SJ, et al
    Determinants and consequences of heart rate and stroke volume response to exercise in patients with heart failure and preserved ejection fraction.
    Eur J Heart Fail. 2021 Mar 8. doi: 10.1002/ejhf.2146.
    PubMed     Abstract available


  103. WOOLLEY RJ, Ceelen D, Ouwerkerk W, Tromp J, et al
    Machine learning based on biomarker profiles identifies distinct subgroups of heart failure with preserved ejection fraction.
    Eur J Heart Fail. 2021 Mar 2. doi: 10.1002/ejhf.2144.
    PubMed     Abstract available


  104. CARAVITA S, Senni M, Parati G
    Reply to: 'The hyperdynamic circulatory profile of patients with COVID-19-related acute vascular distress syndrome'.
    Eur J Heart Fail. 2021;23:493-494.
    PubMed    


  105. TOMASONI D, Petrie MC, Adamo M, Metra M, et al
    Renin-angiotensin-aldosterone inhibitors and COVID-19: nearing the end of a media-fuelled controversy.
    Eur J Heart Fail. 2021;23:486-488.
    PubMed    


  106. MAHJOUB Y, Rodenstein DO, Jounieaux V
    The hyperdynamic circulatory profile of patients with COVID-19-related acute vascular distress syndrome. Letter regarding the article 'Haemodynamic characteristics of COVID-19 patients with acute respiratory distress syndrome requiring mechanical vent
    Eur J Heart Fail. 2021;23:493.
    PubMed    


  107. PAGNESI M, Adamo M, Metra M
    March 2021 at a glance: focus on epidemiology, prevention and COVID-19.
    Eur J Heart Fail. 2021;23:347-349.
    PubMed    


  108. CARO-CODON J, Rey JR, Buno A, Iniesta AM, et al
    Characterization of NT-proBNP in a large cohort of COVID-19 patients.
    Eur J Heart Fail. 2021;23:456-464.
    PubMed     Abstract available


  109. GARG A, Seeliger B, Derda AA, Xiao K, et al
    Circulating cardiovascular microRNAs in critically ill COVID-19 patients.
    Eur J Heart Fail. 2021;23:468-475.
    PubMed     Abstract available


  110. SAVARESE G, Benson L, Sundstrom J, Lund LH, et al
    Association between renin-angiotensin-aldosterone system inhibitor use and COVID-19 hospitalization and death: a 1.4 million patient nationwide registry analysis.
    Eur J Heart Fail. 2021;23:476-485.
    PubMed     Abstract available


  111. BRAUNWALD E, Antman EM
    The path to universality.
    Eur J Heart Fail. 2021;23:381-383.
    PubMed    


  112. OLSEN FJ, Solomon SD, Biering-Sorensen T
    Piecing together the puzzle of sex-specific differences in left ventricular ejection fraction.
    Eur J Heart Fail. 2021;23:417-419.
    PubMed    


  113. CHESSA M, Tutarel O
    Adults with congenital heart disease - we need more Europe for a better care.
    Eur J Heart Fail. 2021;23:454-455.
    PubMed    


  114. STEWART S, Playford D, Scalia GM, Currie P, et al
    Ejection fraction and mortality: a nationwide register-based cohort study of 499 153 women and men.
    Eur J Heart Fail. 2021;23:406-416.
    PubMed     Abstract available


  115. BRIDA M, Simkova I, Jovovic L, Prokselj K, et al
    European Society of Cardiology Working Group on Adult Congenital Heart Disease and Study Group for Adult Congenital Heart Care in Central and South Eastern European Countries consensus paper: current status, provision gaps and investment required.
    Eur J Heart Fail. 2021;23:445-453.
    PubMed     Abstract available


  116. SPERRY BW, Tang Y, Jones PG, Spertus JA, et al
    Cumulative events in the TOPCAT trial.
    Eur J Heart Fail. 2021;23:491-492.
    PubMed    


  117. ITO M, Matsue Y, Minamino T
    Worsening renal function during intensive blood pressure control: another example of not prognostically relevant creatinine rise?
    Eur J Heart Fail. 2021;23:393-395.
    PubMed    


    February 2021
  118. DAUW J, Martens P, Tersalvi G, Schouteden J, et al
    Diuretic Response and Effects of Diuretic Omission in Ambulatory Heart Failure Patients on Chronic Low Dose Loop Diuretic Therapy.
    Eur J Heart Fail. 2021 Feb 28. doi: 10.1002/ejhf.2145.
    PubMed     Abstract available


  119. PASCUAL-FIGAL DA
    Biochemical or clinical heart failure, not so simple.
    Eur J Heart Fail. 2021 Feb 26. doi: 10.1002/ejhf.2128.
    PubMed    


  120. SEFEROVIC PM, Vardas P, Jankowska EA, Maggioni AP, et al
    The Heart Failure Association Atlas: Heart Failure Epidemiology and Management Statistics 2019.
    Eur J Heart Fail. 2021 Feb 26. doi: 10.1002/ejhf.2143.
    PubMed     Abstract available


  121. VERBRUGGE FH, Reddy YNV, Sorimachi H, Omote K, et al
    Diagnostic Scores Predict Morbidity and Mortality in Patients Hospitalised for Heart Failure with Preserved Ejection Fraction.
    Eur J Heart Fail. 2021 Feb 26. doi: 10.1002/ejhf.2142.
    PubMed     Abstract available


  122. TURGEON RD, Barry AR, Hawkins NM, Ellis UM, et al
    Pharmacotherapy for Heart Failure with Reduced Ejection Fraction and Health-Related Quality of Life: Systematic Review and Meta-Analysis.
    Eur J Heart Fail. 2021 Feb 25. doi: 10.1002/ejhf.2141.
    PubMed     Abstract available


  123. LANG NN, Ahmad FA, Cleland JG, O'Connor CM, et al
    Hemodynamic Effects of the Nitroxyl Donor Cimlanod (BMS-986231) in Chronic Heart Failure: A Randomized Trial.
    Eur J Heart Fail. 2021 Feb 23. doi: 10.1002/ejhf.2138.
    PubMed     Abstract available


  124. TROMP J, Ponikowski P, Salsali A, Angermann CE, et al
    SGLT2 inhibition in patients hospitalized for acute decompensated heart failure: rationale for and design of the EMPULSE trial.
    Eur J Heart Fail. 2021 Feb 20. doi: 10.1002/ejhf.2137.
    PubMed     Abstract available


  125. BHATIA K, Jain V, Gupta K, Bansal A, et al
    Prevention of Heart Failure Events with SGLT-2 Inhibitors Across a Spectrum of Cardio-Renal-Metabolic Risk.
    Eur J Heart Fail. 2021 Feb 20. doi: 10.1002/ejhf.2135.
    PubMed     Abstract available


  126. SLIWA K, van der Meer P, Petrie MC, Frogoudaki A, et al
    Risk stratification and management of women with cardiomyopathy/heart failure planning pregnancy or presenting during/after pregnancy: a position statement from the Heart Failure Association of the European Society of Cardiology Study Group on Peripar
    Eur J Heart Fail. 2021 Feb 20. doi: 10.1002/ejhf.2133.
    PubMed     Abstract available


  127. FERREIRA JP, Claggett BL, Liu J, Desai AS, et al
    Serum potassium and outcomes in heart failure with preserved ejection fraction: a post-hoc analysis of the PARAGON-HF trial.
    Eur J Heart Fail. 2021 Feb 20. doi: 10.1002/ejhf.2134.
    PubMed     Abstract available


  128. BOZKURT B, Coats A, Tsutsui H
    A Report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure Consensus Conference.
    Eur J Heart Fail. 2021 Feb 19. doi: 10.1002/ejhf.2115.
    PubMed    


  129. CHIONCEL O, Ambrosy AP, Maggioni AP
    Temporal Trends in the Outcomes of Acute Heart Failure: Between Consolatory Evidences and Real Progress.
    Eur J Heart Fail. 2021 Feb 18. doi: 10.1002/ejhf.2130.
    PubMed    


  130. BECHER PM, Schrage B, Ferrannini G, Benson L, et al
    Use of Sodium-Glucose Co-transporter 2 Inhibitors in Patients with Heart Failure and Type 2 Diabetes Mellitus: Data from the Swedish Heart Failure Registry.
    Eur J Heart Fail. 2021 Feb 18. doi: 10.1002/ejhf.2131.
    PubMed     Abstract available


  131. BUTT JH, Nicolau JC, Verma S, Docherty KF, et al
    Efficacy and Safety of Dapagliflozin According to Aetiology in Heart Failure with Reduced Ejection Fraction: Insights from the DAPA-HF trial.
    Eur J Heart Fail. 2021 Feb 16. doi: 10.1002/ejhf.2124.
    PubMed     Abstract available


  132. RICHARDS AM
    Cardiac Myosin-Binding Protein C as a candidate biomarker in Heart Failure: rational but not revolutionary.
    Eur J Heart Fail. 2021 Feb 15. doi: 10.1002/ejhf.2126.
    PubMed    


  133. ALHAKAK AS, Teerlink JR, Lindenfeld J, Bohm M, et al
    The Significance of Left Ventricular Ejection Time in Heart Failure with Reduced Ejection Fraction.
    Eur J Heart Fail. 2021 Feb 15. doi: 10.1002/ejhf.2125.
    PubMed     Abstract available


  134. MILLER WL, Sorimachi H, Grill DE, Fischer K, et al
    Contributions of Cardiac Dysfunction and Volume Status to Central Hemodynamics in Chronic Heart Failure.
    Eur J Heart Fail. 2021 Feb 9. doi: 10.1002/ejhf.2121.
    PubMed     Abstract available


  135. ROHDE LE, Vaduganathan M, Claggett BL, Polanczyk CA, et al
    Dynamic Changes in Cardiovascular and Systemic Variables Prior to Sudden Cardiac Death in Heart Failure with Reduced Ejection Fraction: a PARADIGM-HF Analysis.
    Eur J Heart Fail. 2021 Feb 9. doi: 10.1002/ejhf.2120.
    PubMed     Abstract available


  136. VOLTERRANI M, Perrone V, Degli Esposti L
    Reply letter regarding the article "Effects of hyperkalemia and non-adherence to renin angiotensin aldosterone system inhibitors (RAASi) in patients affected by heart failure in Italy: a propensity-matched study".
    Eur J Heart Fail. 2021 Feb 8. doi: 10.1002/ejhf.2123.
    PubMed    


  137. PAITAZOGLOU C, Bergmann MW, Ozdemir R, Pfister R, et al
    One-year results of the first-in-man study investigating the Atrial-Flow-Regulator for left-atrial shunting in symptomatic heart failure patients: the PRELIEVE study.
    Eur J Heart Fail. 2021 Feb 8. doi: 10.1002/ejhf.2119.
    PubMed     Abstract available


  138. COTTER G, Davison BA, Edwards C, Takagi K, et al
    Acute Heart Failure Treatment - A Light at The End of the Tunnel?
    Eur J Heart Fail. 2021 Feb 6. doi: 10.1002/ejhf.2116.
    PubMed    


  139. CLERICO A, Aimo A, Passino C
    The pathophysiological and clinical relevance of combined measurement of natriuretic peptides and cardiac troponins for risk prediction of incident heart failure in community-dwelling individuals.
    Eur J Heart Fail. 2021 Feb 2. doi: 10.1002/ejhf.2112.
    PubMed    



  140. Corrigendum to 'Epidemiology, pathophysiology and contemporary management of cardiogenic shock - a position statement from the Heart Failure Association of the European Society of Cardiology' [Eur J Heart Fail 2020;22:1315-1341].
    Eur J Heart Fail. 2021;23:345.
    PubMed    



  141. Corrigendum to 'Role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a position statement on behalf of the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio-Oncolog
    Eur J Heart Fail. 2021;23:345.
    PubMed    


  142. SMITH N, Tampakakis E
    COVID-19 acute respiratory distress syndrome: intriguing haemodynamics of an intriguing syndrome.
    Eur J Heart Fail. 2021;23:208-210.
    PubMed    


  143. PAGNESI M, Adamo M, Metra M
    February 2021 at a glance: focus on amyloidosis, myocarditis and cardiomyopathy.
    Eur J Heart Fail. 2021;23:201-202.
    PubMed    


  144. STOGIOS N, Fezza G, Wong JV, Ross HJ, et al
    Current challenges for using the Kansas City Cardiomyopathy Questionnaire to obtain a standardized patient-reported health status outcome.
    Eur J Heart Fail. 2021;23:205-207.
    PubMed    


  145. ARNOLD SV, Butler J, Spertus JA
    Standardizing the standard: reporting health status in clinical trials.
    Eur J Heart Fail. 2021;23:203-204.
    PubMed    


  146. CASTIGLIONE V, Franzini M, Aimo A, Carecci A, et al
    Use of biomarkers to diagnose and manage cardiac amyloidosis.
    Eur J Heart Fail. 2021;23:217-230.
    PubMed     Abstract available


  147. PERLINI S, Mussinelli R, Salinaro F
    New effective treatment options reinforce disease awareness: the case of transthyretin cardiac amyloidosis.
    Eur J Heart Fail. 2021;23:290-292.
    PubMed    


  148. LYLE MA, Cooper LT
    Failure of intravenous immunoglobulin to improve cardiac function in parvovirus B19-associated chronic dilated cardiomyopathy.
    Eur J Heart Fail. 2021;23:310-311.
    PubMed    


  149. RAPEZZI C, Aimo A, Emdin M
    Tafamidis is entering the clinical arena for the treatment of transthyretin-related cardiomyopathy: certainties and unmet needs.
    Eur J Heart Fail. 2021;23:286-289.
    PubMed    


  150. ASLEH R, Amir O, Kushwaha SS
    Dynamics of myocardial fibrosis after left ventricular assist device implantation: should speeding up the scar have us scared stiff?
    Eur J Heart Fail. 2021;23:335-338.
    PubMed    


  151. HAZEBROEK MR, Henkens MTHM, Raafs AG, Verdonschot JAJ, et al
    Intravenous immunoglobulin therapy in adult patients with idiopathic chronic cardiomyopathy and cardiac parvovirus B19 persistence: a prospective, double-blind, randomized, placebo-controlled clinical trial.
    Eur J Heart Fail. 2021;23:302-309.
    PubMed     Abstract available


  152. BONDERMAN D
    How to ATTR-ACT the perfect match?
    Eur J Heart Fail. 2021;23:275-276.
    PubMed    


  153. RAPEZZI C, Giannini F, Campo G
    Aortic stenosis, transcatheter aortic valve replacement and transthyretin cardiac amyloidosis: are we progressively unraveling the tangle?
    Eur J Heart Fail. 2021;23:259-263.
    PubMed    


  154. BEZARD M, Kharoubi M, Galat A, Poullot E, et al
    Natural history and impact of treatment with tafamidis on major cardiovascular outcome-free survival time in a cohort of patients with transthyretin amyloidosis.
    Eur J Heart Fail. 2021;23:264-274.
    PubMed     Abstract available


  155. DAMY T, Garcia-Pavia P, Hanna M, Judge DP, et al
    Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and long-term extension study.
    Eur J Heart Fail. 2021;23:277-285.
    PubMed     Abstract available


  156. NICOL M, Deney A, Lairez O, Vergaro G, et al
    Prognostic value of cardiopulmonary exercise testing in cardiac amyloidosis.
    Eur J Heart Fail. 2021;23:231-239.
    PubMed     Abstract available


  157. ROSENBLUM H, Masri A, Narotsky DL, Goldsmith J, et al
    Unveiling outcomes in coexisting severe aortic stenosis and transthyretin cardiac amyloidosis.
    Eur J Heart Fail. 2021;23:250-258.
    PubMed     Abstract available


  158. SINAGRA G, Porcari A, Gentile P, Artico J, et al
    Viral presence-guided immunomodulation in lymphocytic myocarditis: an update.
    Eur J Heart Fail. 2021;23:211-216.
    PubMed     Abstract available


    January 2021
  159. CANEPA M, Ameri P, Lainscak M
    COPD and comorbidities in heart failure: the next frontier of SGLT2 inhibitors?
    Eur J Heart Fail. 2021 Jan 27. doi: 10.1002/ejhf.2109.
    PubMed    


  160. PETRIE MC, Lee MMY, Docherty KF
    Sodium-glucose co-transporter 2 inhibitors-the first successful treatment for heart failure with preserved ejection fraction?
    Eur J Heart Fail. 2021 Jan 27. doi: 10.1002/ejhf.2108.
    PubMed    


  161. DOCHERTY KF, Vaduganathan M
    OUTSTEP-HF: re-evaluating the role of physical activity measures in drug and device development in heart failure.
    Eur J Heart Fail. 2021 Jan 22. doi: 10.1002/ejhf.2106.
    PubMed    


  162. SUTHAHAR N, Meems LMG, Groothof D, Bakker SJL, et al
    Relationship between Body-Mass Index, Cardiovascular Biomarkers and Incident Heart Failure.
    Eur J Heart Fail. 2021 Jan 14. doi: 10.1002/ejhf.2102.
    PubMed     Abstract available


  163. KIMMOUN A, Takagi K, Gall E, Ishihara S, et al
    Temporal trends in mortality and readmission after acute heart failure: A systematic review and meta-regression in the past four decades.
    Eur J Heart Fail. 2021 Jan 14. doi: 10.1002/ejhf.2103.
    PubMed     Abstract available


  164. KOZHUHAROV N, Wussler D, Kaier T, Strebel I, et al
    Cardiac Myosin-Binding Protein C in the Diagnosis and Risk Stratification of Acute Heart Failure.
    Eur J Heart Fail. 2021 Jan 9. doi: 10.1002/ejhf.2094.
    PubMed     Abstract available


  165. REDDY YNV, Stewart GM, Obokata M, Koepp KE, et al
    Peripheral and Pulmonary Effects of Inorganic-Nitrite during Exercise in Heart Failure with Preserved Ejection Fraction.
    Eur J Heart Fail. 2021 Jan 9. doi: 10.1002/ejhf.2093.
    PubMed     Abstract available


  166. KARAVIDAS A, Troganis E, Lazaros G, Balta D, et al
    Oral Sucrosomial iron improves exercise capacity and quality of life in heart failure with reduced ejection fraction and iron deficiency: A non-randomized, open-label, proof-of-concept study.
    Eur J Heart Fail. 2021 Jan 9. doi: 10.1002/ejhf.2092.
    PubMed     Abstract available


  167. TOMASONI D, Adamo M, Metra M
    January 2021 at a glance: focus on sex differences, acute heart failure and exercise capacity.
    Eur J Heart Fail. 2021;23:1-2.
    PubMed    


  168. MULLENS W, Martens P
    Empagliflozin and renal sodium handling: an intriguing smart osmotic diuretic.
    Eur J Heart Fail. 2021;23:79-82.
    PubMed    


  169. FARMAKIS D, Filippatos G
    Arrhythmias in cancer: rhythm is gonna get you!
    Eur J Heart Fail. 2021;23:154-156.
    PubMed    


  170. ANKER MS, von Haehling S, Coats AJS, Riess H, et al
    Ventricular tachycardia, premature ventricular contractions, and mortality in unselected patients with lung, colon, or pancreatic cancer: a prospective study.
    Eur J Heart Fail. 2021;23:145-153.
    PubMed     Abstract available


  171. CHIONCEL O, Collins SP, Seferovic P
    Does end-organ dysfunction precede or follow cardiogenic shock in acute decompensated heart failure? The two-faced Janus. Reply.
    Eur J Heart Fail. 2021;23:197-198.
    PubMed    


    December 2020
  172. PABEL S, Hamdani N, Sossalla S
    A mechanistic rationale for the investigation of SGLT2 inhibitors in HFpEF - Letter regarding the article 'Baseline Characteristics of Patients with Heart Failure with Preserved Ejection Fraction in the EMPEROR-Preserved Trial'.
    Eur J Heart Fail. 2020 Dec 29. doi: 10.1002/ejhf.2091.
    PubMed    


  173. DEWAN P, Docherty KF, Bengtsson O, de Boer RA, et al
    Effects of dapagliflozin in heart failure with reduced ejection fraction, and COPD: An analysis of DAPA-HF.
    Eur J Heart Fail. 2020 Dec 23. doi: 10.1002/ejhf.2083.
    PubMed     Abstract available


  174. ASLAM MI, Jani V, Lin B, Dunkerly-Eyring B, et al
    Pulmonary Artery Pulsatility Index Predicts Right Ventricular Myofilament Dysfunction in Advanced Human Heart Failure.
    Eur J Heart Fail. 2020 Dec 21. doi: 10.1002/ejhf.2084.
    PubMed    


  175. MORIYAMA H, Kohno T, Kohsaka S
    Letter regarding the article "Effects of hyperkalemia and non-adherence to renin angiotensin aldosterone system inhibitors (RAASi) in patients affected by heart failure in Italy: a propensity-matched study".
    Eur J Heart Fail. 2020 Dec 19. doi: 10.1002/ejhf.2081.
    PubMed    


  176. DAVISON BA, Senger S, Sama IE, Koch GG, et al
    Is Acute heart failure a distinctive disorder? An analysis from BIOSTAT-CHF.
    Eur J Heart Fail. 2020 Dec 19. doi: 10.1002/ejhf.2077.
    PubMed     Abstract available


  177. SCHNEIDER B, Ong P
    Improving female enrolment in randomized clinical trials of heart failure with reduced ejection fraction to ensure evidence-based health care recommendations.
    Eur J Heart Fail. 2020 Dec 19. doi: 10.1002/ejhf.2078.
    PubMed    


  178. PIEPOLI MF, Hussain RI, Comin-Colet J, Dosantos R, et al
    OUTSTEP-HF: Randomised controlled trial comparing short-term effects of sacubitril/valsartan versus enalapril on daily physical activity in patients with chronic heart failure with reduced ejection fraction.
    Eur J Heart Fail. 2020 Dec 13. doi: 10.1002/ejhf.2076.
    PubMed     Abstract available


  179. DOCHERTY KF, McMurray JJV
    SOLOIST-WHF: Sodium-glucose cotransporter 2 (SGLT2) inhibitors should be initiated in patients hospitalised with worsening heart failure.
    Eur J Heart Fail. 2020 Dec 6. doi: 10.1002/ejhf.2075.
    PubMed    


  180. ZELNIKER TA, Morrow DA, Mosenzon O, Goodrich EL, et al
    Relationship between baseline cardiac biomarkers and cardiovascular death or hospitalization for heart failure with and without SGLT2 inhibitor therapy in DECLARE-TIMI 58.
    Eur J Heart Fail. 2020 Dec 2. doi: 10.1002/ejhf.2073.
    PubMed     Abstract available



  181. Addendum to the article: 'Improving risk prediction in heart failure using machine learning' [Eur J Heart Fail 2020;22:139-147].
    Eur J Heart Fail. 2020;22:2399.
    PubMed    


  182. WANG N, Cao J, Lal S
    COVID-19: getting to the heart of the matter.
    Eur J Heart Fail. 2020;22:2216-2218.
    PubMed    


  183. TOMASONI D, Adamo M, Metra M
    December 2020 at a glance: focus on COVID-19, comorbidities and palliative care.
    Eur J Heart Fail. 2020;22:2173-2174.
    PubMed    


  184. LEBEK S, Tafelmeier M, Messmann R, Provaznik Z, et al
    Angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker treatment and haemodynamic factors are associated with increased cardiac mRNA expression of angiotensin-converting enzyme 2 in patients with cardiovascular disease.
    Eur J Heart Fail. 2020;22:2248-2257.
    PubMed     Abstract available


  185. BHATT AS, Vaduganathan M
    Discovery and care innovation amidst a pandemic.
    Eur J Heart Fail. 2020;22:2202-2204.
    PubMed    


  186. FARMAKIS D
    Is cardio-oncology a rapidly growing field of precision medicine?
    Eur J Heart Fail. 2020;22:2310-2313.
    PubMed    


  187. KONSTAM MA
    Ventricular remodelling: an equal-opportunity prognosticator.
    Eur J Heart Fail. 2020;22:2269-2271.
    PubMed    


    November 2020
  188. PACKER M, Butler J, Filippatos G, Zannad F, et al
    Design of a Prospective Patient-Level Pooled Analysis of Two Parallel Trials of Empagliflozin in Patients With Established Heart Failure.
    Eur J Heart Fail. 2020 Nov 30. doi: 10.1002/ejhf.2065.
    PubMed     Abstract available


  189. GREENBERG B, Janvanishstaporn S, Feng S
    Reply to Letter: Worsening Renal Function After Diuresis Among Heart Failure Patients with Preserved Ejection Fraction --- A Dilemma to Heart Failure Management.
    Eur J Heart Fail. 2020 Nov 29. doi: 10.1002/ejhf.2067.
    PubMed    


  190. ANKER SD, Butler J, Filippatos G, Khan MS, et al
    Baseline Characteristics of Patients with Heart Failure with Preserved Ejection Fraction in the EMPEROR-Preserved Trial.
    Eur J Heart Fail. 2020 Nov 29. doi: 10.1002/ejhf.2064.
    PubMed     Abstract available


  191. BOORSMA EM, Beusekamp JC, Ter Maaten JM, Figarska SM, et al
    Effects of Empagliflozin on Renal Sodium and Glucose Handling in Patients with Acute Heart Failure.
    Eur J Heart Fail. 2020 Nov 29. doi: 10.1002/ejhf.2066.
    PubMed     Abstract available


  192. ANKER MS, Sanz AP, Zamorano JL, Mehra MR, et al
    Advanced cancer is also a heart failure syndrome - an hypothesis.
    Eur J Heart Fail. 2020 Nov 28. doi: 10.1002/ejhf.2071.
    PubMed     Abstract available


  193. MADELAIRE C, Kristensen SL
    Patterns of unplanned readmissions after heart failure hospitalization: novel longitudinal perspectives from Australia and New Zealand.
    Eur J Heart Fail. 2020 Nov 28. doi: 10.1002/ejhf.2068.
    PubMed    


  194. D'AMARIO D, Borovac JA, Crea F
    Coronary microvascular dysfunction in heart failure with preserved ejection fraction: not the end but the end of the beginning.
    Eur J Heart Fail. 2020 Nov 28. doi: 10.1002/ejhf.2069.
    PubMed    


  195. HALLIDAY BP, Owen R, Gregson J, Vassiliou V, et al
    Myocardial remodelling after withdrawing therapy for heart failure in patients with recovered dilated cardiomyopathy - insights from TRED-HF.
    Eur J Heart Fail. 2020 Nov 22. doi: 10.1002/ejhf.2063.
    PubMed     Abstract available


  196. CANEPA M, Kapelios CJ, Lund LH
    Acknowledging the complex puzzle that links heart failure hospitalizations and outcomes.
    Eur J Heart Fail. 2020 Nov 22. doi: 10.1002/ejhf.2061.
    PubMed    


  197. DONAL E, Galli E, Paven E, Sade LE, et al
    Haemodynamic evaluation: a key tool for heart failure management.
    Eur J Heart Fail. 2020 Nov 20. doi: 10.1002/ejhf.2055.
    PubMed    


  198. BIEGUS J, Zymlinski R, Testani J, Marciniak D, et al
    Renal profiling based on estimated glomerular filtration rate and spot urine sodium identifies high risk acute heart failure patients.
    Eur J Heart Fail. 2020 Nov 14. doi: 10.1002/ejhf.2053.
    PubMed     Abstract available


  199. TOMASONI D, Inciardi RM, Lombardi CM, Tedino C, et al
    Impact of heart failure on the clinical course and outcomes of patients hospitalized for COVID-19. Results of the Cardio-COVID-Italy multicentre study.
    Eur J Heart Fail. 2020 Nov 12. doi: 10.1002/ejhf.2052.
    PubMed     Abstract available


  200. VERNOOY K, Brunner-La Rocca HP
    The importance of the electrocardiographic follow-up in heart failure.
    Eur J Heart Fail. 2020 Nov 12. doi: 10.1002/ejhf.2054.
    PubMed    


  201. DUSI V, Vitolo V, Frigerio L, Totaro R, et al
    The First-in-Man Case of Non-invasive Proton Radiotherapy to Treat Refractory Ventricular Tachycardia in Advanced Heart Failure.
    Eur J Heart Fail. 2020 Nov 12. doi: 10.1002/ejhf.2056.
    PubMed    


  202. STARWALT JL, Ho AF, Wang H
    Worsening Renal Function After Diuresis Among Heart Failure Patients with Preserved Ejection Fraction --- A Dilemma to Heart Failure Management.
    Eur J Heart Fail. 2020 Nov 8. doi: 10.1002/ejhf.2050.
    PubMed    


  203. KRESOJA KP, Rommel KP, Thiele H, Lurz P, et al
    Response to the letter regarding the article: Transcatheter Tricuspid Valve Repair in the Setting of Heart Failure with Preserved or Reduced Left Ventricular Ejection Fraction.
    Eur J Heart Fail. 2020 Nov 4. doi: 10.1002/ejhf.2048.
    PubMed    


  204. KONIG S, Hohenstein S, Meier-Hellmann A, Kuhlen R, et al
    In-hospital Care in Acute Heart Failure during the COVID-19 Pandemic: Insights from the German-wide Helios Hospital Network.
    Eur J Heart Fail. 2020 Nov 2. doi: 10.1002/ejhf.2044.
    PubMed     Abstract available


  205. FABRIS E, Sinagra G, Valgimigli M
    Antithrombotic therapy in heart failure and sinus rhythm: the ongoing search for a better match of patients to therapy.
    Eur J Heart Fail. 2020 Nov 1. doi: 10.1002/ejhf.2045.
    PubMed    


  206. VOLTERRANI M, Perrone V, Sangiorgi D, Giacomini E, et al
    Effects of hyperkalaemia and non-adherence to renin-angiotensin-aldosterone system inhibitor therapy in patients with heart failure in Italy: a propensity-matched study.
    Eur J Heart Fail. 2020;22:2049-2055.
    PubMed     Abstract available



  207. Corrigendum to 'Departments involved during the first episode of acute heart failure and analysis of emergency department revisits and rehospitalisations: an outlook through the NOVICA cohort' [Eur J Heart Fail 2019;21:1231-1244].
    Eur J Heart Fail. 2020;22:2172.
    PubMed    


  208. JANKOWSKA EA, Tkaczyszyn M, Ponikowski P
    Myocardial iron content in non-ischaemic cardiomyopathy: how much is known?
    Eur J Heart Fail. 2020;22:2047-2048.
    PubMed    


  209. RICHARDS AM
    Beating the bushes for biomarkers.
    Eur J Heart Fail. 2020;22:2075-2077.
    PubMed    


  210. OKWUOSA TM, Keramida K, Filippatos G, Yancy CW, et al
    Cancer therapy and the heart; the necessity to calibrate risk.
    Eur J Heart Fail. 2020;22:1961-1965.
    PubMed    


  211. SEFEROVIC PM, Polovina M
    In search of a 'safety zone' for glycaemic control: association between glycosylated haemoglobin levels and outcomes in patients with type 2 diabetes and cardiovascular disease.
    Eur J Heart Fail. 2020;22:2035-2037.
    PubMed    


  212. KEHLER DS, Arora RC
    Frailty and the failing heart do not travel alone.
    Eur J Heart Fail. 2020;22:2120-2122.
    PubMed    


  213. COWIE MR
    DAPA-HF: does dapagliflozin provide 'bang for your buck' as a treatment for heart failure with reduced ejection fraction?
    Eur J Heart Fail. 2020;22:2157-2159.
    PubMed    


    October 2020
  214. KOUDSTAAL S, Den Ruijter HM, Peters SAE
    Sex Differences and Heart Failure - A Story of Two Tales.
    Eur J Heart Fail. 2020 Oct 30. doi: 10.1002/ejhf.2041.
    PubMed    


  215. WAGNER J, Ambrosy AP
    Hospitalizations for Heart Failure and Mortality Risk During the Evolving Coronavirus Disease 2019 Pandemic - The Wave May Break but A Dangerous Undertow Persists.
    Eur J Heart Fail. 2020 Oct 30. doi: 10.1002/ejhf.2043.
    PubMed    


  216. AHMED F
    Letter regarding the article Transcatheter Tricuspid Valve Repair in the Setting of Heart Failure with Preserved or Reduced Left Ventricular Ejection Fraction.
    Eur J Heart Fail. 2020 Oct 30. doi: 10.1002/ejhf.2037.
    PubMed    


  217. PELLICORI P, Platz E, Dauw J, Ter Maaten JM, et al
    Ultrasound imaging of congestion in heart failure - Examinations beyond the heart.
    Eur J Heart Fail. 2020 Oct 29. doi: 10.1002/ejhf.2032.
    PubMed     Abstract available


  218. WHITELAW S, Sullivan K, Eliya Y, Alruwayeh M, et al
    Trial characteristics associated with under-enrolment of females in randomized controlled trials of heart failure with reduced ejection fraction: A systematic review.
    Eur J Heart Fail. 2020 Oct 29. doi: 10.1002/ejhf.2034.
    PubMed     Abstract available


  219. KLOMPSTRA L, Kyriakou M, Lambrinou E, Piepoli MF, et al
    Measuring physical activity with activity monitors in patients with heart failure. From literature to practice. A position paper from the Committee on Exercise Physiology and Training of the Heart Failure Association of the European Society of Cardiol
    Eur J Heart Fail. 2020 Oct 27. doi: 10.1002/ejhf.2035.
    PubMed     Abstract available


  220. SIERPINSKI R, Josiak K, Suchocki T, Wojtas-Polc K, et al
    High Soluble Transferrin Receptor in Patients With Heart Failure: a Measure of Iron Deficiency And a Strong Predictor of Mortality.
    Eur J Heart Fail. 2020 Oct 27. doi: 10.1002/ejhf.2036.
    PubMed     Abstract available


  221. BEKFANI T, Fudim M, Cleland JGF, Jorbenadze A, et al
    A Current and Future Outlook on Upcoming Technologies in the Remote Monitoring of Patients with Heart Failure.
    Eur J Heart Fail. 2020 Oct 27. doi: 10.1002/ejhf.2033.
    PubMed     Abstract available


  222. CULIC V, Velat I
    Spironolactone discontinuation in patients with heart failure: complex interactions with loop diuretics.
    Eur J Heart Fail. 2020 Oct 23. doi: 10.1002/ejhf.2031.
    PubMed    


  223. LABROSCIANO C, Horton D, Air T, Tavella R, et al
    Frequency, Trends and Institutional Variation in 30-Day All-Cause Mortality and Unplanned Readmissions Following Hospitalisation for Heart Failure in Australia and New Zealand.
    Eur J Heart Fail. 2020 Oct 23. doi: 10.1002/ejhf.2030.
    PubMed     Abstract available


  224. DE BOER RA, Hulot JS, Gabriele Tocchetti C, Aboumsallem JP, et al
    Common Mechanistic Pathways in Cancer and Heart Failure.
    Eur J Heart Fail. 2020 Oct 22. doi: 10.1002/ejhf.2029.
    PubMed     Abstract available


  225. SEFEROVIC PM, Fragasso G, Petrie M, Mullens W, et al
    Heart Failure Association of the European Society of Cardiology Update on Sodium Glucose Co-transporter-2 Inhibitors in Heart Failure (an update on the Sodium-glucose co-transporter 2 inhibitors in heart failure: beyond glycaemic control. The position
    Eur J Heart Fail. 2020 Oct 17. doi: 10.1002/ejhf.2026.
    PubMed     Abstract available


  226. KOEHLER J, Stengel A, Hofmann T, Wegscheider K, et al
    Telemonitoring in patients with chronic heart failure and moderate depressed symptoms - results of the Telemedical Interventional Monitoring in Heart Failure (TIM-HF) study.
    Eur J Heart Fail. 2020 Oct 15. doi: 10.1002/ejhf.2025.
    PubMed     Abstract available


  227. KASSNER A, Oezpeker C, Gummert J, Zittermann A, et al
    Mechanical circulatory support does not reduce advanced myocardial fibrosis in patients with terminal heart failure.
    Eur J Heart Fail. 2020 Oct 10. doi: 10.1002/ejhf.2021.
    PubMed    


  228. SAED ALHAKAK A, Sengelov M, Jorgensen PG, Bruun NE, et al
    Left Ventricular Systolic Ejection Time is an Independent Predictor of All-Cause Mortality in Heart Failure with Reduced Ejection Fraction.
    Eur J Heart Fail. 2020 Oct 9. doi: 10.1002/ejhf.2022.
    PubMed     Abstract available


  229. ABRAHAM WT, Psotka MA, Fiuzat M, Filippatos G, et al
    Standardized Definitions for Evaluation of Heart Failure Therapies: Scientific Expert Panel from the Heart Failure Collaboratory and Academic Research Consortium (HF-ARC).
    Eur J Heart Fail. 2020 Oct 5. doi: 10.1002/ejhf.2018.
    PubMed     Abstract available


  230. PUDIL R, Mueller C, Celutkiene J, Henriksen PA, et al
    The role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio-Oncology Study Group of the Heart Failure Association and Cardio-Oncology Council of the European Society of Cardiology.
    Eur J Heart Fail. 2020 Oct 2. doi: 10.1002/ejhf.2017.
    PubMed     Abstract available


  231. COATS AJS
    Pulmonary artery pressure monitoring, a reality for Europe?
    Eur J Heart Fail. 2020;22:1905-1906.
    PubMed    


  232. GUSTAFSSON F, Lund LH, Metra M
    If it ain't broken, don't fix it (but if it is, make sure you know): aortic valve interventions during left ventricular assist device implantation.
    Eur J Heart Fail. 2020;22:1888-1890.
    PubMed    


  233. PARIKH PB, Tsigkas G, Kalogeropoulos AP
    Transcatheter aortic valve replacement after heart failure hospitalization: too little, too late?
    Eur J Heart Fail. 2020;22:1875-1877.
    PubMed    


  234. ADAMO M, Metra M, Alfieri O
    Percutaneous valve repair of functional mitral regurgitation: aiming at optimal and durable results.
    Eur J Heart Fail. 2020;22:1849-1851.
    PubMed    


  235. GRIFFIN JM, Maurer MS
    Cardiac amyloidosis in severe aortic stenosis: we can find it but what should we do?
    Eur J Heart Fail. 2020;22:1863-1865.
    PubMed    


  236. SCHNEIDER M, Mascherbauer J
    Improvement in nutritional status - a determinant of successful transcatheter tricuspid valve repair?
    Eur J Heart Fail. 2020;22:1837-1839.
    PubMed    


    September 2020
  237. TEERLINK JR, Diaz R, Felker GM, McMurray JJV, et al
    Omecamtiv Mecarbil in Chronic Heart Failure with Reduced Ejection Fraction, GALACTIC-HF: Baseline Characteristics and Comparison with Contemporary Clinical Trials.
    Eur J Heart Fail. 2020 Sep 27. doi: 10.1002/ejhf.2015.
    PubMed     Abstract available


  238. JAARSMA T, Celutkiene J, Lopatin Y, Vugrak L, et al
    Learning together: insights from the first Heart Failure Association Patient Forum.
    Eur J Heart Fail. 2020 Sep 23. doi: 10.1002/ejhf.2013.
    PubMed    


  239. COATS AJ
    Figures of the Heart Failure Association: Prof Lars H. Lund, Chair of the HFA Committee on Registries, Surveys and Epidemiology and HFA Board Member (from 2016).
    Eur J Heart Fail. 2020 Sep 23. doi: 10.1002/ejhf.2014.
    PubMed    


  240. FENG S, Janwanishstaporn S, Teerlink J, Metra M, et al
    Association of Left Ventricular Ejection Fraction with Worsening Renal Function in Patients with Acute Heart Failure: Insights from the RELAX-AHF-2 Study.
    Eur J Heart Fail. 2020 Sep 22. doi: 10.1002/ejhf.2012.
    PubMed     Abstract available


  241. FERREIRA JP, Lam CSP, Anker SD, Mehra MR, et al
    Plasma D-dimer concentrations predicting stroke risk and rivaroxaban benefit in patients with heart failure and sinus rhythm: an analysis from the COMMANDER-HF trial.
    Eur J Heart Fail. 2020 Sep 21. doi: 10.1002/ejhf.2003.
    PubMed     Abstract available


  242. AHMAD A, Corban MT, Toya T, Verbrugge FH, et al
    Coronary microvascular dysfunction is associated with exertional haemodynamic abnormalities in patients with heart failure with preserved ejection fraction.
    Eur J Heart Fail. 2020 Sep 19. doi: 10.1002/ejhf.2010.
    PubMed     Abstract available


  243. MCMURRAY JJ
    EMPEROR-Reduced: Confirming sodium-glucose cotransporter 2 (SGLT2) inhibitors as an essential treatment for patients with heart failure with reduced ejection fraction.
    Eur J Heart Fail. 2020 Sep 18. doi: 10.1002/ejhf.2006.
    PubMed    


  244. IBRAHIM NE, Pina IL, Camacho A, Bapat D, et al
    Sex-Based Differences in Biomarkers, Health Status, and Reverse Cardiac Remodeling in Patients with Heart Failure with Reduced Ejection Fraction Treated with Sacubitril/Valsartan.
    Eur J Heart Fail. 2020 Sep 18. doi: 10.1002/ejhf.2005.
    PubMed    


  245. MONDRITZKI T, Mai TA, Vogel J, Pook E, et al
    Cardiac output improvement by pecavaptan: A novel dual-acting vasopressin V1a/V2 receptor antagonist in experimental heart failure.
    Eur J Heart Fail. 2020 Sep 18. doi: 10.1002/ejhf.2001.
    PubMed     Abstract available


  246. JAARSMA T, Hill L, Bayes-Genis A, Brunner La Rocca HP, et al
    Self-care of heart failure patients: practical management recommendations from the Heart Failure Association of the European Society of Cardiology.
    Eur J Heart Fail. 2020 Sep 18. doi: 10.1002/ejhf.2008.
    PubMed     Abstract available


  247. TAYLOR CJ, Ordonez-Mena JM, Jones NR, Roalfe AK, et al
    National Trends in Heart Failure Mortality in Men and Women, United Kingdom, 2000-2017.
    Eur J Heart Fail. 2020 Sep 6. doi: 10.1002/ejhf.1996.
    PubMed     Abstract available


  248. HILL L, Geller TP, Baruah R, Beattie JM, et al
    Integration of a palliative approach into heart failure care: a European Society of Cardiology Heart Failure Association position paper.
    Eur J Heart Fail. 2020 Sep 6. doi: 10.1002/ejhf.1994.
    PubMed     Abstract available


  249. GRAZETTE LP, Goldberger JJ
    Addressing the sudden cardiac death conundrum in heart failure with preserved ejection fraction: do we need a microscope or a telescope?
    Eur J Heart Fail. 2020 Sep 6. doi: 10.1002/ejhf.1995.
    PubMed    


  250. HASENFUSS G
    Is myosin activation a new treatment for heart failure?
    Eur J Heart Fail. 2020 Sep 2. doi: 10.1002/ejhf.1983.
    PubMed    


  251. TOMASONI D, Adamo M, Metra M
    September 2020 at a glance: focus on heart failure with preserved ejection fraction and medical therapy.
    Eur J Heart Fail. 2020;22:1493-1494.
    PubMed    


  252. KALOGEROPOULOS AP, Simitsis P, Skopicki HA
    Secrets of spironolactone: continuing insights from TOPCAT Americas.
    Eur J Heart Fail. 2020;22:1625-1627.
    PubMed    


  253. RITCHIE R, Galougahi KK, Figtree GA
    Targeting longevity genes in the battle against diabetic heart disease - is there a gene delivery fountain of youth?
    Eur J Heart Fail. 2020;22:1582-1585.
    PubMed    


  254. BISTOLA V, Polyzogopoulou E, Parissis J
    A novel strategy for the management of lung congestion: targeting TRPV4 channel, the 'gate keeper' of pulmonary capillary permeability.
    Eur J Heart Fail. 2020;22:1646-1648.
    PubMed    


  255. ZIAEIAN B, Butler J, Fonarow GC
    With great power comes great... reliability.
    Eur J Heart Fail. 2020;22:1708-1710.
    PubMed    


    August 2020
  256. SRIVASTAVA A, Heywood JT
    Replacing Art with Numbers: Decongesting Congestive Heart Failure.
    Eur J Heart Fail. 2020 Aug 27. doi: 10.1002/ejhf.1980.
    PubMed    


  257. MCNAUGHTON CD, Collins SP, Testani JM
    Accelerated decline in renal function after hospitalization for acute heart failure: An opportunity to intervene, or a sign of the inevitable?
    Eur J Heart Fail. 2020 Aug 25. doi: 10.1002/ejhf.1992.
    PubMed    


  258. SELVARAJ S, Claggett BL, Pfeffer MA, Desai AS, et al
    Serum Uric Acid, Influence of Sacubitril/Valsartan, and Cardiovascular Outcomes in Heart Failure with Preserved Ejection Fraction: PARAGON-HF.
    Eur J Heart Fail. 2020 Aug 25. doi: 10.1002/ejhf.1984.
    PubMed     Abstract available


  259. REY JR, Caro-Codon J, Rosillo SO, Iniesta AM, et al
    Heart Failure In Covid-19 Patients: Prevalence, Incidence And Prognostic Implications.
    Eur J Heart Fail. 2020 Aug 24. doi: 10.1002/ejhf.1990.
    PubMed     Abstract available


  260. VERBRUGGE FH, Damman K
    Spironolactone: Diuretic or Disease-modifying Drug in Heart Failure with Preserved Ejection Fraction?
    Eur J Heart Fail. 2020 Aug 19. doi: 10.1002/ejhf.1979.
    PubMed    


  261. CANNATA A, Bromage DI, Rind IA, Gregorio C, et al
    Temporal trends in decompensated heart failure and outcomes during COVID-19: A multisite report from heart failure referral centres in London.
    Eur J Heart Fail. 2020 Aug 18. doi: 10.1002/ejhf.1986.
    PubMed     Abstract available


  262. PIEK A, Suthahar N, Voors AA, de Boer RA, et al
    A combined bioinformatics, experimental and clinical approach to identify novel cardiac specific heart failure biomarkers: Is Dickkopf-3 (DKK3) a possible candidate?
    Eur J Heart Fail. 2020 Aug 18. doi: 10.1002/ejhf.1988.
    PubMed     Abstract available


  263. MCEWAN P, Darlington O, McMurray JJV, Jhund PS, et al
    Cost-effectiveness of dapagliflozin as a treatment for heart failure with reduced ejection fraction: a multinational health-economic analysis of DAPA-HF.
    Eur J Heart Fail. 2020 Aug 4. doi: 10.1002/ejhf.1978.
    PubMed     Abstract available


  264. AIMO A, Georgiopoulos G, Senni M, Emdin M, et al
    Searching for diagnostic biomarkers of heart failure with preserved ejection fraction: methodological issues.
    Eur J Heart Fail. 2020 Aug 4. doi: 10.1002/ejhf.1977.
    PubMed    


  265. VADUGANATHAN M, McMurray JJV, Solomon SD
    Angiotensin Receptor-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction: Lessons from PARAGON-HF.
    Eur J Heart Fail. 2020 Aug 2. doi: 10.1002/ejhf.1976.
    PubMed    


  266. KRESOJA KP, Lauten A, Orban M, Rommel KP, et al
    Transcatheter Tricuspid Valve Repair in the Setting of Heart Failure with Preserved or Reduced Left Ventricular Ejection Fraction.
    Eur J Heart Fail. 2020 Aug 2. doi: 10.1002/ejhf.1975.
    PubMed     Abstract available


  267. HOWLETT JG
    The time has finally come to prioritize drug initiation before dose titration for patients with heart failure and reduced ejection fraction.
    Eur J Heart Fail. 2020;22:1483-1485.
    PubMed    


  268. MONTGOMERY RA, Tang WHW
    A means to an end: the promise of tracking natriuresis with diuretic therapy.
    Eur J Heart Fail. 2020;22:1448-1450.
    PubMed    


    July 2020
  269. KRISTENSEN SL, Castagno D, Shen L, Jhund P, et al
    Prevalence and incidence of intraventricular conduction delays and outcomes in patients with heart failure and reduced ejection fraction: Insights from PARADIGM-HF and ATMOSPHERE.
    Eur J Heart Fail. 2020 Jul 28. doi: 10.1002/ejhf.1972.
    PubMed     Abstract available


  270. VADUGANATHAN M, Pareek M, Kristensen AMD, Biering-Sorensen T, et al
    Prevention of heart failure events with intensive versus standard blood pressure lowering across the spectrum of kidney function and albuminuria: a SPRINT substudy.
    Eur J Heart Fail. 2020 Jul 21. doi: 10.1002/ejhf.1971.
    PubMed     Abstract available


  271. VAN VELDHUISEN DJ, van Woerden G, Gorter TM, van Empel VPM, et al
    Ventricular Tachyarrhythmia Detection by Implantable Loop Recording in Patients with Heart Failure and Preserved Ejection Fraction: The VIP-HF study.
    Eur J Heart Fail. 2020 Jul 19. doi: 10.1002/ejhf.1970.
    PubMed     Abstract available


  272. MORTARA A, Margonato D
    Proactive management of heart failure by digital health: is monitoring of invasive pulmonary artery pressure the Holy Grail?
    Eur J Heart Fail. 2020 Jul 15. doi: 10.1002/ejhf.1966.
    PubMed    


  273. ISRAR MZ, Salzano A, Yazaki Y, Voors AA, et al
    Implications of serial measurements of natriuretic peptides in heart failure: insights from BIOSTAT-CHF.
    Eur J Heart Fail. 2020 Jul 14. doi: 10.1002/ejhf.1951.
    PubMed    


  274. QUARTA G, Gori M, Iorio A, D'Elia E, et al
    Cardiovascular magnetic resonance in heart failure with preserved ejection fraction: myocyte, interstitium, microvascular, and metabolic abnormalities.
    Eur J Heart Fail. 2020 Jul 12. doi: 10.1002/ejhf.1961.
    PubMed     Abstract available


  275. CELUTKIENE J, Pudil R, Lopez-Fernandez T, Grapsa J, et al
    The role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a Position statement on behalf of the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio-Oncology Council of
    Eur J Heart Fail. 2020 Jul 4. doi: 10.1002/ejhf.1957.
    PubMed     Abstract available


  276. RAO VN, Fudim M, Mentz RJ, Michos ED, et al
    Regional Adiposity and Heart Failure with Preserved Ejection Fraction.
    Eur J Heart Fail. 2020 Jul 3. doi: 10.1002/ejhf.1956.
    PubMed     Abstract available


  277. BASIC C, Rosengren A, Alehagen U, Dahlstrom U, et al
    Young patients with heart failure - clinical characteristics and outcomes. Data from the Swedish Heart Failure, National Patient, Population and Cause of Death Registers.
    Eur J Heart Fail. 2020 Jul 2. doi: 10.1002/ejhf.1952.
    PubMed     Abstract available


  278. SEFEROVIC PM, Fragasso G, Petrie M, Mullens W, et al
    Sodium glucose co-transporter-2 inhibitors in heart failure: beyond glycaemic control. The Position Paper of the Heart Failure Association of the European Society of Cardiology.
    Eur J Heart Fail. 2020 Jul 2. doi: 10.1002/ejhf.1954.
    PubMed     Abstract available


  279. AMBROSY AP, Fitzpatrick JK, Fudim M
    Hospitalizations for heart failure during the COVID-19 pandemic: making sense of the known knowns, known unknowns, and unknown unknowns.
    Eur J Heart Fail. 2020 Jul 2. doi: 10.1002/ejhf.1955.
    PubMed    



  280. Corrigendum to 'Sex- and age-related differences in the management and outcomes of chronic heart failure: an analysis of patients from the ESC HFA EORP Heart Failure Long-Term Registry' [Eur J Heart Fail 2020;22:92-102].
    Eur J Heart Fail. 2020;22:1287.
    PubMed    



  281. Corrigendum to 'Association between beta-blocker use and mortality/morbidity in older patients with heart failure with reduced ejection fraction. A propensity score-matched analysis from the Swedish Heart Failure Registry' [Eur J Heart Fail 2020;22:10
    Eur J Heart Fail. 2020;22:1287.
    PubMed    



  282. Corrigendum to 'Imaging in patients with suspected acute heart failure: timeline approach position statement on behalf of the Heart Failure Association of the European Society of Cardiology' [Eur J Heart Fail 2020;22:181-195].
    Eur J Heart Fail. 2020;22:1287.
    PubMed    


  283. EKSTROM K, Raisanen-Sokolowski A, Lehtonen J, Kupari M, et al
    Long-term outcome and its predictors in giant cell myocarditis. Letter regarding the article 'Long-term outcome and its predictors in giant cell myocarditis'.
    Eur J Heart Fail. 2020;22:1283-1284.
    PubMed    


  284. SEFEROVIC PM, Asanin M, Polovina M
    Practice makes perfect: improved long-term survival in non-ischaemic dilated cardiomyopathy with contemporary treatment.
    Eur J Heart Fail. 2020;22:1122-1124.
    PubMed    


  285. GORTER TM, van Veldhuisen DJ, Dickinson MG
    Right-sided cardiac disease: no longer the 'dark side of the heart'.
    Eur J Heart Fail. 2020;22:1226-1229.
    PubMed    


  286. INCIARDI RM, Rossi A
    Mitral regurgitation, edge-to-edge valve repair and the left atrium: one step beyond the left ventricle?
    Eur J Heart Fail. 2020;22:1211-1213.
    PubMed    


  287. SEFEROVIC PM, Polovina MM
    A new perspective of an old tool: an everlasting benefit of the electrocardiogram in dilated cardiomyopathy.
    Eur J Heart Fail. 2020;22:1108-1110.
    PubMed    


  288. MICHEL L, Rassaf T, Totzeck M
    Evaluating biomarkers as predictors of cancer therapy cardiotoxicity: all you need is a meta-analysis? Reply.
    Eur J Heart Fail. 2020;22:1285-1286.
    PubMed    


  289. AIMO A, Fabiani I, Emdin M
    Evaluating biomarkers as predictors of cancer therapy cardiotoxicity: all you need is a meta-analysis?. Letter regarding the article 'Troponins and brain natriuretic peptides for the prediction of cardiotoxicity in cancer patients: a meta-analysis.'
    Eur J Heart Fail. 2020;22:1284-1285.
    PubMed    


  290. TER MAATEN JM, Said F, Maass AH
    Factors predicting recovery of left ventricular dysfunction in non-ischaemic cardiomyopathy.
    Eur J Heart Fail. 2020;22:1171-1173.
    PubMed    


  291. ZWEERINK A, Allaart CP, Burri H
    Shifting diastolic filling from right to left in non-obstructive hypertrophic cardiomyopathy: exploring new indications for biventricular pacing.
    Eur J Heart Fail. 2020;22:1273-1275.
    PubMed    


    June 2020
  292. YAMANAKA S, Sakata Y, Nochioka K, Miura M, et al
    Prognostic impacts of dynamic cardiac structural changes in heart failure patients with preserved left ventricular ejection fraction.
    Eur J Heart Fail. 2020 Jun 27. doi: 10.1002/ejhf.1945.
    PubMed     Abstract available


  293. HENKENS MTHM, Remmelzwaal S, Robinson EL, van Ballegooijen AJ, et al
    Risk of bias in studies investigating novel diagnostic biomarkers for Heart Failure with Preserved Ejection Fraction. A systematic review.
    Eur J Heart Fail. 2020 Jun 27. doi: 10.1002/ejhf.1944.
    PubMed     Abstract available


  294. MULDER BA, van Veldhuisen DJ, Rienstra M
    What should the C ("Congestive heart failure") represent in the CHA2 DS2 -VASc score?
    Eur J Heart Fail. 2020 Jun 27. doi: 10.1002/ejhf.1946.
    PubMed    


  295. ANGERMANN CE, Assmus B, Anker SD, Asselbergs FW, et al
    Pulmonary artery pressure-guided therapy in ambulatory patients with symptomatic heart failure: the CardioMEMS European Monitoring Study for Heart Failure (MEMS-HF).
    Eur J Heart Fail. 2020 Jun 27. doi: 10.1002/ejhf.1943.
    PubMed     Abstract available


  296. OUWERKERK W, Teng TK, Tromp J, Tay WT, et al
    Effects of combined renin-angiotensin-aldosterone system inhibitor and beta-blocker treatment on outcomes in heart failure with reduced ejection fraction: insights from BIOSTAT-CHF and ASIAN-HF registries.
    Eur J Heart Fail. 2020 Jun 25. doi: 10.1002/ejhf.1869.
    PubMed     Abstract available


  297. BARTKO PE, Goliasch G
    Tricuspid regurgitation secondary to heart failure: more pieces to solve the puzzle.
    Eur J Heart Fail. 2020 Jun 22. doi: 10.1002/ejhf.1941.
    PubMed    


  298. ANGELINI F, Bocchino PP, Frea S, De Ferrari GM, et al
    Does end-organ dysfunction precede or follow cardiogenic shock in acute decompensated heart failure? The two-faced Janus.
    Eur J Heart Fail. 2020 Jun 22. doi: 10.1002/ejhf.1940.
    PubMed    


  299. DE FILIPPO O, D'Ascenzo F, De Ferrari GM
    Heart failure related hospitalisation and management during COVID-19 pandemic: are we ready to reflect? - REPLY.
    Eur J Heart Fail. 2020 Jun 21. doi: 10.1002/ejhf.1939.
    PubMed    


  300. VOORS AA, Tamby JF, Cleland JG, Koren M, et al
    Effects of danicamtiv, a novel cardiac myosin activator, in heart failure with reduced ejection fraction: experimental data and clinical results from a phase 2a trial.
    Eur J Heart Fail. 2020 Jun 19. doi: 10.1002/ejhf.1933.
    PubMed     Abstract available


  301. GOETZE JP, Balling L, Deis T, Struck J, et al
    Bioactive adrenomedullin in plasma is associated to biventricular filling pressures in patients with advanced heart failure.
    Eur J Heart Fail. 2020 Jun 18. doi: 10.1002/ejhf.1937.
    PubMed    


  302. ZYMLINSKI R, Ponikowski P, Biegus J
    Looking at the heart failure through the prism of liver dysfunction.
    Eur J Heart Fail. 2020 Jun 13. doi: 10.1002/ejhf.1932.
    PubMed    


  303. AMBROSY AP, Chioncel O
    Improving Physical Activity and Exercise Capacity in Heart Failure Taking the First Step is Always the Hardest.
    Eur J Heart Fail. 2020 Jun 13. doi: 10.1002/ejhf.1934.
    PubMed    


  304. FARMAKIS D, Butler J, Filippatos G
    Sodium-glucose co-transporter-2 inhibitors: "A Tale of Two Sisters", diabetes and heart failure.
    Eur J Heart Fail. 2020 Jun 13. doi: 10.1002/ejhf.1935.
    PubMed    


  305. LYRA V, Parissis J, Kallergi M, Rizos E, et al
    (18) F-FDG PET/CT brain glucose metabolism as a marker of different types of depression comorbidity in chronic heart failure patients with impaired systolic function.
    Eur J Heart Fail. 2020 Jun 12. doi: 10.1002/ejhf.1866.
    PubMed     Abstract available


  306. NAZIR T
    Heart failure related hospitalisation and management during COVID-19 pandemic: are we ready to reflect?
    Eur J Heart Fail. 2020 Jun 10. doi: 10.1002/ejhf.1931.
    PubMed    


  307. FARMAKIS D, Mehra MR, Parissis J, Filippatos G, et al
    Heart failure in the course of a pandemic.
    Eur J Heart Fail. 2020 Jun 7. doi: 10.1002/ejhf.1929.
    PubMed    


  308. TARTIERE JM, Solal AC, Roubille F, Girerd N, et al
    Response to the letter "All rise! Orthostatic Hypotension in Heart Failure".
    Eur J Heart Fail. 2020 Jun 5. doi: 10.1002/ejhf.1927.
    PubMed    


  309. MATSUE Y, Kamiya K, Saito H, Saito K, et al
    Prevalence and prognostic impact of the coexistence of multiple frailty domains in elderly patients with heart failure: The FRAGILE-HF cohort study.
    Eur J Heart Fail. 2020 Jun 5. doi: 10.1002/ejhf.1926.
    PubMed     Abstract available


  310. GROENEWEGEN A, Rutten FH, Mosterd A, Hoes AW, et al
    Epidemiology of heart failure.
    Eur J Heart Fail. 2020 Jun 1. doi: 10.1002/ejhf.1858.
    PubMed     Abstract available


  311. BROMAGE DI, Cannata A, Rind IA, Gregorio C, et al
    The impact of COVID-19 on heart failure hospitalization and management: report from a Heart Failure Unit in London during the peak of the pandemic.
    Eur J Heart Fail. 2020 Jun 1. doi: 10.1002/ejhf.1925.
    PubMed     Abstract available



  312. Erratum to 'New-onset heart failure in the STOP-HF programme. Natriuretic peptide defines and tracks risk and enables earlier diagnosis of heart failure' [Eur J Heart Fail 2020;22:378-380].
    Eur J Heart Fail. 2020;22:1056.
    PubMed    


  313. DE BROUWER R, van Veldhuisen DJ, de Boer RA
    Surviving the first COVID-19 wave and learning lessons for the second.
    Eur J Heart Fail. 2020;22:975-977.
    PubMed    


  314. XANTHOPOULOS A, Triposkiadis F, Starling RC
    Care for patients with ventricular assist devices and suspected COVID-19 infection.
    Eur J Heart Fail. 2020;22:937-940.
    PubMed    


  315. VAN LINTHOUT S, Klingel K, Tschope C
    SARS-CoV-2-related myocarditis-like syndromes Shakespeare's question: what's in a name?
    Eur J Heart Fail. 2020;22:922-925.
    PubMed    


  316. ADAMO M, Lombardi CM, Metra M
    June 2020 at a glance: focus on COVID-19, quality of life and comorbidities.
    Eur J Heart Fail. 2020;22:917-918.
    PubMed    


  317. BEAN DM, Kraljevic Z, Searle T, Bendayan R, et al
    Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers are not associated with severe COVID-19 infection in a multi-site UK acute hospital trust.
    Eur J Heart Fail. 2020;22:967-974.
    PubMed     Abstract available


  318. FARMAKIS D, Keramida K, Filippatos G
    Cardio-oncology services during the COVID-19 pandemic: practical considerations and challenges.
    Eur J Heart Fail. 2020;22:929-932.
    PubMed    


  319. BEN GAL T, Ben Avraham B, Abu-Hazira M, Frigerio M, et al
    The consequences of the COVID-19 pandemic for self-care in patients supported with a left ventricular assist device.
    Eur J Heart Fail. 2020;22:933-936.
    PubMed    


  320. KLEIN P, Anker SD, Wechsler A, Kelle S, et al
    Left ventricular volume reduction and reshape - 'Re-STICHING' the field. Reply.
    Eur J Heart Fail. 2020;22:1053-1054.
    PubMed    


  321. FERREIRA JP
    Health-related quality of life scores: ending the minimum 5-point difference as the clinically meaningful threshold.
    Eur J Heart Fail. 2020;22:1006-1008.
    PubMed    


  322. BONIOS MJ, Kogerakis N, Adamopoulos SN
    Left ventricular volume reduction and reshape - 'Re-STICHING' the field. Letter regarding the article 'Less invasive ventricular reconstruction for ischaemic heart failure'.
    Eur J Heart Fail. 2020;22:1053.
    PubMed    


    May 2020
  323. MULLENS W, Sharif F, Dupont M, Rothman AMK, et al
    Digital health care solution for proactive heart failure management with the Cordella Heart Failure System: results of the SIRONA first-in-human study.
    Eur J Heart Fail. 2020 May 31. doi: 10.1002/ejhf.1870.
    PubMed     Abstract available


  324. KALOGEROPOULOS AP, Thankachen J, Butler J, Fang JC, et al
    Diuretic and Renal Effects of Spironolactone and Heart Failure Hospitalizations: A TOPCAT Americas Analysis.
    Eur J Heart Fail. 2020 May 29. doi: 10.1002/ejhf.1917.
    PubMed     Abstract available


  325. CHIONCEL O, Parissis J, Mebazaa A, Thiele H, et al
    Epidemiology, Pathophysiology and Contemporary Management of Cardiogenic Shock - A position statement from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC).
    Eur J Heart Fail. 2020 May 29. doi: 10.1002/ejhf.1922.
    PubMed     Abstract available


  326. COX ZL, Lai P, Lindenfeld J
    Deceases in Acute Heart Failure Hospitalizations during COVID-19.
    Eur J Heart Fail. 2020 May 29. doi: 10.1002/ejhf.1921.
    PubMed    


  327. PIEPOLI MF, Ponikowski PP, Volterrani M, Francis DP, et al
    Do Cheyne and Stokes have an important message for modern-day patients with heart failure? Yes they do.
    Eur J Heart Fail. 2020 May 29. doi: 10.1002/ejhf.1923.
    PubMed    


  328. SBOLLI M, Fiuzat M, Cani D, O'Connor CM, et al
    Depression and heart failure: the lonely comorbidity.
    Eur J Heart Fail. 2020 May 29. doi: 10.1002/ejhf.1865.
    PubMed     Abstract available


  329. EDELMANN F, Jaarsma T, Comin-Colet J, Schorr J, et al
    Rationale and Study Design of OUTSTEP-HF: A Randomized Controlled Study to Assess the Effect of Sacubitril/Valsartan and Enalapril on Physical Activity measured by Accelerometry in Patients with Heart Failure with Reduced Ejection Fraction.
    Eur J Heart Fail. 2020 May 28. doi: 10.1002/ejhf.1919.
    PubMed     Abstract available


  330. BAJAJ NS, Vaduganathan M
    Using antimatter to uncover what matters: metformin effects on myocardial efficiency in heart failure.
    Eur J Heart Fail. 2020 May 28. doi: 10.1002/ejhf.1856.
    PubMed    


  331. LYON AR, Dent S, Stanway S, Earl H, et al
    Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a Position Statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Soci
    Eur J Heart Fail. 2020 May 28. doi: 10.1002/ejhf.1920.
    PubMed     Abstract available


  332. ZHANG Y, Stewart Coats AJ, Zheng Z, Adamo M, et al
    Management of Heart Failure Patients with COVID-19. A Joint Position Paper of the Chinese Heart Failure Association & National Heart Failure Committee and the Heart Failure Association of the European Society of Cardiology.
    Eur J Heart Fail. 2020 May 28. doi: 10.1002/ejhf.1915.
    PubMed     Abstract available


  333. SALZANO A, D'Assante R, Stagnaro FM, Valente V, et al
    Heart failure management during COVID-19 outbreak in Italy. Telemedicine experience from a heart failure university tertiary referral centre.
    Eur J Heart Fail. 2020 May 28. doi: 10.1002/ejhf.1911.
    PubMed    


  334. VELAGALETI RS, Larson MG, Enserro D, Song RJ, et al
    Clinical Course after a First Episode of Heart Failure: Insights from the Framingham Heart Study.
    Eur J Heart Fail. 2020 May 28. doi: 10.1002/ejhf.1918.
    PubMed     Abstract available


  335. FUDIM M, Soloveva A
    All rise! Orthostatic Hypotension in Heart Failure.
    Eur J Heart Fail. 2020 May 27. doi: 10.1002/ejhf.1904.
    PubMed    


  336. FARMAKIS D, Thodi M, Elpidoforou M, Filippatos G, et al
    Assessing frailty in heart failure.
    Eur J Heart Fail. 2020 May 27. doi: 10.1002/ejhf.1905.
    PubMed    


  337. REDDY YNV, Borlaug BA
    New Insights into the Role of Left Atrial Function During Exercise in Heart Failure.
    Eur J Heart Fail. 2020 May 27. doi: 10.1002/ejhf.1903.
    PubMed    


  338. FERREIRA JP, Rossello X, Pocock SJ, Rossignol P, et al
    Spironolactone dose in Heart Failure with Preserved Ejection Fraction: findings from TOPCAT.
    Eur J Heart Fail. 2020 May 25. doi: 10.1002/ejhf.1909.
    PubMed     Abstract available


  339. SLIWA K, Bauersachs J, Coats AJ
    The European Society of Cardiology Heart Failure Association Study Group on Peripartum Cardiomyopathy - what has been achieved in 10 years.
    Eur J Heart Fail. 2020 May 25. doi: 10.1002/ejhf.1912.
    PubMed    


  340. SANTIAGO-VACAS E, Lupon J, Gavidia-Bovadilla G, Gual-Capllonch F, et al
    Pulmonary hypertension and right ventricular dysfunction in heart failure: prognosis and 15-year prospective longitudinal trajectories in survivors.
    Eur J Heart Fail. 2020 May 25. doi: 10.1002/ejhf.1862.
    PubMed     Abstract available


  341. ROSSIGNOL P, Williams B, Mayo MR, Warren S, et al
    Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): results in the pre-specified subgroup with heart failure.
    Eur J Heart Fail. 2020 May 25. doi: 10.1002/ejhf.1860.
    PubMed     Abstract available


  342. PACKER M, Lam CSP, Lund LH, Maurer MS, et al
    Characterization of the Inflammatory-Metabolic Phenotype of Heart Failure and a Preserved Ejection Fraction: a Hypothesis to Explain Influence of Sex on the Evolution and Potential Treatment of the Disease.
    Eur J Heart Fail. 2020 May 22. doi: 10.1002/ejhf.1902.
    PubMed     Abstract available


  343. GIANNONI A, Borrelli C, Mirizzi G, Richerson GB, et al
    Benefit of buspirone on chemoreflex and central apnoeas in heart failure: a randomized controlled crossover trial.
    Eur J Heart Fail. 2020 May 22. doi: 10.1002/ejhf.1854.
    PubMed     Abstract available


  344. CHEN S, Redfors B, Crowley A, Ben-Yehuda O, et al
    Impact of recent heart failure hospitalization on clinical outcomes in patients with severe aortic stenosis undergoing transcatheter aortic valve replacement: an analysis from the PARTNER 2 trial and registries.
    Eur J Heart Fail. 2020 May 22. doi: 10.1002/ejhf.1841.
    PubMed     Abstract available


  345. GALINIER M, Roubille F, Berdague P, Brierre G, et al
    Telemonitoring versus standard of care in heart failure: a randomised multicentre trial.
    Eur J Heart Fail. 2020 May 21. doi: 10.1002/ejhf.1906.
    PubMed     Abstract available


  346. GUAZZI M, Moroni A
    The Dilemma of Renin Angiotensin System Blockers in Coronavirus Disease (Covid-19): Insights on the Lung Fluid Handling and Gas Exchange in Heart Failure Patients.
    Eur J Heart Fail. 2020 May 21. doi: 10.1002/ejhf.1910.
    PubMed    


  347. KAPELIOS CJ, Lund LH
    Do chronic heart failure patients receive optimal decongestive interventions in a real-life setting?: Reply.
    Eur J Heart Fail. 2020 May 20. doi: 10.1002/ejhf.1859.
    PubMed    


  348. PACKER M, Metra M
    Guideline-directed medical therapy for heart failure does not exist: a non-judgmental framework for describing the level of adherence to evidence-based drug treatments for patients with a reduced ejection fraction.
    Eur J Heart Fail. 2020 May 20. doi: 10.1002/ejhf.1857.
    PubMed     Abstract available


  349. D'AMARIO D, Restivo A, Canonico F, Rodolico D, et al
    Experience of Remote Cardiac Care during Covid-19 Pandemic: the V-LAP device in advanced heart failure.
    Eur J Heart Fail. 2020 May 19. doi: 10.1002/ejhf.1900.
    PubMed    


  350. TOMASONI D, Italia L, Adamo M, Inciardi RM, et al
    COVID 19 and heart failure: from infection to inflammation and angiotensin II stimulation. Searching for evidence from a new disease.
    Eur J Heart Fail. 2020 May 15. doi: 10.1002/ejhf.1871.
    PubMed     Abstract available


  351. SUZUKI K, Claggett B, Minamisawa M, Packer M, et al
    Liver function and prognosis, and influence of sacubitril/valsartan in patients with heart failure with reduced ejection fraction.
    Eur J Heart Fail. 2020 May 14. doi: 10.1002/ejhf.1853.
    PubMed     Abstract available


  352. VON HAEHLING S, Arzt M, Doehner W, Edelmann F, et al
    Improving exercise capacity and quality of life using non-invasive heart failure treatments: evidence from clinical trials.
    Eur J Heart Fail. 2020 May 11. doi: 10.1002/ejhf.1838.
    PubMed     Abstract available


  353. COATS AJS
    Exergaming for heart failure: an idea so good it just ought to work.
    Eur J Heart Fail. 2020 May 11. doi: 10.1002/ejhf.1842.
    PubMed    


  354. GLENISTER RT, McCullough PA
    Analysing risk in heart failure: a Kalium check.
    Eur J Heart Fail. 2020 May 10. doi: 10.1002/ejhf.1855.
    PubMed    


  355. CLELAND JG, Clark RA, Pellicori P, Inglis SC, et al
    Caring for people with heart failure and many other medical problems through and beyond the COVID-19 pandemic; the advantages of universal-access to home telemonitoring.
    Eur J Heart Fail. 2020 May 9. doi: 10.1002/ejhf.1864.
    PubMed    


  356. OUWERKERK W, Tromp J, Jin X, Jaufeerally F, et al
    Heart failure with preserved ejection fraction diagnostic scores in an Asian population.
    Eur J Heart Fail. 2020 May 6. doi: 10.1002/ejhf.1851.
    PubMed    


  357. KHAN MS, Butler J, Greene SJ
    The real world of de novo heart failure: the next frontier for heart failure clinical trials?
    Eur J Heart Fail. 2020 May 6. doi: 10.1002/ejhf.1844.
    PubMed    


  358. CHIONCEL O, Collins SP, Butler J
    Istaroxime in acute heart failure: the holy grail is at HORIZON?
    Eur J Heart Fail. 2020 May 6. doi: 10.1002/ejhf.1843.
    PubMed    


  359. MESSIKA-ZEITOUN D, Verta P, Gregson J, Pocock SJ, et al
    Impact of tricuspid regurgitation on survival in patients with heart failure: a large electronic health record patient-level database analysis.
    Eur J Heart Fail. 2020 May 5. doi: 10.1002/ejhf.1830.
    PubMed     Abstract available


  360. ADAMO M, Lombardi CM, Metra M
    May 2020 at a glance: ischaemic heart failure and sex-related differences.
    Eur J Heart Fail. 2020;22:761-762.
    PubMed    


  361. TAVAZZI G, Pellegrini C, Maurelli M, Belliato M, et al
    Myocardial localization of coronavirus in COVID-19 cardiogenic shock.
    Eur J Heart Fail. 2020;22:911-915.
    PubMed     Abstract available


  362. HAWKINS NM, Osmanska J, Petrie MC
    Implantable cardioverter-defibrillators and survival - the fine line between efficacy concerns and ageism.
    Eur J Heart Fail. 2020;22:868-870.
    PubMed    


  363. BOLLI R, Kahlon A
    Time to end the war on cell therapy.
    Eur J Heart Fail. 2020;22:893-897.
    PubMed    


  364. FURTADO RHM, Bergmark B
    Ejection fraction versus B-type natriuretic peptide for revascularization strategy in left main disease: two sides of the same coin or a wooden nickel?
    Eur J Heart Fail. 2020;22:880-883.
    PubMed    


  365. CHATTERJEE NA, Levy WC
    Sudden cardiac death after myocardial infarction.
    Eur J Heart Fail. 2020;22:856-858.
    PubMed    


    April 2020
  366. CAUTELA J, Tartiere JM, Cohen-Solal A, Bellemain-Appaix A, et al
    Management of low blood pressure in ambulatory heart failure with reduced ejection fraction patients.
    Eur J Heart Fail. 2020 Apr 30. doi: 10.1002/ejhf.1835.
    PubMed     Abstract available


  367. DEWAN P, Jackson A, Jhund PS, Shen L, et al
    The prevalence and importance of frailty in heart failure with reduced ejection fraction - an analysis of PARADIGM-HF and ATMOSPHERE.
    Eur J Heart Fail. 2020 Apr 30. doi: 10.1002/ejhf.1832.
    PubMed     Abstract available


  368. ALMUFLEH A, Desai AS, Fay R, Ferreira JP, et al
    Correlation of laboratory haemoconcentration measures with filling pressures obtained via pulmonary arterial pressure sensors in ambulatory heart failure patients.
    Eur J Heart Fail. 2020 Apr 30. doi: 10.1002/ejhf.1848.
    PubMed     Abstract available


  369. AIMO A, Castiglione V, Lombardi CM
    Effects of vericiguat in heart failure with reduced ejection fraction: do not forget sST2.
    Eur J Heart Fail. 2020 Apr 30. doi: 10.1002/ejhf.1852.
    PubMed    


  370. ELHARRAM M, Ferreira JP, Sharma A
    The intersecting role of glycaemia and cardiac function in the development of heart failure among patients with type 2 diabetes mellitus after an acute coronary syndrome.
    Eur J Heart Fail. 2020 Apr 30. doi: 10.1002/ejhf.1845.
    PubMed    


  371. SUGIMOTO T, Barletta M, Bandera F, Generati G, et al
    Central role of left atrial dynamics in limiting exercise cardiac output increase and oxygen uptake in heart failure: insights by cardiopulmonary imaging.
    Eur J Heart Fail. 2020 Apr 30. doi: 10.1002/ejhf.1829.
    PubMed     Abstract available


  372. AIMO A, Barison A, Castiglione V, Emdin M, et al
    The unbearable underreporting of comorbidities in heart failure clinical trials.
    Eur J Heart Fail. 2020 Apr 29. doi: 10.1002/ejhf.1846.
    PubMed    


  373. SIMONAVICIUS J, Brunner-La Rocca HP
    Do chronic heart failure patients receive optimal decongestive interventions in a real-life setting?
    Eur J Heart Fail. 2020 Apr 29. doi: 10.1002/ejhf.1839.
    PubMed    


  374. HARJOLA VP, Parissis J, Bauersachs J, Brunner-La Rocca HP, et al
    Acute coronary syndromes and acute heart failure: a diagnostic dilemma and high-risk combination. A statement from the Acute Heart Failure Committee of the Heart Failure Association of the European Society of Cardiology.
    Eur J Heart Fail. 2020 Apr 29. doi: 10.1002/ejhf.1831.
    PubMed     Abstract available


  375. HENRI C, Mielniczuk L, O'Meara E
    Age and biomarkers in heart failure: challenging the current model to select patients for clinical trials.
    Eur J Heart Fail. 2020 Apr 16. doi: 10.1002/ejhf.1817.
    PubMed    


  376. JAARSMA T, Hill L, Stromberg A
    What is what? From a palliative care approach to specialized palliative care in heart failure management.
    Eur J Heart Fail. 2020 Apr 16. doi: 10.1002/ejhf.1823.
    PubMed    


  377. DAMMAN K, Ter Maaten JM, van der Meer P
    Urinary sodium evaluation: the missing target for diuretic treatment optimization in acute heart failure patients? Reply.
    Eur J Heart Fail. 2020 Apr 16. doi: 10.1002/ejhf.1825.
    PubMed    


  378. TROMBARA F, Apostolo A, Vignati C, Agostoni P, et al
    Why do left ventricular assist device recipients remain heart failure patients? Reply.
    Eur J Heart Fail. 2020 Apr 15. doi: 10.1002/ejhf.1824.
    PubMed    


  379. PARMA Z, Jasilek A, Greenlaw N, Ferrari R, et al
    Incident heart failure in outpatients with chronic coronary syndrome: results from the international prospective CLARIFY registry.
    Eur J Heart Fail. 2020 Apr 15. doi: 10.1002/ejhf.1827.
    PubMed     Abstract available


  380. TRIPOSKIADIS F, Xanthopoulos A, Butler J
    From PARADIGM to PARAGON Further Evidence Supporting Continuous Heart Failure Spectrum.
    Eur J Heart Fail. 2020 Apr 15. doi: 10.1002/ejhf.1837.
    PubMed    


  381. KHAN MS, Samman Tahhan A, Vaduganathan M, Greene SJ, et al
    Trends in prevalence of comorbidities in heart failure clinical trials.
    Eur J Heart Fail. 2020 Apr 15. doi: 10.1002/ejhf.1818.
    PubMed     Abstract available


  382. MALIK ME, Madelaire C, D'Souza M, Blanche P, et al
    Risk of heart failure in type 2 diabetes complicated by incident ischaemic heart disease and end-stage renal disease.
    Eur J Heart Fail. 2020 Apr 4. doi: 10.1002/ejhf.1819.
    PubMed     Abstract available


  383. SAMA IE, Woolley RJ, Nauta JF, Romaine SPR, et al
    A network analysis to identify pathophysiological pathways distinguishing ischaemic from non-ischaemic heart failure.
    Eur J Heart Fail. 2020 Apr 3. doi: 10.1002/ejhf.1811.
    PubMed     Abstract available


  384. ROSSIGNOL P, Lainscak M, Crespo-Leiro MG, Laroche C, et al
    Unravelling the interplay between hyperkalaemia, renin-angiotensin-aldosterone inhibitor use and clinical outcomes. Data from 9222 chronic heart failure patients of the ESC-HFA-EORP Heart Failure Long-Term Registry.
    Eur J Heart Fail. 2020 Apr 3. doi: 10.1002/ejhf.1793.
    PubMed     Abstract available


  385. VAN DER WAL HH, Beverborg NG, Ter Maaten JM, Vinke JSJ, et al
    Fibroblast growth factor 23 mediates the association between iron deficiency and mortality in worsening heart failure.
    Eur J Heart Fail. 2020 Apr 3. doi: 10.1002/ejhf.1801.
    PubMed    


  386. RUSSO D, Musumeci MB, Volpe M
    The neglected issue of cardiac amyloidosis in trials on heart failure with preserved ejection fraction in the elderly.
    Eur J Heart Fail. 2020 Apr 3. doi: 10.1002/ejhf.1766.
    PubMed    


  387. STIENEN S, Ferreira JP, Pitt B, Cleland JG, et al
    Eplerenone prevents an increase in serum carboxy-terminal propeptide of procollagen type I after myocardial infarction complicated by left ventricular dysfunction and/or heart failure.
    Eur J Heart Fail. 2020 Apr 3. doi: 10.1002/ejhf.1812.
    PubMed    


  388. BUTLER J, Khan MS, Mori C, Filippatos GS, et al
    Minimal clinically important difference in quality of life scores for patients with heart failure and reduced ejection fraction.
    Eur J Heart Fail. 2020 Apr 2. doi: 10.1002/ejhf.1810.
    PubMed     Abstract available


  389. KAPELIOS CJ, Laroche C, Crespo-Leiro MG, Anker SD, et al
    Association between loop diuretic dose changes and outcomes in chronic heart failure: observations from the ESC-EORP Heart Failure Long-Term Registry.
    Eur J Heart Fail. 2020 Apr 1. doi: 10.1002/ejhf.1796.
    PubMed     Abstract available


  390. DE DENUS S, Leclair G, Dube MP, St-Jean I, et al
    Spironolactone metabolite concentrations in decompensated heart failure: insights from the ATHENA-HF trial.
    Eur J Heart Fail. 2020 Apr 1. doi: 10.1002/ejhf.1802.
    PubMed     Abstract available


  391. GALLUZZO A, Bertaina M, Frea S
    Urinary sodium evaluation: the missing target for diuretic treatment optimization in acute heart failure patients?
    Eur J Heart Fail. 2020 Apr 1. doi: 10.1002/ejhf.1814.
    PubMed    


  392. METRA M, Lucioli P
    Corrigendum to 'Prevalence of heart failure and left ventricular dysfunction in China: the China Hypertension Survey, 2012-2015' [Eur J Heart Fail 2019;21:1329-1337].
    Eur J Heart Fail. 2020;22:759.
    PubMed    


  393. DE LUCA L, Savonitto S
    Composite trends of cardiogenic shock complicating acute myocardial infarction.
    Eur J Heart Fail. 2020;22:673-675.
    PubMed    


    March 2020
  394. POZZOLI M, Gonzalez-Costello J, Bayes-Genis A, Sinagra G, et al
    Prevalence of risk of thrombosis and of bleeding and antithrombotic treatment in patients with heart failure.
    Eur J Heart Fail. 2020 Mar 30. doi: 10.1002/ejhf.1789.
    PubMed    


  395. LOARDI C, Zanobini M
    Why do left ventricular assist device recipients remain heart failure patients?
    Eur J Heart Fail. 2020 Mar 30. doi: 10.1002/ejhf.1807.
    PubMed    


  396. DAVISON BA, Takagi K, Senger S, Koch G, et al
    Mega-trials in heart failure: effects of dilution in examination of new therapies.
    Eur J Heart Fail. 2020 Mar 30. doi: 10.1002/ejhf.1780.
    PubMed     Abstract available


  397. BUTT JH, Fosbol EL, Gerds TA, Andersson C, et al
    Readmission and death in patients admitted with new-onset versus worsening of chronic heart failure: insights from a nationwide cohort.
    Eur J Heart Fail. 2020 Mar 30. doi: 10.1002/ejhf.1800.
    PubMed     Abstract available


  398. STEWART GM, Johnson BD, Sprecher DL, Reddy YNV, et al
    Targeting pulmonary capillary permeability to reduce lung congestion in heart failure: a randomized, controlled pilot trial.
    Eur J Heart Fail. 2020 Mar 30. doi: 10.1002/ejhf.1809.
    PubMed     Abstract available


  399. BOUABDALLAOUI N, Rouleau J
    Evolving towards a more realistic approach to the importance of left ventricular ejection fraction and sex in heart failure and its therapy.
    Eur J Heart Fail. 2020 Mar 30. doi: 10.1002/ejhf.1805.
    PubMed    


  400. SUTHAHAR N, Meems LMG, Ho JE, de Boer RA, et al
    Sex-related differences in contemporary biomarkers for heart failure: a review.
    Eur J Heart Fail. 2020 Mar 27. doi: 10.1002/ejhf.1771.
    PubMed     Abstract available


  401. SHIN SH, Claggett B, Pfeffer MA, Skali H, et al
    Hyperglycaemia, ejection fraction and the risk of heart failure or cardiovascular death in patients with type 2 diabetes and a recent acute coronary syndrome.
    Eur J Heart Fail. 2020 Mar 25. doi: 10.1002/ejhf.1790.
    PubMed     Abstract available


  402. BHATT AS, Ambrosy AP, Dunning A, DeVore AD, et al
    The burden of non-cardiac comorbidities and association with clinical outcomes in an acute heart failure trial - insights from ASCEND-HF.
    Eur J Heart Fail. 2020 Mar 25. doi: 10.1002/ejhf.1795.
    PubMed     Abstract available


  403. KRAMER F, Voss S, Roessig L, Igl BW, et al
    Evaluation of high-sensitivity C-reactive protein and uric acid in vericiguat-treated patients with heart failure with reduced ejection fraction.
    Eur J Heart Fail. 2020 Mar 25. doi: 10.1002/ejhf.1787.
    PubMed     Abstract available


  404. MORDI IR, Ouwerkerk W, Anker SD, Cleland JG, et al
    Heart failure treatment up-titration and outcome and age: an analysis of BIOSTAT-CHF.
    Eur J Heart Fail. 2020 Mar 25. doi: 10.1002/ejhf.1799.
    PubMed     Abstract available


  405. SEFEROVIC PM, Piepoli MF, Lopatin Y, Jankowska E, et al
    Heart Failure Association of the European Society of Cardiology Quality of Care Centres Programme: design and accreditation document.
    Eur J Heart Fail. 2020 Mar 18. doi: 10.1002/ejhf.1784.
    PubMed     Abstract available


  406. SAHLOLLBEY N, Lee CKS, Shirin A, Joseph P, et al
    The impact of palliative care on clinical and patient-centred outcomes in patients with advanced heart failure: a systematic review of randomized controlled trials.
    Eur J Heart Fail. 2020 Mar 16. doi: 10.1002/ejhf.1783.
    PubMed     Abstract available


  407. MADAN S, Mehra MR
    Gut dysbiosis and heart failure: navigating the universe within.
    Eur J Heart Fail. 2020 Mar 13. doi: 10.1002/ejhf.1792.
    PubMed    


  408. JAARSMA T, Klompstra L, Ben Gal T, Ben Avraham B, et al
    Effects of exergaming on exercise capacity in patients with heart failure: results of an international multicentre randomized controlled trial.
    Eur J Heart Fail. 2020 Mar 13. doi: 10.1002/ejhf.1754.
    PubMed    


  409. ROSSIGNOL P, Zannad F
    Hypo- and hyperkalaemia in heart failure. Navigating between Scylla and Charybdis.
    Eur J Heart Fail. 2020 Mar 13. doi: 10.1002/ejhf.1791.
    PubMed    


  410. HIRSCH VG, Tongers J, Bode J, Berliner D, et al
    Cardiac iron concentration in relation to systemic iron status and disease severity in non-ischaemic heart failure with reduced ejection fraction.
    Eur J Heart Fail. 2020 Mar 10. doi: 10.1002/ejhf.1781.
    PubMed     Abstract available


  411. KHAN MS, Butler J, Greene SJ
    Patient-reported outcomes for heart failure with preserved ejection fraction: conducting quality studies on quality of life.
    Eur J Heart Fail. 2020 Mar 10. doi: 10.1002/ejhf.1762.
    PubMed    


  412. REDDY YNV, Rikhi A, Obokata M, Shah SJ, et al
    Quality of life in heart failure with preserved ejection fraction: importance of obesity, functional capacity, and physical inactivity.
    Eur J Heart Fail. 2020 Mar 9. doi: 10.1002/ejhf.1788.
    PubMed     Abstract available


  413. JANWANISHSTAPORN S, Feng S, Teerlink J, Metra M, et al
    Relationship between left ventricular ejection fraction and cardiovascular outcomes following hospitalization for heart failure: insights from the RELAX-AHF-2 trial.
    Eur J Heart Fail. 2020 Mar 5. doi: 10.1002/ejhf.1772.
    PubMed     Abstract available


  414. PIESKE B, Tschope C, de Boer RA, Fraser AG, et al
    How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC).
    Eur J Heart Fail. 2020 Mar 5. doi: 10.1002/ejhf.1741.
    PubMed     Abstract available


  415. COATS AJS
    Figures of the Heart Failure Association (HFA): Dr. Rudolf de Boer, HFA Board Member (2014-2020), Chair of the Basic Science Section (2016-2018), coordinator of the Study Group on Heart Failure with Preserved Ejection Fraction, and member of the HFA s
    Eur J Heart Fail. 2020 Mar 4. doi: 10.1002/ejhf.1779.
    PubMed    


  416. DE BUYZERE ML, Delanghe JR
    Fibroblast growth factor 23 and the quest for the Holy Grail in heart failure: will the Crusaders be forced to surrender?
    Eur J Heart Fail. 2020 Mar 4. doi: 10.1002/ejhf.1786.
    PubMed    


  417. SEFEROVIC PM, Jankowska E, Coats AJS, Maggioni AP, et al
    The Heart Failure Association Atlas: rationale, objectives, and methods.
    Eur J Heart Fail. 2020 Mar 3. doi: 10.1002/ejhf.1768.
    PubMed     Abstract available


  418. DEWAN P, Jackson A, Lam CSP, Pfeffer MA, et al
    Interactions between left ventricular ejection fraction, sex and effect of neurohumoral modulators in heart failure.
    Eur J Heart Fail. 2020 Mar 2. doi: 10.1002/ejhf.1776.
    PubMed    


  419. COATS AJS
    Vericiguat for heart failure and the VICTORIA trial - the dog that didn't bark?
    Eur J Heart Fail. 2020 Mar 1. doi: 10.1002/ejhf.1778.
    PubMed    


  420. ADAMO M, Lombardi CM, Metra M
    March 2020 at a glance: heart failure with preserved ejection fraction, left atrial myopathy, atrial fibrillation and cardiac amyloidosis.
    Eur J Heart Fail. 2020;22:389-390.
    PubMed    


  421. STEWART COATS AJ
    Validating the HFA-PEFF score - or how to define a disease?
    Eur J Heart Fail. 2020;22:428-431.
    PubMed    


  422. WESTIN O, Fosbol E, Gustafsson F
    Refining the role of carpal tunnel syndrome in cardiac amyloidosis.
    Eur J Heart Fail. 2020;22:516-518.
    PubMed    


  423. SHEN L, Jhund P, McMurray J
    Dyslipidaemia, a factor worthy of adjustment: reply.
    Eur J Heart Fail. 2020;22:564-565.
    PubMed    


  424. SKELIN M, Lucijanic M, Lucijanic J
    Dyslipidaemia, a factor worthy of adjustment.
    Eur J Heart Fail. 2020;22:564.
    PubMed    


    February 2020
  425. STOLFO D, Savarese G
    Sex-related differences in therapeutic response to mineralocorticoid receptor antagonists in heart failure: summarizing trial evidence.
    Eur J Heart Fail. 2020 Feb 26. doi: 10.1002/ejhf.1761.
    PubMed    


  426. KARASON K, Lund LH, Dalen M, Bjorklund E, et al
    Randomized trial of a left ventricular assist device as destination therapy versus guideline-directed medical therapy in patients with advanced heart failure. Rationale and design of the SWEdish evaluation of left Ventricular Assist Device (SweVAD) tr
    Eur J Heart Fail. 2020 Feb 26. doi: 10.1002/ejhf.1773.
    PubMed     Abstract available


  427. THOMPSON DR, Clark AM
    Heart failure disease management interventions: time for a reappraisal.
    Eur J Heart Fail. 2020 Feb 24. doi: 10.1002/ejhf.1777.
    PubMed    


  428. BEHNES M, Schupp T, Mashayekhi K, Akin I, et al
    'Off-pump' left ventricular reconstruction - A causal and less invasive surgical option for patients with advanced systolic heart failure?
    Eur J Heart Fail. 2020 Feb 22. doi: 10.1002/ejhf.1737.
    PubMed    


  429. DAMMAN K, Ter Maaten JM, Coster JE, Krikken JA, et al
    Clinical importance of urinary sodium excretion in acute heart failure.
    Eur J Heart Fail. 2020 Feb 22. doi: 10.1002/ejhf.1753.
    PubMed     Abstract available


  430. KRISTENSEN SL, McMurray JJV
    Diagnosing heart failure with preserved ejection fraction - what's the score?
    Eur J Heart Fail. 2020 Feb 22. doi: 10.1002/ejhf.1764.
    PubMed    


  431. ARMSTRONG PW, Pieske B, O'Connor CM
    Effects of vericiguat in heart failure with reduced ejection fraction: do not forget sST2. Reply.
    Eur J Heart Fail. 2020 Feb 21. doi: 10.1002/ejhf.1765.
    PubMed    


  432. COOPER LB, Benson L, Mentz RJ, Savarese G, et al
    Association between potassium level and outcomes in heart failure with reduced ejection fraction: a cohort study from the Swedish Heart Failure Registry.
    Eur J Heart Fail. 2020 Feb 20. doi: 10.1002/ejhf.1757.
    PubMed     Abstract available


  433. GROENEWEGEN A, Rutten FH
    Sodium-glucose co-transporter 2 inhibitors and acute heart failure.
    Eur J Heart Fail. 2020 Feb 18. doi: 10.1002/ejhf.1759.
    PubMed    


  434. REDDY YNV, Borlaug BA
    Hypertension and heart failure: insights from exercise stress testing.
    Eur J Heart Fail. 2020 Feb 18. doi: 10.1002/ejhf.1760.
    PubMed    


  435. NJOROGE JN, Teerlink JR
    Systolic time intervals in patients with heart failure: time to teach new dogs old tricks.
    Eur J Heart Fail. 2020 Feb 13. doi: 10.1002/ejhf.1725.
    PubMed    


  436. STOHR R, Brandenburg VM, Heine GH, Maeder MT, et al
    Limited role for fibroblast growth factor 23 in assessing prognosis in heart failure patients: data from the TIME-CHF trial.
    Eur J Heart Fail. 2020 Feb 5. doi: 10.1002/ejhf.1749.
    PubMed     Abstract available


  437. JONES NR, Roalfe AK, Adoki I, Taylor CJ, et al
    Survival rates in elderly patients with heart failure: reply.
    Eur J Heart Fail. 2020 Feb 5. doi: 10.1002/ejhf.1751.
    PubMed    


  438. ADAMO M, Lombardi CM, Metra M
    February 2020 at a glance: acute heart failure and cardio-oncology.
    Eur J Heart Fail. 2020;22:171-172.
    PubMed    


  439. GRODIN JL, Rao A, Zaha VG
    Myocardial dysfunction in breast cancer survivors: 'you can observe a lot by just watching'.
    Eur J Heart Fail. 2020;22:347-349.
    PubMed    


  440. MAGLIOCCA A, Omland T, Latini R
    Dipeptidyl peptidase 3, a biomarker in cardiogenic shock and hopefully much more.
    Eur J Heart Fail. 2020;22:300-302.
    PubMed    


  441. RAJU B, McCullough PA
    Circulating plasma dipeptidyl dipeptidase 3 and the prognosis of cardiogenic shock.
    Eur J Heart Fail. 2020;22:287-289.
    PubMed    


    January 2020
  442. BORIANI G, Imberti JF, Vitolo M
    Atrial fibrillation and remote monitoring through cardiac implantable electronic devices in heart failure patients.
    Eur J Heart Fail. 2020 Jan 23. doi: 10.1002/ejhf.1745.
    PubMed    


  443. CARUBELLI V, Zhang Y, Metra M, Lombardi C, et al
    Treatment with 24 hour istaroxime infusion in patients hospitalised for acute heart failure: a randomised, placebo-controlled trial.
    Eur J Heart Fail. 2020 Jan 23. doi: 10.1002/ejhf.1743.
    PubMed     Abstract available


  444. KALUZA J, Levitan EB, Michaelsson K, Wolk A, et al
    Anti-inflammatory diet and risk of heart failure: two prospective cohort studies.
    Eur J Heart Fail. 2020 Jan 23. doi: 10.1002/ejhf.1746.
    PubMed     Abstract available


  445. PUGLIESE NR, Mazzola M, Fabiani I, Gargani L, et al
    Haemodynamic and metabolic phenotyping of hypertensive patients with and without heart failure by combining cardiopulmonary and echocardiographic stress test.
    Eur J Heart Fail. 2020 Jan 16. doi: 10.1002/ejhf.1739.
    PubMed     Abstract available


  446. MAURER MS, Packer M
    Impaired systemic venous capacitance: the neglected mechanism in patients with heart failure and a preserved ejection fraction?
    Eur J Heart Fail. 2020 Jan 16. doi: 10.1002/ejhf.1702.
    PubMed    


  447. PELLICORI P, Ferreira JP, Mariottoni B, Brunner-La Rocca HP, et al
    Effects of spironolactone on serum markers of fibrosis in people at high risk of developing heart failure: rationale, design and baseline characteristics of a proof-of-concept, randomised, precision-medicine, prevention trial. The Heart OMics in AGing
    Eur J Heart Fail. 2020 Jan 16. doi: 10.1002/ejhf.1716.
    PubMed     Abstract available


  448. BUTLER J, Handelsman Y, Bakris G, Verma S, et al
    Use of sodium-glucose co-transporter-2 inhibitors in patients with and without type 2 diabetes: implications for incident and prevalent heart failure.
    Eur J Heart Fail. 2020 Jan 11. doi: 10.1002/ejhf.1708.
    PubMed     Abstract available


  449. JHUND PS
    The recurring problem of heart failure hospitalisations.
    Eur J Heart Fail. 2020 Jan 11. doi: 10.1002/ejhf.1721.
    PubMed    


  450. REDDY YNV, Borlaug BA
    Left atrial myopathy in heart failure with preserved ejection fraction.
    Eur J Heart Fail. 2020 Jan 9. doi: 10.1002/ejhf.1688.
    PubMed    


  451. KHAN MS, Memon MM, Murad MH, Vaduganathan M, et al
    Left atrial function in heart failure with preserved ejection fraction: a systematic review and meta-analysis.
    Eur J Heart Fail. 2020 Jan 9. doi: 10.1002/ejhf.1643.
    PubMed     Abstract available


  452. ROSSIGNOL P, Duarte K, Girerd N, Karoui M, et al
    Cardiovascular risk associated with serum potassium in the context of mineralocorticoid receptor antagonist use in patients with heart failure and left ventricular dysfunction.
    Eur J Heart Fail. 2020 Jan 9. doi: 10.1002/ejhf.1724.
    PubMed     Abstract available


  453. RIVAS-LASARTE M, Alvarez-Garcia J, Mirabet S, Sionis A, et al
    Is lung ultrasound monitoring really useful for impacting rehospitalization and mortality in worsening heart failure? Reply.
    Eur J Heart Fail. 2020 Jan 9. doi: 10.1002/ejhf.1719.
    PubMed    


  454. KLOOSTERMAN M, Santema BT, Roselli C, Nelson CP, et al
    Genetic risk and atrial fibrillation in patients with heart failure.
    Eur J Heart Fail. 2020 Jan 9. doi: 10.1002/ejhf.1735.
    PubMed     Abstract available


  455. AIMO A, Januzzi JL Jr, Vergaro G, Richards AM, et al
    Circulating levels and prognostic value of soluble ST2 in heart failure are less influenced by age than N-terminal pro-B-type natriuretic peptide and high-sensitivity troponin T.
    Eur J Heart Fail. 2020 Jan 9. doi: 10.1002/ejhf.1701.
    PubMed     Abstract available


  456. BAUERSACHS J, Veltmann C
    Heart rate control in heart failure with reduced ejection fraction: the bright and the dark side of the moon.
    Eur J Heart Fail. 2020 Jan 7. doi: 10.1002/ejhf.1733.
    PubMed    


  457. DAMMAN K, Beusekamp JC, Boorsma EM, Swart HP, et al
    Randomized, double-blind, placebo-controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPA-RESPONSE-AHF).
    Eur J Heart Fail. 2020 Jan 7. doi: 10.1002/ejhf.1713.
    PubMed     Abstract available


  458. PETUTSCHNIGG J, Ferreira JP, Holzendorf V, Trippel TD, et al
    Body fat phenotypes and treatment response to spironolactone in ambulatory patients with heart failure and preserved ejection fraction: a post-hoc analysis of the Aldo-DHF trial.
    Eur J Heart Fail. 2020 Jan 7. doi: 10.1002/ejhf.1723.
    PubMed    


  459. VAN LINTHOUT S, Rimoldi O, Tschope C, Camici PG, et al
    Coronary microvascular dysfunction in heart failure with preserved ejection fraction - adding new pieces to the jigsaw puzzle.
    Eur J Heart Fail. 2020 Jan 7. doi: 10.1002/ejhf.1720.
    PubMed    


  460. ZAKERI R, Morgan JM, Phillips P, Kitt S, et al
    Impact of remote monitoring on clinical outcomes for patients with heart failure and atrial fibrillation: results from the REM-HF trial.
    Eur J Heart Fail. 2020 Jan 7. doi: 10.1002/ejhf.1709.
    PubMed     Abstract available


  461. TAMARGO M, Obokata M, Reddy YNV, Pislaru SV, et al
    Functional mitral regurgitation and left atrial myopathy in heart failure with preserved ejection fraction.
    Eur J Heart Fail. 2020 Jan 7. doi: 10.1002/ejhf.1699.
    PubMed     Abstract available


  462. MULLENS W, Damman K, Testani JM, Martens P, et al
    Evaluation of kidney function throughout the heart failure trajectory - a position statement from the Heart Failure Association of the European Society of Cardiology.
    Eur J Heart Fail. 2020 Jan 7. doi: 10.1002/ejhf.1697.
    PubMed     Abstract available


  463. MCCLELLAND S, Zhou S, O'Connell E, Gallagher J, et al
    New-onset heart failure in the STOP-HF programme. Natriuretic peptide defines and tracks risk and enables earlier diagnosis of heart failure.
    Eur J Heart Fail. 2020 Jan 7. doi: 10.1002/ejhf.1661.
    PubMed    



  464. Corrigendum to 'Efficacy and safety of serelaxin when added to standard of care in patients with acute heart failure: results from a PROBE study, RELAX-AHF-EU' [Eur J Heart Fail 2019;21:322-333].
    Eur J Heart Fail. 2020;22:170.
    PubMed    


  465. MEWTON N, Cucherat M
    To clip, or not to clip heart failure patients, that is the question.
    Eur J Heart Fail. 2020;22:16-19.
    PubMed    


  466. SCHLENDORF K, Stone GW, Abraham WT, Mack MJ, et al
    Who and when to clip: that is the question.
    Eur J Heart Fail. 2020;22:20-22.
    PubMed    


  467. HARRISON SL, Lane DA, Lip GYH
    Reducing risk of adverse cardiovascular and renal outcomes for patients with atrial fibrillation and type 2 diabetes.
    Eur J Heart Fail. 2020;22:136-138.
    PubMed    


  468. HO G, Wettersten N, Greenberg B
    Implantable cardioverter-defibrillator therapy in patients with left ventricular assist devices: a shocking tale of survival.
    Eur J Heart Fail. 2020;22:29-31.
    PubMed    


  469. HELGESTAD OKL, Ravn HB, Josiassen J, Udesen NLJ, et al
    Mechanical respiratory support in cardiogenic shock: reply.
    Eur J Heart Fail. 2020;22:168-169.
    PubMed    


  470. MILLER PE, Gimenez MR, Thiele H
    Mechanical respiratory support in cardiogenic shock.
    Eur J Heart Fail. 2020;22:168.
    PubMed    


    December 2019
  471. TEERLINK JR, Davison BA, Cotter G, Maggioni AP, et al
    Effects of serelaxin in patients admitted for acute heart failure: a meta-analysis.
    Eur J Heart Fail. 2019 Dec 30. doi: 10.1002/ejhf.1692.
    PubMed     Abstract available


  472. COATS AJS
    Figures of the Heart Failure Association (HFA): Prof. Dr. Tiny Jaarsma, HFA Board Member (2018-2020), Coordinator Patient Care: Management and Delivery Committee and Co-Chair HFA Task Force on Palliative Care.
    Eur J Heart Fail. 2019 Dec 30. doi: 10.1002/ejhf.1705.
    PubMed    


  473. PONIKOWSKI P, Kirwan BA, Anker SD, Dorobantu M, et al
    Rationale and design of the AFFIRM-AHF trial: a randomised, double-blind, placebo-controlled trial comparing the effect of intravenous ferric carboxymaltose on hospitalisations and mortality in iron-deficient patients admitted for acute heart failure.
    Eur J Heart Fail. 2019 Dec 28. doi: 10.1002/ejhf.1710.
    PubMed     Abstract available


  474. ANKER MS, von Haehling S, Papp Z, Anker SD, et al
    ESC Heart Failure receives its first impact factor.
    Eur J Heart Fail. 2019 Dec 27. doi: 10.1002/ejhf.1665.
    PubMed    


  475. DEVAUX Y, Nossent AY
    A role for m6A RNA methylation in heart failure development?
    Eur J Heart Fail. 2019 Dec 21. doi: 10.1002/ejhf.1714.
    PubMed    


  476. ANKER MS, Hulsmann M, Cleland JG
    What do patients with heart failure die from? A single assassin or a conspiracy?
    Eur J Heart Fail. 2019 Dec 21. doi: 10.1002/ejhf.1689.
    PubMed    


  477. WETTERSTEN N, Horiuchi Y, van Veldhuisen DJ, Mueller C, et al
    Short-term prognostic implications of serum and urine neutrophil gelatinase-associated lipocalin in acute heart failure: findings from the AKINESIS study.
    Eur J Heart Fail. 2019 Dec 21. doi: 10.1002/ejhf.1642.
    PubMed     Abstract available


  478. GOSMANOVA EO, Lyubarova R
    Neutrophil gelatinase-associated lipocalin in acute heart failure: time to move on?
    Eur J Heart Fail. 2019 Dec 21. doi: 10.1002/ejhf.1684.
    PubMed    


  479. MYHRE PL, Vaduganathan M, Greene SJ
    Diagnosing heart failure with preserved ejection fraction in 2019: the search for a gold standard.
    Eur J Heart Fail. 2019 Dec 21. doi: 10.1002/ejhf.1638.
    PubMed    


  480. MATHIASEN AB, Qayyum AA, Jorgensen E, Helqvist S, et al
    Bone marrow-derived mesenchymal stromal cell treatment in patients with ischaemic heart failure: final 4-year follow-up of the MSC-HF trial.
    Eur J Heart Fail. 2019 Dec 21. doi: 10.1002/ejhf.1700.
    PubMed     Abstract available


  481. LARSEN AH, Jessen N, Norrelund H, Tolbod LP, et al
    A randomised, double-blind, placebo-controlled trial of metformin on myocardial efficiency in insulin-resistant chronic heart failure patients without diabetes.
    Eur J Heart Fail. 2019 Dec 21. doi: 10.1002/ejhf.1656.
    PubMed     Abstract available


  482. PATEL PA, Ambrosy AP, Phelan M, Alenezi F, et al
    Association between systolic ejection time and outcomes in heart failure by ejection fraction.
    Eur J Heart Fail. 2019 Dec 21. doi: 10.1002/ejhf.1659.
    PubMed     Abstract available


  483. LAINSCAK M, Milinkovic I, Polovina M, Crespo-Leiro MG, et al
    Sex- and age-related differences in the management and outcomes of chronic heart failure: an analysis of patients from the ESC HFA EORP Heart Failure Long-Term Registry.
    Eur J Heart Fail. 2019 Dec 20. doi: 10.1002/ejhf.1645.
    PubMed     Abstract available


  484. BEUSEKAMP JC, Teng TK, Tay WT, Ouwerkerk W, et al
    Potassium abnormalities in patients with heart failure from 11 Asian regions: insights from the ASIAN-HF registry.
    Eur J Heart Fail. 2019 Dec 18. doi: 10.1002/ejhf.1640.
    PubMed    


  485. TENG TK, Cooper L, Tay WT, Luo N, et al
    Association between body surface area and prescribed doses of guideline-directed medications among international patients with heart failure and reduced ejection fraction.
    Eur J Heart Fail. 2019 Dec 18. doi: 10.1002/ejhf.1648.
    PubMed    


  486. DOCHERTY KF, Shen L, Castagno D, Petrie MC, et al
    Relationship between heart rate and outcomes in patients in sinus rhythm or atrial fibrillation with heart failure and reduced ejection fraction.
    Eur J Heart Fail. 2019 Dec 17. doi: 10.1002/ejhf.1682.
    PubMed     Abstract available


  487. BERULAVA T, Buchholz E, Elerdashvili V, Pena T, et al
    Changes in m6A RNA methylation contribute to heart failure progression by modulating translation.
    Eur J Heart Fail. 2019 Dec 17. doi: 10.1002/ejhf.1672.
    PubMed     Abstract available


  488. PACKER M
    Do most patients with obesity or type 2 diabetes, and atrial fibrillation, also have undiagnosed heart failure? A critical conceptual framework for understanding mechanisms and improving diagnosis and treatment.
    Eur J Heart Fail. 2019 Dec 17. doi: 10.1002/ejhf.1646.
    PubMed     Abstract available


  489. LIN F, Greenberg B
    Considering the gender gap in heart failure.
    Eur J Heart Fail. 2019 Dec 16. doi: 10.1002/ejhf.1706.
    PubMed    


  490. COATS AJS
    Heart Failure Association position papers - a new way to advance the field.
    Eur J Heart Fail. 2019 Dec 16. doi: 10.1002/ejhf.1704.
    PubMed    


  491. BHATT AS, Vaduganathan M, Butler J
    Angiotensin-neprilysin inhibition in de novo heart failure - starting off strong.
    Eur J Heart Fail. 2019 Dec 16. doi: 10.1002/ejhf.1675.
    PubMed    


  492. KHAN T
    Survival rates in elderly patients with heart failure.
    Eur J Heart Fail. 2019 Dec 16. doi: 10.1002/ejhf.1712.
    PubMed    


  493. YANG JH, Obokata M, Reddy YNV, Redfield MM, et al
    Endothelium-dependent and independent coronary microvascular dysfunction in patients with heart failure with preserved ejection fraction.
    Eur J Heart Fail. 2019 Dec 15. doi: 10.1002/ejhf.1671.
    PubMed     Abstract available


  494. COATS AJS
    Figures of the Heart Failure Association (HFA): Prof. Dr. Jelena Celutkiene, HFA Board Member (2016-2020) and co-coordinator of the Imaging Study Group of the HFA Diagnosis Committee.
    Eur J Heart Fail. 2019 Dec 12. doi: 10.1002/ejhf.1703.
    PubMed    


  495. MORONI A, Viva T, Guazzi M
    Is lung ultrasound monitoring really useful for impacting rehospitalization and mortality in worsening heart failure?
    Eur J Heart Fail. 2019 Dec 12. doi: 10.1002/ejhf.1707.
    PubMed    


  496. MOCKEL M, de Boer RA, Slagman AC, von Haehling S, et al
    Improve Management of acute heart failure with ProcAlCiTonin in EUrope: results of the randomized clinical trial IMPACT EU Biomarkers in Cardiology (BIC) 18.
    Eur J Heart Fail. 2019 Dec 12. doi: 10.1002/ejhf.1667.
    PubMed     Abstract available


  497. BAYES-GENIS A, Emdin M, Nunez J
    Biomarker-guided management in acute heart failure: is there light at the end of the tunnel?
    Eur J Heart Fail. 2019 Dec 12. doi: 10.1002/ejhf.1690.
    PubMed    


  498. POLOVINA M, Lund LH, Dikic D, Petrovic-Dordevic I, et al
    Type 2 diabetes increases the long-term risk of heart failure and mortality in patients with atrial fibrillation.
    Eur J Heart Fail. 2019 Dec 10. doi: 10.1002/ejhf.1666.
    PubMed     Abstract available


  499. KESHVANI N, Gupta A, Pandey A
    Towards global improvement in heart failure care.
    Eur J Heart Fail. 2019 Dec 9. doi: 10.1002/ejhf.1687.
    PubMed    


  500. BOHM M, Slawik J, Brueckmann M, Mattheus M, et al
    Efficacy of empagliflozin on heart failure and renal outcomes in patients with atrial fibrillation: data from the EMPA-REG OUTCOME trial.
    Eur J Heart Fail. 2019 Dec 9. doi: 10.1002/ejhf.1663.
    PubMed     Abstract available


  501. PIESKE B, Patel MJ, Westerhout CM, Anstrom KJ, et al
    Baseline features of the VICTORIA (Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction) trial.
    Eur J Heart Fail. 2019 Dec 9. doi: 10.1002/ejhf.1664.
    PubMed     Abstract available


  502. SENNI M, Wachter R, Witte KK, Straburzynska-Migaj E, et al
    Initiation of sacubitril/valsartan shortly after hospitalisation for acutely decompensated heart failure in patients with newly diagnosed (de novo) heart failure: a subgroup analysis of the TRANSITION study.
    Eur J Heart Fail. 2019 Dec 9. doi: 10.1002/ejhf.1670.
    PubMed     Abstract available


  503. LI L, Liu R, Jiang C, Du X, et al
    Assessing the evidence-practice gap for heart failure in China: the Heart Failure Registry of Patient Outcomes (HERO) study design and baseline characteristics.
    Eur J Heart Fail. 2019 Dec 9. doi: 10.1002/ejhf.1630.
    PubMed     Abstract available


  504. SEFEROVIC PM, Coats AJS, Ponikowski P, Filippatos G, et al
    European Society of Cardiology/Heart Failure Association position paper on the role and safety of new glucose-lowering drugs in patients with heart failure.
    Eur J Heart Fail. 2019 Dec 9. doi: 10.1002/ejhf.1673.
    PubMed     Abstract available


  505. CELUTKIENE J, Lainscak M, Anderson L, Gayat E, et al
    Imaging in patients with suspected acute heart failure: timeline approach position statement on behalf of the Heart Failure Association of the European Society of Cardiology.
    Eur J Heart Fail. 2019 Dec 9. doi: 10.1002/ejhf.1678.
    PubMed     Abstract available


  506. KUAN WS, Ibrahim I, Chan SP, Li Z, et al
    Mid-regional pro-adrenomedullin outperforms N-terminal pro-B-type natriuretic peptide for the diagnosis of acute heart failure in the presence of atrial fibrillation.
    Eur J Heart Fail. 2019 Dec 6. doi: 10.1002/ejhf.1660.
    PubMed     Abstract available


  507. BOMER N, Grote Beverborg N, Hoes MF, Streng KW, et al
    Selenium and outcome in heart failure.
    Eur J Heart Fail. 2019 Dec 6. doi: 10.1002/ejhf.1644.
    PubMed     Abstract available


  508. JANUZZI JL JR, Ibrahim NE
    It is time for consistency in the use of biomarkers in heart failure clinical trials.
    Eur J Heart Fail. 2019 Dec 3. doi: 10.1002/ejhf.1696.
    PubMed    


  509. PANDHI P, Ter Maaten JM, Emmens JE, Struck J, et al
    Clinical value of pre-discharge bio-adrenomedullin as a marker of residual congestion and high risk of heart failure hospital readmission.
    Eur J Heart Fail. 2019 Dec 3. doi: 10.1002/ejhf.1693.
    PubMed     Abstract available


  510. HOES MF, Tromp J, Ouwerkerk W, Bomer N, et al
    The role of cathepsin D in the pathophysiology of heart failure and its potentially beneficial properties: a translational approach.
    Eur J Heart Fail. 2019 Dec 3. doi: 10.1002/ejhf.1674.
    PubMed     Abstract available


  511. KLEIN P, Anker SD, Wechsler A, Skalsky I, et al
    Less invasive ventricular reconstruction for ischaemic heart failure.
    Eur J Heart Fail. 2019 Dec 3. doi: 10.1002/ejhf.1669.
    PubMed     Abstract available


  512. BHATT AS, Vaduganathan M, Patel RB, Fonarow GC, et al
    Post-discharge haemodilution, congestion, and clinical outcomes among patients hospitalized for heart failure with reduced ejection fraction: results from the EVEREST trial.
    Eur J Heart Fail. 2019 Dec 3. doi: 10.1002/ejhf.1651.
    PubMed    


  513. GARGANI L, Ferre RM, Pang PS
    B-lines in heart failure: will comets guide us?
    Eur J Heart Fail. 2019;21:1616-1618.
    PubMed    


    November 2019
  514. O'MEARA E, Allen BG
    Cardiac remodelling patterns and proteomics: the keys to move beyond ejection fraction in heart failure?
    Eur J Heart Fail. 2019 Nov 28. doi: 10.1002/ejhf.1691.
    PubMed    


  515. ROVAI S, Corra U, Piepoli M, Vignati C, et al
    Exercise oscillatory ventilation and prognosis in heart failure patients with reduced and mid-range ejection fraction.
    Eur J Heart Fail. 2019 Nov 28. doi: 10.1002/ejhf.1595.
    PubMed     Abstract available


  516. INCIARDI RM, Giugliano RP, Claggett B, Gupta DK, et al
    Left atrial structure and function and the risk of death or heart failure in atrial fibrillation.
    Eur J Heart Fail. 2019 Nov 27. doi: 10.1002/ejhf.1606.
    PubMed     Abstract available


  517. LOPEZ-FERNANDEZ T, Lopez-Sendon JL
    Heart failure after treatment for breast cancer: old cancer therapies, new clinical data. What do we need to complete the puzzle?
    Eur J Heart Fail. 2019 Nov 27. doi: 10.1002/ejhf.1662.
    PubMed    


  518. MCALISTER FA, Ezekowitz JA, Armstrong PW
    Heart failure treatment and the art of medical decision making.
    Eur J Heart Fail. 2019 Nov 25. doi: 10.1002/ejhf.1655.
    PubMed    


  519. WETTERSTEN N, Horiuchi Y, van Veldhuisen DJ, Mueller C, et al
    B-type natriuretic peptide trend predicts clinical significance of worsening renal function in acute heart failure.
    Eur J Heart Fail. 2019 Nov 25. doi: 10.1002/ejhf.1627.
    PubMed     Abstract available


  520. VAN WOERDEN G, van Veldhuisen DJ, Rienstra M, Westenbrink BD, et al
    Myocardial adiposity in heart failure with preserved ejection fraction: the plot thickens.
    Eur J Heart Fail. 2019 Nov 25. doi: 10.1002/ejhf.1653.
    PubMed    


  521. PRIMESSNIG U, Bracic T, Levijoki J, Otsomaa L, et al
    Long-term effects of Na(+) /Ca(2+) exchanger inhibition with ORM-11035 improves cardiac function and remodelling without lowering blood pressure in a model of heart failure with preserved ejection fraction.
    Eur J Heart Fail. 2019 Nov 24. doi: 10.1002/ejhf.1619.
    PubMed     Abstract available


  522. KAO D, Purohit S, Jhund P
    Therapeutic futility and phenotypic heterogeneity in heart failure with preserved ejection fraction: what is the role of bionic learning?
    Eur J Heart Fail. 2019 Nov 20. doi: 10.1002/ejhf.1658.
    PubMed    


  523. KHAN MS, Irfan S, Khan SU, Mehra MR, et al
    Transforming the interpretation of significance in heart failure trials.
    Eur J Heart Fail. 2019 Nov 14. doi: 10.1002/ejhf.1668.
    PubMed    


  524. BOEKEL NB, Duane FK, Jacobse JN, Hauptmann M, et al
    Heart failure after treatment for breast cancer.
    Eur J Heart Fail. 2019 Nov 12. doi: 10.1002/ejhf.1620.
    PubMed     Abstract available


  525. ADLER ED, Voors AA, Klein L, Macheret F, et al
    Improving risk prediction in heart failure using machine learning.
    Eur J Heart Fail. 2019 Nov 12. doi: 10.1002/ejhf.1628.
    PubMed     Abstract available


  526. NAUTA JF, Hummel YM, Tromp J, Ouwerkerk W, et al
    Concentric vs. eccentric remodelling in heart failure with reduced ejection fraction: clinical characteristics, pathophysiology and response to treatment.
    Eur J Heart Fail. 2019 Nov 11. doi: 10.1002/ejhf.1632.
    PubMed     Abstract available


  527. PLATZ E, Solomon SD, McMurray JJV
    Lung ultrasound: monitoring congestion in patients with heart failure.
    Eur J Heart Fail. 2019 Nov 8. doi: 10.1002/ejhf.1636.
    PubMed    


  528. CAO TH, Jones DJL, Voors AA, Quinn PA, et al
    Plasma proteomic approach in patients with heart failure: insights into pathogenesis of disease progression and potential novel treatment targets.
    Eur J Heart Fail. 2019 Nov 6. doi: 10.1002/ejhf.1608.
    PubMed     Abstract available


  529. ADAMO M, Lombardi CM, Metra M
    November 2019 at a glance. Chronic and acute heart failure: from epidemiology to treatment.
    Eur J Heart Fail. 2019;21:1297-1298.
    PubMed    


  530. HAO G, Wang X, Chen Z, Zhang L, et al
    Prevalence of heart failure and left ventricular dysfunction in China: the China Hypertension Survey, 2012-2015.
    Eur J Heart Fail. 2019;21:1329-1337.
    PubMed     Abstract available


  531. GROENEWEGEN A, Rutten FH
    Decelerating trends in heart failure survival.
    Eur J Heart Fail. 2019;21:1326-1328.
    PubMed    


  532. TROMP J, Collins SP
    Dapagliflozin in heart failure: new frontiers.
    Eur J Heart Fail. 2019;21:1412-1414.
    PubMed    


    October 2019
  533. RIVAS-LASARTE M, Alvarez-Garcia J, Fernandez-Martinez J, Maestro A, et al
    Lung ultrasound-guided treatment in ambulatory patients with heart failure: a randomized controlled clinical trial (LUS-HF study).
    Eur J Heart Fail. 2019 Oct 31. doi: 10.1002/ejhf.1604.
    PubMed     Abstract available


  534. RAMALHO SHR, Claggett BL, Sweitzer NK, Fang JC, et al
    Impact of pulmonary disease on the prognosis in heart failure with preserved ejection fraction: the TOPCAT trial.
    Eur J Heart Fail. 2019 Oct 31. doi: 10.1002/ejhf.1593.
    PubMed    


  535. SULO G, Igland J, Overland S, Egeland GM, et al
    Heart failure in Norway, 2000-2014: analysing incident, total and readmission rates using data from the Cardiovascular Disease in Norway (CVDNOR) Project.
    Eur J Heart Fail. 2019 Oct 23. doi: 10.1002/ejhf.1609.
    PubMed     Abstract available


  536. VITALE C, Jankowska E, Hill L, Piepoli M, et al
    Heart Failure Association/European Society of Cardiology position paper on frailty in patients with heart failure.
    Eur J Heart Fail. 2019 Oct 23. doi: 10.1002/ejhf.1611.
    PubMed     Abstract available


  537. RACHWAN RJ, Butler J, Collins SP, Cotter G, et al
    Is plasma renin activity associated with worse outcomes in acute heart failure? A secondary analysis from the BLAST-AHF trial.
    Eur J Heart Fail. 2019 Oct 23. doi: 10.1002/ejhf.1607.
    PubMed     Abstract available


  538. GO YY, Allen JC Jr, Lam CSP
    Reply: in response to 'Defining a "frequent admitter" phenotype among patients with repeat heart failure admissions' by Go et al.
    Eur J Heart Fail. 2019 Oct 21. doi: 10.1002/ejhf.1622.
    PubMed    


  539. SEGAR MW, Patel KV, Ayers C, Basit M, et al
    Phenomapping of patients with heart failure with preserved ejection fraction using machine learning-based unsupervised cluster analysis.
    Eur J Heart Fail. 2019 Oct 21. doi: 10.1002/ejhf.1621.
    PubMed     Abstract available


    September 2019
  540. ANKER SD, Butler J, Filippatos GS, Jamal W, et al
    Evaluation of the effects of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR-Preserved Trial.
    Eur J Heart Fail. 2019 Sep 16. doi: 10.1002/ejhf.1596.
    PubMed     Abstract available


  541. JONES NR, Roalfe AK, Adoki I, Hobbs FDR, et al
    Survival of patients with chronic heart failure in the community: a systematic review and meta-analysis.
    Eur J Heart Fail. 2019 Sep 16. doi: 10.1002/ejhf.1594.
    PubMed     Abstract available


  542. VOORS AA, Bax JJ, Hernandez AF, Wirtz AB, et al
    Safety and efficacy of the partial adenosine A1 receptor agonist neladenoson bialanate in patients with chronic heart failure with reduced ejection fraction: a phase IIb, randomized, double-blind, placebo-controlled trial.
    Eur J Heart Fail. 2019 Sep 16. doi: 10.1002/ejhf.1591.
    PubMed     Abstract available


  543. SCHULZ M, Griese-Mammen N, Bohm M, Laufs U, et al
    Letter on 'Pharmacy-based interdisciplinary intervention for patients with chronic heart failure: results of the PHARM-CHF randomized controlled trial': reply.
    Eur J Heart Fail. 2019 Sep 16. doi: 10.1002/ejhf.1613.
    PubMed    


  544. SEFEROVIC PM, Polovina M
    The eyes are the mirror of the heart: role of retinal microvascular abnormalities in predicting long-term risk of heart failure.
    Eur J Heart Fail. 2019 Sep 11. doi: 10.1002/ejhf.1597.
    PubMed    


  545. WU CK, Lee JK, Hsu JC, Su MM, et al
    Myocardial adipose deposition and the development of heart failure with preserved ejection fraction.
    Eur J Heart Fail. 2019 Sep 11. doi: 10.1002/ejhf.1617.
    PubMed     Abstract available


  546. KALMANOVICH E, Roubille F, Castet-Nicolas A
    Response to 'Pharmacy-based interdisciplinary intervention for patients with chronic heart failure: results of the PHARM-CHF randomized controlled trial'.
    Eur J Heart Fail. 2019 Sep 9. doi: 10.1002/ejhf.1602.
    PubMed    


  547. MYHRE PL, Januzzi JL Jr, Butler J, Vaduganathan M, et al
    De novo heart failure: where the journey begins.
    Eur J Heart Fail. 2019 Sep 9. doi: 10.1002/ejhf.1586.
    PubMed    


  548. STOLFO D, Uijl A, Benson L, Schrage B, et al
    Association between beta-blocker use and mortality/morbidity in older patients with heart failure with reduced ejection fraction A propensity score-matched analysis from the Swedish Heart Failure Registry.
    Eur J Heart Fail. 2019 Sep 3. doi: 10.1002/ejhf.1615.
    PubMed     Abstract available


  549. COIRO S, Girerd N, Sharma A, Rossignol P, et al
    Association of diabetes and kidney function according to age and systolic function with the incidence of sudden cardiac death and non-sudden cardiac death in myocardial infarction survivors with heart failure.
    Eur J Heart Fail. 2019 Sep 2. doi: 10.1002/ejhf.1541.
    PubMed     Abstract available



  550. Corrigendum to 'Prognostic implications of plasma volume status estimates in heart failure with preserved ejection fraction: insights from TOPCAT' [Eur J Heart Fail 2019;21:634-642].
    Eur J Heart Fail. 2019;21:1166.
    PubMed    


    August 2019
  551. AIZPURUA AB, Wijk SS, Rocca HB, Henkens M, et al
    Validation of the HFA-PEFF-score for the Diagnosis of Heart Failure with Preserved Ejection Fraction.
    Eur J Heart Fail. 2019 Aug 31. doi: 10.1002/ejhf.1614.
    PubMed    


  552. MARTYN T, Tang WHW
    Can saline repletion be the true TARGET for achieving fluid balance in acute heart failure?
    Eur J Heart Fail. 2019 Aug 29. doi: 10.1002/ejhf.1558.
    PubMed    


  553. BLUMER V, Greene SJ, Sun JL, Bart BA, et al
    Haemoconcentration during treatment of acute heart failure with cardiorenal syndrome: from the CARRESS-HF trial.
    Eur J Heart Fail. 2019 Aug 27. doi: 10.1002/ejhf.1592.
    PubMed    


  554. JAARSMA T, Stromberg A
    We told you so: 'knowledge is not enough to improve heart failure self-care behaviour'.
    Eur J Heart Fail. 2019 Aug 27. doi: 10.1002/ejhf.1580.
    PubMed    


  555. KIMMOUN A, Cotter G, Davison B, Takagi K, et al
    Safety, Tolerability and efficacy of Rapid Optimization, helped by NT-proBNP and GDF-15, of Heart Failure therapies (STRONG-HF): rationale and design for a multicentre, randomized, parallel-group study.
    Eur J Heart Fail. 2019 Aug 19. doi: 10.1002/ejhf.1575.
    PubMed     Abstract available


  556. TROMP J, Ferreira JP, Janwanishstaporn S, Shah M, et al
    Heart failure around the world.
    Eur J Heart Fail. 2019 Aug 16. doi: 10.1002/ejhf.1585.
    PubMed     Abstract available


  557. PATEL RB, Nohria A, Butler J, Vaduganathan M, et al
    Dying is not what it used to be! Impact of evolving epidemiology and treatment on mode of death in heart failure.
    Eur J Heart Fail. 2019 Aug 13. doi: 10.1002/ejhf.1587.
    PubMed    


  558. COATS AJS
    Figures of the Heart Failure Association (HFA): Prof. Dr. med. Thomas Thum, Chair of the ESC Working Group on Myocardial Function and ex-officio HFA Board Member (2018-2020).
    Eur J Heart Fail. 2019 Aug 13. doi: 10.1002/ejhf.1584.
    PubMed    


  559. BOTTLE A, Cowie MR
    Letter in reference to "Defining a 'frequent admitter' phenotype among patients with repeat heart failure admissions".
    Eur J Heart Fail. 2019 Aug 13. doi: 10.1002/ejhf.1590.
    PubMed    


  560. AHMAD T, Miller PE, McCullough M, Desai NR, et al
    Why has positive inotropy failed in chronic heart failure? Lessons from prior inotrope trials.
    Eur J Heart Fail. 2019 Aug 13. doi: 10.1002/ejhf.1557.
    PubMed     Abstract available


  561. MIRO O, Garcia Sarasola A, Fuenzalida C, Calderon S, et al
    Departments involved during the first episode of acute heart failure and analysis of emergency department revisits and rehospitalisations: an outlook through the NOVICA cohort.
    Eur J Heart Fail. 2019 Aug 7. doi: 10.1002/ejhf.1567.
    PubMed     Abstract available


  562. TER MAATEN JM, Damman K
    Down the road from challenges in acute heart failure trials.
    Eur J Heart Fail. 2019 Aug 7. doi: 10.1002/ejhf.1571.
    PubMed    


  563. MAURICIO R, Patel KV, Agusala V, Singh K, et al
    Sex differences in cardiac function, biomarkers and exercise performance in heart failure with preserved ejection fraction: findings from the RELAX trial.
    Eur J Heart Fail. 2019 Aug 5. doi: 10.1002/ejhf.1554.
    PubMed    


  564. VIDAN MT, Martin Sanchez FJ, Sanchez E, Ortiz FJ, et al
    Most elderly patients hospitalized for heart failure lack the abilities needed to perform the tasks required for self-care: impact on outcomes.
    Eur J Heart Fail. 2019 Aug 1. doi: 10.1002/ejhf.1559.
    PubMed     Abstract available


  565. CHIONCEL O, Butler J
    Mid-regional pro-atrial natriuretic peptide for diagnosis of heart failure in non-acute settings: biomarkers plus clinical sense make good sense.
    Eur J Heart Fail. 2019 Aug 1. doi: 10.1002/ejhf.1578.
    PubMed    


  566. CHANDRA A, Seidelmann SB, Claggett BL, Klein BE, et al
    The association of retinal vessel calibres with heart failure and long-term alterations in cardiac structure and function: the Atherosclerosis Risk in Communities (ARIC) Study.
    Eur J Heart Fail. 2019 Aug 1. doi: 10.1002/ejhf.1564.
    PubMed     Abstract available


  567. COATS AJS
    Figures of the Heart Failure Association: Dr. Ovidiu Chioncel, HFA Board Member, 2018-2020.
    Eur J Heart Fail. 2019;21:953-954.
    PubMed    


    July 2019
  568. MOLINER P, Lupon J, de Antonio M, Domingo M, et al
    Trends in modes of death in heart failure over the last two decades: less sudden death but cancer deaths on the rise.
    Eur J Heart Fail. 2019 Jul 30. doi: 10.1002/ejhf.1569.
    PubMed     Abstract available


  569. ECHOUFFO-TCHEUGUI JB, Masoudi FA, Bao H, Curtis JP, et al
    Body mass index and outcomes of cardiac resynchronization with implantable cardioverter-defibrillator therapy in older patients with heart failure.
    Eur J Heart Fail. 2019 Jul 29. doi: 10.1002/ejhf.1552.
    PubMed     Abstract available


  570. BUNDGAARD JS, Mogensen UM, Christensen S, Ploug U, et al
    The economic burden of heart failure in Denmark from 1998 to 2016.
    Eur J Heart Fail. 2019 Jul 29. doi: 10.1002/ejhf.1577.
    PubMed     Abstract available


  571. HALLEN J, Maggioni AP, Lopez-De-Sa E, Turazza FM, et al
    Reproducibility of in-hospital worsening heart failure event adjudication in the RELAX-AHF-EU trial.
    Eur J Heart Fail. 2019 Jul 29. doi: 10.1002/ejhf.1574.
    PubMed    


  572. YAZAKI Y, Salzano A, Nelson CP, Voors AA, et al
    Geographical location affects the levels and association of trimethylamine N-oxide with heart failure mortality in BIOSTAT-CHF: a post-hoc analysis.
    Eur J Heart Fail. 2019 Jul 28. doi: 10.1002/ejhf.1550.
    PubMed    


  573. PIEPOLI MF, Binno S, Coats AJS, Cohen-Solal A, et al
    Regional differences in exercise training implementation in heart failure: findings from the Exercise Training in Heart Failure (ExTraHF) survey.
    Eur J Heart Fail. 2019 Jul 25. doi: 10.1002/ejhf.1538.
    PubMed     Abstract available


  574. DISERTORI M, Mase M, Rigoni M, Nollo G, et al
    Heart failure patients unresponsive to implantable cardioverter-defibrillator therapy: a neglected problem.
    Eur J Heart Fail. 2019 Jul 22. doi: 10.1002/ejhf.1551.
    PubMed    


  575. MYHRE PL, Vaduganathan M, Claggett BL, Lam CSP, et al
    Application of the H2 FPEF score to a global clinical trial of patients with heart failure with preserved ejection fraction: the TOPCAT trial.
    Eur J Heart Fail. 2019 Jul 22. doi: 10.1002/ejhf.1542.
    PubMed    


  576. WIGGERS H
    Insulin treatment in heart failure patients: the good, the bad or the ugly?
    Eur J Heart Fail. 2019 Jul 22. doi: 10.1002/ejhf.1556.
    PubMed    


  577. PACKER M, Butler J, Filippatos GS, Jamal W, et al
    Evaluation of the effect of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR-Reduced trial.
    Eur J Heart Fail. 2019 Jul 16. doi: 10.1002/ejhf.1536.
    PubMed     Abstract available


  578. MCMURRAY JJV, DeMets DL, Inzucchi SE, Kober L, et al
    The Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure (DAPA-HF) trial: baseline characteristics.
    Eur J Heart Fail. 2019 Jul 15. doi: 10.1002/ejhf.1548.
    PubMed     Abstract available


  579. FRIGERIO M, Carugo S, Voltolini A
    Of hearts, minds, and guts: difficulties in diagnosing heart failure in the young.
    Eur J Heart Fail. 2019 Jul 15. doi: 10.1002/ejhf.1544.
    PubMed    


  580. XANTHOPOULOS A, Papamichalis M, Zajichek A, Milinovich A, et al
    In-hospital red blood cell distribution width change in patients with heart failure.
    Eur J Heart Fail. 2019 Jul 4. doi: 10.1002/ejhf.1546.
    PubMed    


  581. HANSEN D
    Access to exercise-based rehabilitation across Europe for patients with heart failure: where evidence-based practice is hampered by lacking resources.
    Eur J Heart Fail. 2019 Jul 4. doi: 10.1002/ejhf.1545.
    PubMed    


  582. BARTHELMES J, Nagele MP, Cantatore S, Novruzov E, et al
    Retinal microvascular dysfunction in patients with coronary artery disease with and without heart failure: a continuum?
    Eur J Heart Fail. 2019 Jul 4. doi: 10.1002/ejhf.1537.
    PubMed     Abstract available


  583. SHEN L, Rorth R, Cosmi D, Kristensen SL, et al
    Insulin treatment and clinical outcomes in patients with diabetes and heart failure with preserved ejection fraction.
    Eur J Heart Fail. 2019 Jul 4. doi: 10.1002/ejhf.1535.
    PubMed     Abstract available


    June 2019
  584. BAUERSACHS J, Konig T, van der Meer P, Petrie MC, et al
    Pathophysiology, diagnosis and management of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathy.
    Eur J Heart Fail. 2019 Jun 27. doi: 10.1002/ejhf.1493.
    PubMed     Abstract available


  585. PLATZ E, Jhund PS, Girerd N, Pivetta E, et al
    Expert consensus document: Reporting checklist for quantification of pulmonary congestion by lung ultrasound in heart failure.
    Eur J Heart Fail. 2019 Jun 19. doi: 10.1002/ejhf.1499.
    PubMed     Abstract available


  586. ABRAHAM WT, Ponikowski P, Brueckmann M, Zeller C, et al
    Rationale and design of the EMPERIAL-Preserved and EMPERIAL-Reduced trials of empagliflozin in patients with chronic heart failure.
    Eur J Heart Fail. 2019 Jun 19. doi: 10.1002/ejhf.1486.
    PubMed     Abstract available


  587. AMBROSY AP, DeVore AD, Velazquez EJ
    In-hospital initiation of sacubitril/valsartan in acute decompensated heart failure: being in the right place at the right time.
    Eur J Heart Fail. 2019 Jun 19. doi: 10.1002/ejhf.1540.
    PubMed    


  588. GOHAR A, Rutten FH, den Ruijter H, Kelder JC, et al
    Mid-regional pro-atrial natriuretic peptide for the early detection of non-acute heart failure.
    Eur J Heart Fail. 2019 Jun 17. doi: 10.1002/ejhf.1495.
    PubMed     Abstract available


  589. CAO J, Koay YC, Quek LE, Parker B, et al
    Myocardial substrate changes in advanced ischaemic and advanced dilated human heart failure.
    Eur J Heart Fail. 2019 Jun 11. doi: 10.1002/ejhf.1479.
    PubMed    


  590. FELKER GM, Borentain M, Cleland JG, DeSouza MM, et al
    Rationale and design for the development of a novel nitroxyl donor in patients with acute heart failure.
    Eur J Heart Fail. 2019 Jun 6. doi: 10.1002/ejhf.1504.
    PubMed     Abstract available


  591. MUELLER C, McDonald K, de Boer RA, Maisel A, et al
    Heart Failure Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations.
    Eur J Heart Fail. 2019;21:715-731.
    PubMed     Abstract available


    May 2019
  592. PACKER M
    Major reduction in the risk of sudden cardiac death in patients with chronic heart failure with the use of drug and device combinations that favourably affect left ventricular structure.
    Eur J Heart Fail. 2019 May 29. doi: 10.1002/ejhf.1501.
    PubMed    


  593. WACHTER R, Senni M, Belohlavek J, Straburzynska-Migaj E, et al
    Initiation of sacubitril/valsartan in haemodynamically stabilised heart failure patients in hospital or early after discharge: primary results of the randomised TRANSITION study.
    Eur J Heart Fail. 2019 May 27. doi: 10.1002/ejhf.1498.
    PubMed     Abstract available


  594. KAPELIOS CJ, Lainscak M, Savarese G, Laroche C, et al
    Sacubitril/valsartan eligibility and outcomes in the ESC HFA EORP Heart Failure Long-Term Registry: bridging between EMA/FDA label, the PARADIGM-HF trial, ESC Guidelines, and real-world.
    Eur J Heart Fail. 2019 May 27. doi: 10.1002/ejhf.1532.
    PubMed     Abstract available


  595. SEFEROVIC PM, Ponikowski P, Anker SD, Bauersachs J, et al
    Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of The Heart Failure Association of the European Society of Cardiology.
    Eur J Heart Fail. 2019 May 26. doi: 10.1002/ejhf.1531.
    PubMed     Abstract available


  596. MOCKEL M, Koehler K, Anker SD, Vollert J, et al
    Biomarker Guidance allows a more personalized allocation of patients for Remote Patient Management in Heart Failure Results from the TIM-HF2 Trial.
    Eur J Heart Fail. 2019 May 25. doi: 10.1002/ejhf.1530.
    PubMed     Abstract available


  597. SCHULZ M, Griese-Mammen N, Anker SD, Koehler F, et al
    Pharmacy-based interdisciplinary intervention for patients with chronic heart failure: results of the PHARM-CHF randomized controlled trial.
    Eur J Heart Fail. 2019 May 25. doi: 10.1002/ejhf.1503.
    PubMed     Abstract available


  598. CHIONCEL O, Mebazaa A, Maggioni AP, Harjola VP, et al
    Acute heart failure congestion and perfusion status - impact of the clinical classification on in-hospital and long-term outcomes; insights from the ESC-EORP-HFA Heart Failure Long-Term Registry.
    Eur J Heart Fail. 2019 May 24. doi: 10.1002/ejhf.1492.
    PubMed     Abstract available


  599. JAVALOYES P, Miro O, Gil V, Martin-Sanchez FJ, et al
    Clinical phenotypes of acute heart failure based on signs and symptoms of perfusion and congestion at emergency department presentation and their relationship with patient management and outcomes.
    Eur J Heart Fail. 2019 May 24. doi: 10.1002/ejhf.1502.
    PubMed     Abstract available


  600. BIEGUS J, Zymlinski R, Siwolowski P, Testani J, et al
    Controlled decongestion by Reprieve Therapy in acute heart failure: the results of the TARGET-1 and TARGET-2 Studies.
    Eur J Heart Fail. 2019 May 24. doi: 10.1002/ejhf.1533.
    PubMed     Abstract available


  601. DOEHNER W, von Haehling S
    Intravenous iron supplementation is state of the art therapy in patients with heart failure and iron deficiency.
    Eur J Heart Fail. 2019 May 22. doi: 10.1002/ejhf.1496.
    PubMed    


  602. SENNI M, Adamo M, Metra M, Alfieri O, et al
    Treatment of functional mitral regurgitation in chronic heart failure: can we get a 'proof of concept' from the MITRA-FR and COAPT trials?
    Eur J Heart Fail. 2019 May 22. doi: 10.1002/ejhf.1491.
    PubMed     Abstract available


  603. SEFEROVIC PM, Seferovic JP, Polovina MM
    Diving into the unknown: sodium-glucose cotransporter-2 inhibitors in heart failure without diabetes.
    Eur J Heart Fail. 2019 May 21. doi: 10.1002/ejhf.1500.
    PubMed    


  604. MARKOUSIS-MAVROGENIS G, Tromp J, Ouwerkerk W, Devalaraja M, et al
    The clinical significance of interleukin-6 in heart failure: results from the BIOSTAT-CHF study.
    Eur J Heart Fail. 2019 May 14. doi: 10.1002/ejhf.1482.
    PubMed     Abstract available


  605. VERBRUGGE FH, Martens P, Ameloot K, Haemels V, et al
    Acetazolamide to increase natriuresis in congestive heart failure at high risk for diuretic resistance.
    Eur J Heart Fail. 2019 May 9. doi: 10.1002/ejhf.1478.
    PubMed     Abstract available


  606. MULLENS W, Damman K
    Response to letters on "The use of diuretics in heart failure with congestion - a position statement from the Heart Failure Association of the European Society of Cardiology".
    Eur J Heart Fail. 2019 May 7. doi: 10.1002/ejhf.1477.
    PubMed    


  607. COATS AJS
    Figures of the Heart Failure Association: Professor Dr. med. Johann Bauersachs, Chair of the Clinical Science Section.
    Eur J Heart Fail. 2019;21:545-548.
    PubMed    


  608. COATS AJS
    The first heart failure meeting in the Republic of Kazakhstan.
    Eur J Heart Fail. 2019;21:549.
    PubMed    


  609. COATS AJS
    HFA Committee on Comorbidities - report of a meeting on physiological monitoring in the complex multi-morbid heart failure patient.
    Eur J Heart Fail. 2019;21:543-544.
    PubMed    



  610. Abstracts of the Heart Failure 2019 and the World Congress on Acute Heart Failure, 25-28 May 2019, Megaron Athens International Conference Centre, Greece.
    Eur J Heart Fail. 2019;21 Suppl 1:3-592.
    PubMed    


    April 2019
  611. CHIA YMF, Teng TK, Tay WT, Anand I, et al
    Prescription patterns of anti-diabetic medications and clinical outcomes in Asian patients with heart failure and diabetes mellitus.
    Eur J Heart Fail. 2019 Apr 29. doi: 10.1002/ejhf.1467.
    PubMed    


  612. KOZHUHAROV N, Sabti Z, Wussler D, Nowak A, et al
    Prospective validation of N-terminal pro B-type natriuretic peptide cut-off concentrations for the diagnosis of acute heart failure.
    Eur J Heart Fail. 2019 Apr 24. doi: 10.1002/ejhf.1471.
    PubMed    


  613. PACKER M
    Disproportionate functional mitral regurgitation: a new therapeutic target in patients with heart failure and a reduced ejection fraction.
    Eur J Heart Fail. 2019 Apr 24. doi: 10.1002/ejhf.1469.
    PubMed    


  614. BUTLER J, Khan MS, Anker SD
    Novel potassium binders as enabling therapy in heart failure.
    Eur J Heart Fail. 2019 Apr 16. doi: 10.1002/ejhf.1474.
    PubMed    


  615. SEFEROVIC PM, Polovina M, Bauersachs J, Arad M, et al
    Heart failure in cardiomyopathies: a position paper from the Heart Failure Association of the European Society of Cardiology.
    Eur J Heart Fail. 2019 Apr 16. doi: 10.1002/ejhf.1461.
    PubMed     Abstract available


  616. UIJL A, Lund LH, Savarese G
    The GUIDE-IT heart failure risk prediction model: another fish in the sea?
    Eur J Heart Fail. 2019 Apr 14. doi: 10.1002/ejhf.1472.
    PubMed    


  617. SUDHAKARAN S, McCullough PA
    Common laboratory parameters as indicators of multi-organ dysfunction in acute heart failure.
    Eur J Heart Fail. 2019 Apr 11. doi: 10.1002/ejhf.1466.
    PubMed    


  618. AHMAD FA, Petrie MC, McMurray JJV, Lang NN, et al
    Personalized medicine and hospitalization for heart failure: if we understand it, we may be successful in treating it.
    Eur J Heart Fail. 2019 Apr 11. doi: 10.1002/ejhf.1463.
    PubMed    


  619. DONG Y, Teo SY, Kang K, Tan M, et al
    Cognitive impairment in Asian patients with heart failure: prevalence, biomarkers, clinical correlates, and outcomes.
    Eur J Heart Fail. 2019 Apr 2. doi: 10.1002/ejhf.1442.
    PubMed    


  620. PILICHOU K, Basso C
    Heart failure in arrhythmogenic cardiomyopathy: is phenotypic variability just a matter of genetics?
    Eur J Heart Fail. 2019 Apr 1. doi: 10.1002/ejhf.1456.
    PubMed    


  621. KOMAJDA M, Schope J, Wagenpfeil S, Tavazzi L, et al
    Physicians' guideline adherence is associated with long-term heart failure mortality in outpatients with heart failure with reduced ejection fraction: the QUALIFY international registry.
    Eur J Heart Fail. 2019 Apr 1. doi: 10.1002/ejhf.1459.
    PubMed     Abstract available


  622. PANDEY A, Patel KV, Ayers C, Tang WHW, et al
    Temporal association between hospitalization event and subsequent risk of mortality among patients with stable chronic heart failure with preserved ejection fraction: insights from the TOPCAT trial.
    Eur J Heart Fail. 2019 Apr 1. doi: 10.1002/ejhf.1460.
    PubMed    


  623. METRA M
    April 2019 at a glance: prediction of heart failure, left atrial function, cardio-oncology.
    Eur J Heart Fail. 2019;21:393-394.
    PubMed    


  624. COATS AJS
    Heart Failure Atlas, a major project of the Heart Failure Association in concert with the European Society of Cardiology.
    Eur J Heart Fail. 2019;21:395-397.
    PubMed    


    March 2019
  625. REDDY YNV, Obokata M, Egbe A, Yang JH, et al
    Left atrial strain and compliance in the diagnostic evaluation of heart failure with preserved ejection fraction.
    Eur J Heart Fail. 2019 Mar 28. doi: 10.1002/ejhf.1464.
    PubMed     Abstract available


  626. O'CONNOR C, Fiuzat M, Mulder H, Coles A, et al
    Clinical factors related to morbidity and mortality in high-risk heart failure patients: the GUIDE-IT predictive model and risk score.
    Eur J Heart Fail. 2019 Mar 27. doi: 10.1002/ejhf.1450.
    PubMed     Abstract available


  627. WESSLER BS, McCauley M, Morine K, Konstam MA, et al
    Relation between therapy-induced changes in natriuretic peptide levels and long-term therapeutic effects on mortality in patients with heart failure and reduced ejection fraction.
    Eur J Heart Fail. 2019 Mar 27. doi: 10.1002/ejhf.1411.
    PubMed     Abstract available


  628. MULLENS W, Damman K
    Reply to letters on "The use of diuretics in heart failure with congestion - a position statement from the Heart Failure Association of the European Society of Cardiology".
    Eur J Heart Fail. 2019 Mar 22. doi: 10.1002/ejhf.1462.
    PubMed    


  629. TEMPORELLI PL, Tilz RR, Arbelo E, Dagres N, et al
    Clinical characteristics of heart failure patients undergoing atrial fibrillation ablation today in Europe. Data from the atrial fibrillation registries of the European Society of Cardiology and the European Heart Rhythm Association.
    Eur J Heart Fail. 2019 Mar 21. doi: 10.1002/ejhf.1458.
    PubMed    


  630. MCMURRAY JJV, DeMets DL, Inzucchi SE, Kober L, et al
    A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF).
    Eur J Heart Fail. 2019 Mar 21. doi: 10.1002/ejhf.1432.
    PubMed     Abstract available


  631. BAVENDIEK U, Berliner D, Davila LA, Schwab J, et al
    Rationale and design of the DIGIT-HF trial (DIGitoxin to Improve ouTcomes in patients with advanced chronic Heart Failure): a randomized, double-blind, placebo-controlled study.
    Eur J Heart Fail. 2019 Mar 20. doi: 10.1002/ejhf.1452.
    PubMed     Abstract available


  632. TRULLAS JC, Formiga F, Manzano L
    The use of thiazide and thiazide-like diuretics in heart failure with congestion.
    Eur J Heart Fail. 2019 Mar 20. doi: 10.1002/ejhf.1455.
    PubMed    


  633. RICHARDS AM, Pemberton C, Yandle T
    How does neprilysin inhibition in heart failure work?
    Eur J Heart Fail. 2019 Mar 18. doi: 10.1002/ejhf.1454.
    PubMed    


  634. GHAFOURIAN K, Chang HC, Ardehali H
    Intravenous iron therapy in heart failure: a different perspective.
    Eur J Heart Fail. 2019 Mar 18. doi: 10.1002/ejhf.1434.
    PubMed    


  635. ESCOBAR C, Manzano L
    Mineralocorticoid receptor antagonists and acute heart failure.
    Eur J Heart Fail. 2019 Mar 12. doi: 10.1002/ejhf.1453.
    PubMed    


  636. IKONOMIDIS I, Aboyans V, Blacher J, Brodmann M, et al
    The role of ventricular-arterial coupling in cardiac disease and heart failure: assessment, clinical implications and therapeutic interventions. A consensus document of the European Society of Cardiology Working Group on Aorta & Peripheral Vascula
    Eur J Heart Fail. 2019 Mar 12. doi: 10.1002/ejhf.1436.
    PubMed     Abstract available


  637. SQUIRE I
    Measurement of circulating natriuretic peptides to identify community-based patients at risk of incident heart failure - should we?
    Eur J Heart Fail. 2019 Mar 8. doi: 10.1002/ejhf.1391.
    PubMed    


  638. TER MAATEN JM, Kremer D, Demissei BG, Struck J, et al
    Bio-adrenomedullin as a marker of congestion in patients with new-onset and worsening heart failure.
    Eur J Heart Fail. 2019 Mar 6. doi: 10.1002/ejhf.1437.
    PubMed     Abstract available


  639. PACKER M
    Electrophysiological interventions in the treatment of chronic heart failure: a comparison of the strength of evidence supporting cardiac resynchronization for electrical conduction delay and catheter ablation for atrial fibrillation.
    Eur J Heart Fail. 2019 Mar 6. doi: 10.1002/ejhf.1447.
    PubMed    


  640. PEREIRA NL, Desai VK, Jaffe AS
    Beneficial effects of sacubitril/valsartan in heart failure with reduced ejection fraction: pas a cause du BNP?
    Eur J Heart Fail. 2019 Mar 4. doi: 10.1002/ejhf.1451.
    PubMed    


  641. PAVO N, Gugerell A, Goliasch G, Bartko PE, et al
    Increased granulocyte membrane neprilysin (CD10) expression is associated with better prognosis in heart failure.
    Eur J Heart Fail. 2019 Mar 3. doi: 10.1002/ejhf.1441.
    PubMed    


  642. COATS AJS, Seferovic PM
    News from the American Heart Association: more on sodium-glucose co-transporter 2 inhibitors, diabetes and heart failure.
    Eur J Heart Fail. 2019;21:261-263.
    PubMed    


  643. METRA M
    Figures of the Heart Failure Association: Andrew J. Stewart Coats, President-Elect, 2018-2020.
    Eur J Heart Fail. 2019;21:269-271.
    PubMed    


  644. PAPADAKI A, Martinez-Gonzalez MA, Alonso-Gomez A, Rekondo J, et al
    Mediterranean diet and risk of heart failure: results from the PREDIMED randomized controlled trial. Eur J Heart Fail 2017;19:1179-1185. doi: 10.1002/ejhf.750.
    Eur J Heart Fail. 2019;21:389-391.
    PubMed    


  645. COATS AJS
    Figures of the Heart Failure Association: Petar M. Seferovic, President, 2018-2020.
    Eur J Heart Fail. 2019;21:266-268.
    PubMed    


  646. TER MAATEN JM
    Unravelling the effect of sacubitril/valsartan on loop diuretic dosing.
    Eur J Heart Fail. 2019;21:342-344.
    PubMed    


  647. HAWKINS NM
    Cardiac resynchronization therapy improves survival in selected patients with moderately impaired ejection fraction - the importance of left ventricular remodelling.
    Eur J Heart Fail. 2019;21:370-372.
    PubMed    


  648. METRA M
    March 2019 at a glance: epidemiology and clinical trials.
    Eur J Heart Fail. 2019;21:259-260.
    PubMed    


  649. FERREIRA JP, Abreu P, McMurray JJV, van Veldhuisen DJ, et al
    Renal function stratified dose comparisons of eplerenone versus placebo in the EMPHASIS-HF trial.
    Eur J Heart Fail. 2019;21:345-351.
    PubMed     Abstract available


  650. VARDENY O, Claggett B, Kachadourian J, Desai AS, et al
    Reduced loop diuretic use in patients taking sacubitril/valsartan compared with enalapril: the PARADIGM-HF trial.
    Eur J Heart Fail. 2019;21:337-341.
    PubMed     Abstract available


  651. AMBROSY AP, Stevens SR, Al-Khalidi HR, Rouleau JL, et al
    Burden of medical co-morbidities and benefit from surgical revascularization in patients with ischaemic cardiomyopathy.
    Eur J Heart Fail. 2019;21:373-381.
    PubMed     Abstract available


  652. BUCKLEY LF, Canada JM, Carbone S, Trankle CR, et al
    Potential role for interleukin-1 in the cardio-renal syndrome.
    Eur J Heart Fail. 2019;21:385-386.
    PubMed    


  653. KUTYIFA V, Vermilye K, Solomon SD, McNitt S, et al
    Long-term outcomes of cardiac resynchronization therapy by left ventricular ejection fraction.
    Eur J Heart Fail. 2019;21:360-369.
    PubMed     Abstract available


    February 2019
  654. KUNUTSOR SK, Laukkanen JA
    Heart failure risk reduction: is fit and overweight or obese better than unfit and normal weight?
    Eur J Heart Fail. 2019 Feb 27. doi: 10.1002/ejhf.1440.
    PubMed    


  655. HERMIDA A, Fressart V, Hidden-Lucet F, Donal E, et al
    High risk of heart failure associated with desmoglein-2 mutations compared to plakophilin-2 mutations in arrhythmogenic right ventricular cardiomyopathy/dysplasia.
    Eur J Heart Fail. 2019 Feb 21. doi: 10.1002/ejhf.1423.
    PubMed     Abstract available


  656. KOKKINOS P, Faselis C, Franklin B, Lavie CJ, et al
    Cardiorespiratory fitness, body mass index and heart failure incidence.
    Eur J Heart Fail. 2019 Feb 19. doi: 10.1002/ejhf.1433.
    PubMed     Abstract available


  657. KRISTENSEN SL
    Individualizing surgical revascularization in patients with ischaemic heart failure - a further dive into STICHES.
    Eur J Heart Fail. 2019 Feb 18. doi: 10.1002/ejhf.1426.
    PubMed    


  658. GIRERD N, Platz E
    Beyond clinical examination and natriuretic peptides: comprehensive quantification of congestion with ultrasound in ambulatory heart failure patients.
    Eur J Heart Fail. 2019 Feb 18. doi: 10.1002/ejhf.1422.
    PubMed    


  659. BIEGUS J, Zymlinski R, Sokolski M, Todd J, et al
    Serial assessment of spot urine sodium predicts effectiveness of decongestion and outcome in patients with acute heart failure.
    Eur J Heart Fail. 2019 Feb 17. doi: 10.1002/ejhf.1428.
    PubMed     Abstract available


  660. JANUZZI J, Ferreira JP, Bohm M, Kaul S, et al
    Empagliflozin reduces the risk of a broad spectrum of heart failure outcomes regardless of heart failure status at baseline.
    Eur J Heart Fail. 2019 Feb 14. doi: 10.1002/ejhf.1419.
    PubMed    


  661. OBOKATA M, Borlaug BA
    Left atrial dysfunction: the next key target in heart failure with preserved ejection fraction.
    Eur J Heart Fail. 2019 Feb 8. doi: 10.1002/ejhf.1420.
    PubMed    


  662. AMBROSY AP, Lee KK
    Applying data science approaches to identify frequent flyers in heart failure: rise of the machines.
    Eur J Heart Fail. 2019 Feb 7. doi: 10.1002/ejhf.1387.
    PubMed    


  663. DE BOER RA, De Keulenaer G, Bauersachs J, Brutsaert D, et al
    Towards better definition, quantification and treatment of fibrosis in heart failure. A scientific roadmap by the Committee of Translational Research of the Heart Failure Association (HFA) of the European Society of Cardiology.
    Eur J Heart Fail. 2019 Feb 4. doi: 10.1002/ejhf.1406.
    PubMed     Abstract available


  664. GRODIN JL, Philips S, Mullens W, Nijst P, et al
    Prognostic implications of plasma volume status estimates in heart failure with preserved ejection fraction: insights from TOPCAT.
    Eur J Heart Fail. 2019 Feb 4. doi: 10.1002/ejhf.1407.
    PubMed     Abstract available


  665. USSIA GP
    'Finding the biomarker' for transcatheter mitral valve repair.
    Eur J Heart Fail. 2019;21:193-195.
    PubMed    


  666. PIGHI M, Benfari G, Pesarini G, Ribichini F, et al
    Transcatheter edge-to-edge mitral valve repair: what is the measure of success?
    Eur J Heart Fail. 2019;21:205-207.
    PubMed    


  667. METRA M
    February 2019 at a glance: pathophysiology, exercise capacity, diuretics and valve disease.
    Eur J Heart Fail. 2019;21:135-136.
    PubMed    


  668. PACKER M
    The conundrum of patients with obesity, exercise intolerance, elevated ventricular filling pressures and a measured ejection fraction in the normal range.
    Eur J Heart Fail. 2019;21:156-162.
    PubMed     Abstract available


  669. BLANKINSHIP D, Katz MR, Lozonschi L, Tedford RJ, et al
    Pulmonary artery wedge pressure respiratory variation is correlated with haemodynamic improvement with increased left ventricular assist system speed.
    Eur J Heart Fail. 2019;21:251-253.
    PubMed    


    January 2019
  670. SARTIPY U, Savarese G, Dahlstrom U, Fu M, et al
    Association of heart rate with mortality in sinus rhythm and atrial fibrillation in heart failure with preserved ejection fraction.
    Eur J Heart Fail. 2019 Jan 30. doi: 10.1002/ejhf.1389.
    PubMed     Abstract available


  671. RIENSTRA M, Kotecha D, van Veldhuisen DJ
    Heart rate in patients with atrial fibrillation and heart failure with preserved ejection fraction: a prognosticator like in sinus rhythm?
    Eur J Heart Fail. 2019 Jan 30. doi: 10.1002/ejhf.1425.
    PubMed    


  672. BISTOLA V, Polyzogopoulou E, Ikonomidis I, Parissis J, et al
    Lung ultrasound for the diagnosis of acute heart failure: time to upgrade current indication?
    Eur J Heart Fail. 2019 Jan 28. doi: 10.1002/ejhf.1414.
    PubMed    


  673. STOCKER TJ, Scheck F, Orban M, Braun D, et al
    Physical activity tracking in correlation to conventional heart failure monitoring assessing improvements after transcatheter mitral and tricuspid valve repair.
    Eur J Heart Fail. 2019 Jan 28. doi: 10.1002/ejhf.1418.
    PubMed    


  674. PIVETTA E, Goffi A, Nazerian P, Castagno D, et al
    Lung ultrasound integrated with clinical assessment for the diagnosis of acute decompensated heart failure in the emergency department: a randomized controlled trial.
    Eur J Heart Fail. 2019 Jan 28. doi: 10.1002/ejhf.1379.
    PubMed     Abstract available


  675. KALOGEROPOULOS AP, Butler J
    The other serelaxin in acute heart failure study: lessons from a pragmatic clinical trial.
    Eur J Heart Fail. 2019 Jan 28. doi: 10.1002/ejhf.1416.
    PubMed    


  676. PELLICORI P, Shah P, Cuthbert J, Urbinati A, et al
    Prevalence, pattern and clinical relevance of ultrasound indices of congestion in outpatients with heart failure.
    Eur J Heart Fail. 2019 Jan 22. doi: 10.1002/ejhf.1383.
    PubMed     Abstract available


  677. NAGAI M, Forster CY, Dote K, Shimokawa H, et al
    Sex hormones in heart failure revisited?
    Eur J Heart Fail. 2019 Jan 22. doi: 10.1002/ejhf.1408.
    PubMed    


  678. CAMPBELL DJ, Gong FF, Jelinek MV, Castro JM, et al
    Prediction of incident heart failure by serum amino-terminal pro-B-type natriuretic peptide level in a community-based cohort.
    Eur J Heart Fail. 2019 Jan 18. doi: 10.1002/ejhf.1381.
    PubMed     Abstract available


  679. ANKER SD, Borggrefe M, Neuser H, Ohlow MA, et al
    Cardiac contractility modulation improves long-term survival and hospitalizations in heart failure with reduced ejection fraction.
    Eur J Heart Fail. 2019 Jan 16. doi: 10.1002/ejhf.1374.
    PubMed     Abstract available


  680. TELLES F, Nanayakkara S, Evans S, Patel HC, et al
    Impaired left atrial strain predicts abnormal exercise haemodynamics in heart failure with preserved ejection fraction.
    Eur J Heart Fail. 2019 Jan 16. doi: 10.1002/ejhf.1399.
    PubMed     Abstract available


  681. PAOLILLO S, Veglia F, Salvioni E, Corra U, et al
    Heart failure prognosis over time: how the prognostic role of oxygen consumption and ventilatory efficiency during exercise has changed in the last 20 years.
    Eur J Heart Fail. 2019 Jan 11. doi: 10.1002/ejhf.1364.
    PubMed     Abstract available


  682. CHIONCEL O, Ambrosy AP
    Trimethylamine N-oxide and risk of heart failure progression: marker or mediator of disease.
    Eur J Heart Fail. 2019 Jan 9. doi: 10.1002/ejhf.1409.
    PubMed    


  683. UIJL A, Koudstaal S, Direk K, Denaxas S, et al
    Risk factors for incident heart failure in age- and sex-specific strata: a population-based cohort using linked electronic health records.
    Eur J Heart Fail. 2019 Jan 7. doi: 10.1002/ejhf.1350.
    PubMed     Abstract available


  684. MAGGIONI AP, Lopez-Sendon J, Nielsen OW, Hallen J, et al
    Efficacy and safety of serelaxin when added to standard of care in patients with acute heart failure: results from a PROBE study, RELAX-AHF-EU.
    Eur J Heart Fail. 2019 Jan 2. doi: 10.1002/ejhf.1368.
    PubMed     Abstract available


  685. MULLENS W, Damman K, Harjola VP, Mebazaa A, et al
    The use of diuretics in heart failure with congestion - a position statement from the Heart Failure Association of the European Society of Cardiology.
    Eur J Heart Fail. 2019 Jan 1. doi: 10.1002/ejhf.1369.
    PubMed     Abstract available


  686. FERREIRA JP, Metra M, Anker SD, Dickstein K, et al
    Clinical correlates and outcome associated with changes in 6-minute walking distance in patients with heart failure: findings from the BIOSTAT-CHF study.
    Eur J Heart Fail. 2019 Jan 1. doi: 10.1002/ejhf.1380.
    PubMed     Abstract available


  687. AHMAD T, Freeman JV, Asselbergs FW
    Can advanced analytics fix modern medicine's problem of uncertainty, imprecision, and inaccuracy?
    Eur J Heart Fail. 2019;21:86-89.
    PubMed    


  688. MEHRA MR
    Evolving disruption in left ventricular assist systems: forgiving but not yet forgettable.
    Eur J Heart Fail. 2019;21:98-100.
    PubMed    


  689. LUND LH
    Improving long-term outcomes with left ventricular assist devices-referral, selection, experience, and technology.
    Eur J Heart Fail. 2019;21:101-102.
    PubMed    


  690. FERREIRA JP, Zannad F
    Patient-reported and morbidity-mortality endpoints: can one have the best of both worlds?
    Eur J Heart Fail. 2019;21:71-73.
    PubMed    


  691. VAN KEER JM, Vanassche T, Droogne W, Rex S, et al
    Idarucizumab for the reversal of dabigatran in patients undergoing heart transplantation.
    Eur J Heart Fail. 2019;21:129-131.
    PubMed    


  692. CERISANO G, Buonamici P, Migliorini A, Santini A, et al
    Relation between post-myocardial infarct remodelling and gelatinase activity in patients enrolled in the TIPTOP trial.
    Eur J Heart Fail. 2019;21:127-129.
    PubMed    


  693. METRA M
    January 2019 at a glance: prognostic assessment, left ventricular assist devices, disease management and quality of care.
    Eur J Heart Fail. 2019;21:1-2.
    PubMed    


    December 2018
  694. PIEPOLI MF
    E-health in self-care of heart failure patients: promises become reality.
    Eur J Heart Fail. 2018 Dec 28. doi: 10.1002/ejhf.1386.
    PubMed    


  695. VOORS AA, Kremer D, Geven C, Ter Maaten JM, et al
    Adrenomedullin in heart failure: pathophysiology and therapeutic application.
    Eur J Heart Fail. 2018 Dec 28. doi: 10.1002/ejhf.1366.
    PubMed     Abstract available


  696. KEANE C, McClelland S, Gallagher J, O'Reilly O, et al
    The Heart Failure Virtual Consultation - a powerful tool for the delivery of specialist care and the democratization of knowledge in the community.
    Eur J Heart Fail. 2018 Dec 28. doi: 10.1002/ejhf.1390.
    PubMed    


  697. AMBROSETTI M, La Rovere MT, Scalvini S, Pedretti RFE, et al
    Cardiac rehabilitation in heart failure after the ExTraMATCH II study: who still believes?
    Eur J Heart Fail. 2018 Dec 28. doi: 10.1002/ejhf.1388.
    PubMed    


  698. PATEL RB, Warraich HJ, Butler J, Vaduganathan M, et al
    Surprise, surprise: improving the referral pathway to palliative care interventions in advanced heart failure.
    Eur J Heart Fail. 2018 Dec 28. doi: 10.1002/ejhf.1382.
    PubMed    


  699. MANSOURI I, Allodji RS, Hill C, El-Fayech C, et al
    The role of irradiated heart and left ventricular volumes in heart failure occurrence after childhood cancer.
    Eur J Heart Fail. 2018 Dec 27. doi: 10.1002/ejhf.1376.
    PubMed     Abstract available


  700. ZYMLINSKI R, Sokolski M, Biegus J, Siwolowski P, et al
    Multi-organ dysfunction/injury on admission identifies acute heart failure patients at high risk of poor outcome.
    Eur J Heart Fail. 2018 Dec 18. doi: 10.1002/ejhf.1378.
    PubMed     Abstract available


  701. GO YY, Sellmair R, Allen JC Jr, Sahlen A, et al
    Defining a 'frequent admitter' phenotype among patients with repeat heart failure admissions.
    Eur J Heart Fail. 2018 Dec 13. doi: 10.1002/ejhf.1348.
    PubMed     Abstract available


  702. STRAW S, Byrom R, Gierula J, Paton MF, et al
    Predicting one-year mortality in heart failure using the 'Surprise Question': a prospective pilot study.
    Eur J Heart Fail. 2018 Dec 11. doi: 10.1002/ejhf.1353.
    PubMed     Abstract available


  703. CHANDRAMOULI C, Teng TK, Tay WT, Yap J, et al
    Impact of diabetes and sex in heart failure with reduced ejection fraction patients from the ASIAN-HF registry.
    Eur J Heart Fail. 2018 Dec 10. doi: 10.1002/ejhf.1358.
    PubMed     Abstract available


  704. RORTH R, Jhund PS, Kristensen SL, Desai AS, et al
    The prognostic value of troponin T and N-terminal pro B-type natriuretic peptide, alone and in combination, in heart failure patients with and without diabetes.
    Eur J Heart Fail. 2018 Dec 10. doi: 10.1002/ejhf.1359.
    PubMed     Abstract available


  705. MARTI CN, Fonarow GC, Anker SD, Yancy C, et al
    Medication dosing for heart failure with reduced ejection fraction - opportunities and challenges.
    Eur J Heart Fail. 2018 Dec 10. doi: 10.1002/ejhf.1351.
    PubMed     Abstract available


  706. DEWAN P, Jhund PS, Shen L, Petrie MC, et al
    Heart failure with reduced ejection fraction: comparison of patient characteristics and clinical outcomes within Asia and between Asia, Europe and the Americas.
    Eur J Heart Fail. 2018 Dec 10. doi: 10.1002/ejhf.1347.
    PubMed     Abstract available


  707. NOUGUE H, Pezel T, Picard F, Sadoune M, et al
    Effects of sacubitril/valsartan on neprilysin targets and the metabolism of natriuretic peptides in chronic heart failure: a mechanistic clinical study.
    Eur J Heart Fail. 2018 Dec 6. doi: 10.1002/ejhf.1342.
    PubMed     Abstract available


  708. GROENEWEGEN A, Rutten FH
    Near-home heart failure care.
    Eur J Heart Fail. 2018 Dec 6. doi: 10.1002/ejhf.1345.
    PubMed    


  709. ANKER MS, von Haehling S, Papp Z, Anker SD, et al
    The new Heart Failure Association journal - ESC Heart Failure.
    Eur J Heart Fail. 2018;20:1657-1663.
    PubMed    


  710. FARMAKIS D, Keramida K, Filippatos G
    How to build a cardio-oncology service?
    Eur J Heart Fail. 2018;20:1732-1734.
    PubMed    


  711. FUSSNER LA, Karlstedt E, Hodge DO, Fine NM, et al
    Management and outcomes of cardiac sarcoidosis: a 20-year experience in two tertiary care centres.
    Eur J Heart Fail. 2018;20:1713-1720.
    PubMed     Abstract available


  712. NAUTA JF, Jin X, Hummel YM, Voors AA, et al
    Markers of left ventricular systolic dysfunction when left ventricular ejection fraction is normal.
    Eur J Heart Fail. 2018;20:1636-1638.
    PubMed    


    November 2018
  713. WAGENAAR KP, Broekhuizen BDL, Jaarsma T, Kok I, et al
    Effectiveness of the European Society of Cardiology/Heart Failure Association website 'heartfailurematters.org' and an e-health adjusted care pathway in patients with stable heart failure: results of the 'e-Vita HF' randomized controlled trial.
    Eur J Heart Fail. 2018 Nov 28. doi: 10.1002/ejhf.1354.
    PubMed     Abstract available


  714. TSCHOPE C, Kherad B, Klein O, Lipp A, et al
    Cardiac contractility modulation: mechanisms of action in heart failure with reduced ejection fraction and beyond.
    Eur J Heart Fail. 2018 Nov 28. doi: 10.1002/ejhf.1349.
    PubMed     Abstract available


  715. ADAMOPOULOS S, Corra U, Laoutaris ID, Pistono M, et al
    Exercise training in patients with ventricular assist devices: a review of the evidence and practical advice. A position paper from the Committee on Exercise Physiology and Training and the Committee of Advanced Heart Failure of the Heart Failure Asso
    Eur J Heart Fail. 2018 Nov 26. doi: 10.1002/ejhf.1352.
    PubMed     Abstract available


  716. GEVAERT AB, Beckers PJ, Van Craenenbroeck AH, Lemmens K, et al
    Endothelial dysfunction and cellular repair in heart failure with preserved ejection fraction: response to a single maximal exercise bout.
    Eur J Heart Fail. 2018 Nov 23. doi: 10.1002/ejhf.1339.
    PubMed    


  717. SENNI M, Iorio A, Seferovic P
    Heart failure with preserved ejection fraction in Asia: the far side of the moon?
    Eur J Heart Fail. 2018 Nov 23. doi: 10.1002/ejhf.1335.
    PubMed    


  718. PARATI G, Ochoa JE
    Prognostic value of baroreflex sensitivity in heart failure. A 2018 reappraisal.
    Eur J Heart Fail. 2018 Nov 23. doi: 10.1002/ejhf.1334.
    PubMed    


  719. GREENE SJ, Fonarow GC, Solomon SD, Subacius HP, et al
    Relationship between timing of trial randomization, protocol completion, and clinical outcomes among patients hospitalized for heart failure: from the ASTRONAUT trial.
    Eur J Heart Fail. 2018 Nov 11. doi: 10.1002/ejhf.1310.
    PubMed    


  720. CELUTKIENE J, Plymen CM, Flachskampf FA, de Boer RA, et al
    Innovative imaging methods in heart failure: a shifting paradigm in cardiac assessment. Position statement on behalf of the Heart Failure Association of the European Society of Cardiology.
    Eur J Heart Fail. 2018 Nov 9. doi: 10.1002/ejhf.1330.
    PubMed     Abstract available


  721. GREENE SJ, Felker GM, Butler J
    Outpatient versus inpatient worsening heart failure: distinguishing biology and risk from location of care.
    Eur J Heart Fail. 2018 Nov 5. doi: 10.1002/ejhf.1341.
    PubMed    


  722. METRA M
    November 2018 at a glance: from prediction of heart failure in asymptomatic subjects to advanced chronic heart failure.
    Eur J Heart Fail. 2018;20:1503-1504.
    PubMed    


  723. FLINT K
    Frailty in TOPCAT: a deep dive into the deficit index approach for defining frailty.
    Eur J Heart Fail. 2018;20:1578-1579.
    PubMed    


  724. GORI M, Redfield MM, Calabrese A, Canova P, et al
    Is mild asymptomatic left ventricular systolic dysfunction always predictive of adverse events in high-risk populations? Insights from the DAVID-Berg study.
    Eur J Heart Fail. 2018;20:1540-1548.
    PubMed     Abstract available


  725. SANDERS NA, Supiano MA, Lewis EF, Liu J, et al
    The frailty syndrome and outcomes in the TOPCAT trial.
    Eur J Heart Fail. 2018;20:1570-1577.
    PubMed     Abstract available


    October 2018
  726. SUZUKI T, Yazaki Y, Voors AA, Jones DJL, et al
    Association with outcomes and response to treatment of trimethylamine N-oxide in heart failure (from BIOSTAT-CHF).
    Eur J Heart Fail. 2018 Oct 29. doi: 10.1002/ejhf.1338.
    PubMed     Abstract available


  727. COWIE MR, Gallagher AM, Simonds AK
    Treating central sleep apnoea in heart failure: is pull better than push?
    Eur J Heart Fail. 2018 Oct 23. doi: 10.1002/ejhf.1337.
    PubMed    


  728. VAN DER POL A, van Gilst WH, Voors AA, van der Meer P, et al
    Treating oxidative stress in heart failure: past, present and future.
    Eur J Heart Fail. 2018 Oct 19. doi: 10.1002/ejhf.1320.
    PubMed     Abstract available


  729. FERREIRA JP, Metra M, Mordi I, Gregson J, et al
    Heart failure in the outpatient versus inpatient setting: findings from the BIOSTAT-CHF study.
    Eur J Heart Fail. 2018 Oct 19. doi: 10.1002/ejhf.1323.
    PubMed     Abstract available


  730. LILJEROOS M, Stromberg A
    Introducing nurse-led heart failure clinics in Swedish primary care settings.
    Eur J Heart Fail. 2018 Oct 19. doi: 10.1002/ejhf.1329.
    PubMed     Abstract available


  731. WOLLERT KC
    Growth differentiation factor-15 reveals the dark side of heart failure.
    Eur J Heart Fail. 2018 Oct 17. doi: 10.1002/ejhf.1327.
    PubMed    


  732. SEQUEIRA V, Maack C
    Rebalancing protein phosphorylation in heart failure to prevent arrhythmias.
    Eur J Heart Fail. 2018 Oct 17. doi: 10.1002/ejhf.1315.
    PubMed    


  733. CIKES M, Sanchez-Martinez S, Claggett B, Duchateau N, et al
    Machine learning-based phenogrouping in heart failure to identify responders to cardiac resynchronization therapy.
    Eur J Heart Fail. 2018 Oct 17. doi: 10.1002/ejhf.1333.
    PubMed     Abstract available


  734. CAMPBELL RT, Petrie MC, McMurray JJV
    Redefining heart failure phenotypes based on ejection fraction.
    Eur J Heart Fail. 2018 Oct 17. doi: 10.1002/ejhf.1325.
    PubMed    


  735. PABEL S, Wagner S, Bollenberg H, Bengel P, et al
    Empagliflozin directly improves diastolic function in human heart failure.
    Eur J Heart Fail. 2018 Oct 17. doi: 10.1002/ejhf.1328.
    PubMed     Abstract available


  736. MCDONAGH T, Damy T, Doehner W, Lam CSP, et al
    Screening, diagnosis and treatment of iron deficiency in chronic heart failure: putting the 2016 European Society of Cardiology heart failure guidelines into clinical practice.
    Eur J Heart Fail. 2018 Oct 12. doi: 10.1002/ejhf.1305.
    PubMed     Abstract available


  737. COSTANZO MR, Ponikowski P, Coats A, Javaheri S, et al
    Phrenic nerve stimulation to treat patients with central sleep apnoea and heart failure.
    Eur J Heart Fail. 2018 Oct 10. doi: 10.1002/ejhf.1312.
    PubMed     Abstract available


  738. PATEL HC, Kaye DM
    Exercise training in heart failure: a long way to go yet.
    Eur J Heart Fail. 2018 Oct 9. doi: 10.1002/ejhf.1332.
    PubMed    


  739. MCCARTHY CP, Vaduganathan M, Pandey A
    Developing evidence-based and accountable health policy in heart failure.
    Eur J Heart Fail. 2018 Oct 8. doi: 10.1002/ejhf.1331.
    PubMed    


  740. CAMPBELL RT, Petrie MC, McMurray JJV
    Talking to patients with heart failure about end of life.
    Eur J Heart Fail. 2018 Oct 8. doi: 10.1002/ejhf.1321.
    PubMed    


  741. STRENG KW, Lang CC, Voors AA
    What is the added value of the waist-to-hip ratio on top of the BIOSTAT risk prediction model in patients with heart failure? Reply.
    Eur J Heart Fail. 2018 Oct 8. doi: 10.1002/ejhf.1324.
    PubMed    


  742. PAPP Z, Radovits T, Paulus WJ, Hamdani N, et al
    Molecular and pathophysiological links between heart failure with preserved ejection fraction and type 2 diabetes mellitus.
    Eur J Heart Fail. 2018 Oct 2. doi: 10.1002/ejhf.1318.
    PubMed    


  743. CORRA U, Agostoni PG, Anker SD, Coats AJS, et al
    Corrigendum to 'Role of cardiopulmonary exercise testing in clinical stratification in heart failure. A position paper from the Committee on Exercise Physiology and Training of the Heart Failure Association of the European Society of Cardiology' [Eur
    Eur J Heart Fail. 2018;20:1501.
    PubMed    


  744. CAPTUR G, Bilinska Z, Arbustini E
    Lamin missense mutations-the spectrum of phenotype variability is increasing.
    Eur J Heart Fail. 2018;20:1413-1416.
    PubMed    


  745. TER MAATEN JM, Damman K
    Chloride, what else?
    Eur J Heart Fail. 2018;20:1444-1446.
    PubMed    


  746. BORIANI G, Diemberger I
    Cardiac resynchronization therapy in the real world: need to upgrade outcome research.
    Eur J Heart Fail. 2018;20:1469-1471.
    PubMed    


  747. SINAGRA G, Merlo M, Cannata A
    Gender medicine in dilated cardiomyopathy: pride and prejudice.
    Eur J Heart Fail. 2018;20:1401-1403.
    PubMed    


  748. SKELIN M, Lucijanic M, Javor E
    Risk stratification according to insulin type.
    Eur J Heart Fail. 2018;20:1497.
    PubMed    


  749. LECLERCQ C, Galand V, Behar N, Martins R, et al
    I had a dream....
    Eur J Heart Fail. 2018;20:1482-1484.
    PubMed    


  750. COSMI F, Staszewsky L, McMurray JJV, Latini R, et al
    Risk stratification according to insulin type: reply.
    Eur J Heart Fail. 2018;20:1498.
    PubMed    


  751. AL-SAAIDI RA, Rasmussen TB, Birkler RID, Palmfeldt J, et al
    The clinical outcome of LMNA missense mutations can be associated with the amount of mutated protein in the nuclear envelope.
    Eur J Heart Fail. 2018;20:1404-1412.
    PubMed     Abstract available


  752. LINDE CM, Normand C, Bogale N, Auricchio A, et al
    Upgrades from a previous device compared to de novo cardiac resynchronization therapy in the European Society of Cardiology CRT Survey II.
    Eur J Heart Fail. 2018;20:1457-1468.
    PubMed     Abstract available


    September 2018
  753. TAYLOR RS, Walker S, Smart NA, Piepoli MF, et al
    Impact of exercise-based cardiac rehabilitation in patients with heart failure (ExTraMATCH II) on mortality and hospitalisation: an individual patient data meta-analysis of randomised trials.
    Eur J Heart Fail. 2018 Sep 26. doi: 10.1002/ejhf.1311.
    PubMed     Abstract available


  754. MULLENS W, Verbrugge FH, Nijst P, Martens P, et al
    Rationale and design of the ADVOR (Acetazolamide in Decompensated Heart Failure with Volume Overload) trial.
    Eur J Heart Fail. 2018 Sep 21. doi: 10.1002/ejhf.1307.
    PubMed     Abstract available


  755. KOEHLER F, Koehler K, Deckwart O, Prescher S, et al
    Telemedical Interventional Management in Heart Failure II (TIM-HF2), a randomised, controlled trial investigating the impact of telemedicine on unplanned cardiovascular hospitalisations and mortality in heart failure patients: study design and descrip
    Eur J Heart Fail. 2018 Sep 19. doi: 10.1002/ejhf.1300.
    PubMed     Abstract available


  756. GREENBERG B, Fang J, Mehra M, Stevenson LW, et al
    Advanced heart failure: Trans-Atlantic perspectives on the Heart Failure Association of the European Society of Cardiology position statement.
    Eur J Heart Fail. 2018 Sep 18. doi: 10.1002/ejhf.1313.
    PubMed    


  757. VENTURA HO, Carbone S, Lavie CJ
    Muscling up to improve heart failure prognosis.
    Eur J Heart Fail. 2018 Sep 18. doi: 10.1002/ejhf.1314.
    PubMed    


  758. PACKER M
    The epicardial adipose inflammatory triad: coronary atherosclerosis, atrial fibrillation, and heart failure with a preserved ejection fraction.
    Eur J Heart Fail. 2018 Sep 17. doi: 10.1002/ejhf.1294.
    PubMed    


  759. VOORS AA, Shah SJ, Bax JJ, Butler J, et al
    Rationale and design of the phase 2b clinical trials to study the effects of the partial adenosine A1-receptor agonist neladenoson bialanate in patients with chronic heart failure with reduced (PANTHEON) and preserved (PANACHE) ejection fraction.
    Eur J Heart Fail. 2018 Sep 17. doi: 10.1002/ejhf.1295.
    PubMed     Abstract available


  760. BOUABDALLAOUI N, Claggett B, Zile MR, McMurray JJV, et al
    Growth differentiation factor-15 is not modified by sacubitril/valsartan and is an independent marker of risk in patients with heart failure and reduced ejection fraction: the PARADIGM-HF trial.
    Eur J Heart Fail. 2018 Sep 11. doi: 10.1002/ejhf.1301.
    PubMed     Abstract available


  761. FISCHER TH, Eiringhaus J, Dybkova N, Saadatmand A, et al
    Activation of protein phosphatase 1 by a selective phosphatase disrupting peptide reduces sarcoplasmic reticulum Ca(2+) leak in human heart failure.
    Eur J Heart Fail. 2018 Sep 7. doi: 10.1002/ejhf.1297.
    PubMed     Abstract available


  762. PALECZNY B, Olesinska-Mader M, Siennicka A, Niewinski P, et al
    Assessment of baroreflex sensitivity has no prognostic value in contemporary, optimally managed patients with mild-to-moderate heart failure with reduced ejection fraction: a retrospective analysis of 5-year survival.
    Eur J Heart Fail. 2018 Sep 6. doi: 10.1002/ejhf.1306.
    PubMed     Abstract available


  763. METRA M
    September 2018 at a glance: co-morbidities, heart failure with preserved ejection fraction and mineralocorticoid receptor antagonists.
    Eur J Heart Fail. 2018;20:1245-1246.
    PubMed    


  764. BUTLER J, Vijayakumar S, Pitt B
    Revisiting hyperkalaemia guidelines: rebuttal.
    Eur J Heart Fail. 2018;20:1255.
    PubMed    


  765. BAYES-GENIS A, Lupon J, Nunez J
    No urgent need for revisiting kalaemia guidelines: rebuttal.
    Eur J Heart Fail. 2018;20:1256.
    PubMed    


  766. MAGGIONI AP
    Smartphones, barbershops, and pharmacists to improve adherence to drug treatment in chronic cardiovascular conditions: the end justifies all the means.
    Eur J Heart Fail. 2018;20:1360-1362.
    PubMed    


  767. BAYES-GENIS A, Lupon J, Nunez J
    No need for urgent revisiting of kalaemia levels in guidelines despite use of mineralocorticoid receptor antagonists: bring in more evidence.
    Eur J Heart Fail. 2018;20:1252-1254.
    PubMed    


    August 2018
  768. LUO N, O'Connor CM, Cooper LB, Sun JL, et al
    Relationship between changing patient-reported outcomes and subsequent clinical events in patients with chronic heart failure: insights from HF-ACTION.
    Eur J Heart Fail. 2018 Aug 31. doi: 10.1002/ejhf.1299.
    PubMed     Abstract available


  769. EMAMI A, Saitoh M, Valentova M, Sandek A, et al
    Comparison of sarcopenia and cachexia in men with chronic heart failure: results from the Studies Investigating Co-morbidities Aggravating Heart Failure (SICA-HF).
    Eur J Heart Fail. 2018 Aug 30. doi: 10.1002/ejhf.1304.
    PubMed     Abstract available


  770. CAO TH
    What is the added value of the waist-to-hip ratio on top of the BIOSTAT risk prediction model in patients with heart failure?
    Eur J Heart Fail. 2018 Aug 23. doi: 10.1002/ejhf.1303.
    PubMed    


  771. GODINO C, Scotti A, Munafo A, Taramasso M, et al
    Observed versus predicted mortality after MitraClip treatment in patients with symptomatic heart failure and significant functional mitral regurgitation.
    Eur J Heart Fail. 2018 Aug 23. doi: 10.1002/ejhf.1291.
    PubMed    


  772. TROMP J, Teng TH, Tay WT, Hung CL, et al
    Heart failure with preserved ejection fraction in Asia.
    Eur J Heart Fail. 2018 Aug 16. doi: 10.1002/ejhf.1227.
    PubMed     Abstract available


  773. GRAZIANI F, Varone F, Crea F, Richeldi L, et al
    Treating heart failure with preserved ejection fraction: learning from pulmonary fibrosis.
    Eur J Heart Fail. 2018 Aug 7. doi: 10.1002/ejhf.1286.
    PubMed     Abstract available


  774. GAGLIARDI C, Perfetto F, Lorenzini M, Ferlini A, et al
    Phenotypic profile of Ile68Leu transthyretin amyloidosis: an underdiagnosed cause of heart failure.
    Eur J Heart Fail. 2018 Aug 2. doi: 10.1002/ejhf.1285.
    PubMed     Abstract available


  775. VAN WOERDEN G, Gorter TM, Daan Westenbrink B, Willems TP, et al
    Epicardial fat in heart failure patients with mid-range and preserved ejection fraction.
    Eur J Heart Fail. 2018 Aug 1. doi: 10.1002/ejhf.1283.
    PubMed     Abstract available


  776. CLERICO A, Passino C, Emdin M
    The paradox of low B-type natriuretic peptide levels in obesity revisited: does sex matter?
    Eur J Heart Fail. 2018;20:1215-1216.
    PubMed    


  777. PIZARD A
    In need of signalling pathway data.
    Eur J Heart Fail. 2018;20:1202-1204.
    PubMed    


  778. COOPER LB, Hernandez AF
    Maximizing benefits and mitigating risks with mineralocorticoid receptor antagonist therapy.
    Eur J Heart Fail. 2018;20:1227-1229.
    PubMed    


  779. MADIAS JE
    Tachycardia and hypotension in patients with takotsubo syndrome: any insights about their management?
    Eur J Heart Fail. 2018;20:1243.
    PubMed    


  780. METRA M
    August 2018 at a glance: patients' outcomes, obesity and medical therapy.
    Eur J Heart Fail. 2018;20:1167-1168.
    PubMed    


  781. SUTHAHAR N, Meijers WC, Ho JE, Gansevoort RT, et al
    Sex-specific associations of obesity and N-terminal pro-B-type natriuretic peptide levels in the general population.
    Eur J Heart Fail. 2018;20:1205-1214.
    PubMed     Abstract available


  782. GUPTA A, Fonarow GC
    The Hospital Readmissions Reduction Program-learning from failure of a healthcare policy.
    Eur J Heart Fail. 2018;20:1169-1174.
    PubMed     Abstract available


  783. TREVISAN M, de Deco P, Xu H, Evans M, et al
    Incidence, predictors and clinical management of hyperkalaemia in new users of mineralocorticoid receptor antagonists.
    Eur J Heart Fail. 2018;20:1217-1226.
    PubMed     Abstract available


    July 2018
  784. MAGINI A, Farina S, Riggio D, Sandri MT, et al
    ST2 and B-type natriuretic peptide kinetics during exercise in severe heart failure.
    Eur J Heart Fail. 2018 Jul 27. doi: 10.1002/ejhf.1246.
    PubMed    


  785. COTTER G, Davison BA
    Unmodifiable events, heart failure research, and 'risk-based monitoring' in large studies-the unholy triumvirate.
    Eur J Heart Fail. 2018 Jul 27. doi: 10.1002/ejhf.1282.
    PubMed    


  786. SCHMITTO JD, Pya Y, Zimpfer D, Krabatsch T, et al
    Long-term evaluation of a fully magnetically levitated circulatory support device for advanced heart failure-two-year results from the HeartMate 3 CE Mark Study.
    Eur J Heart Fail. 2018 Jul 27. doi: 10.1002/ejhf.1284.
    PubMed     Abstract available


  787. DOEHNER W, Celutkiene J, Haeusler KG
    Central command in heart failure: was there effect of hemispheric lateralization in insular cortex activation? Reply.
    Eur J Heart Fail. 2018 Jul 13. doi: 10.1002/ejhf.1281.
    PubMed    


  788. CARBONE S, Elagizi A, Lavie CJ
    Obesity and mortality risk in heart failure: when adipose tissue distribution matters.
    Eur J Heart Fail. 2018 Jul 12. doi: 10.1002/ejhf.1279.
    PubMed    


  789. MAHMOOD SS, Patel RB, Butler J, Vaduganathan M, et al
    Epirubicin and long-term heart failure risk in breast cancer survivors.
    Eur J Heart Fail. 2018 Jul 4. doi: 10.1002/ejhf.1215.
    PubMed    


  790. STRENG KW, Voors AA, Hillege HL, Anker SD, et al
    Waist-to-hip ratio and mortality in heart failure.
    Eur J Heart Fail. 2018 Jul 2. doi: 10.1002/ejhf.1244.
    PubMed     Abstract available


  791. JAARSMA T, van der Wal M, Hjelmfors L, Stromberg A, et al
    Talking about palliative care in heart failure.
    Eur J Heart Fail. 2018 Jul 2. doi: 10.1002/ejhf.1239.
    PubMed    


  792. PATEL KV, Pandey A
    Prognostic implications of microvascular complications in patients with diabetes and heart failure with reduced ejection fraction.
    Eur J Heart Fail. 2018 Jul 2. doi: 10.1002/ejhf.1253.
    PubMed    


  793. METRA M
    July 2018 at a glance: practical guidance in acute heart failure, pathophysiology and clinical trials of medical therapy.
    Eur J Heart Fail. 2018;20:1079-1080.
    PubMed    


  794. ALTENBERGER J, Polzl G
    Repetitive levosimendan for a LION's heart?
    Eur J Heart Fail. 2018;20:1137-1138.
    PubMed    


  795. COSTANZO MR, Kazory A
    Better late than never: the true results of CARRESS-HF.
    Eur J Heart Fail. 2018;20:1157-1159.
    PubMed    


    June 2018
  796. CAMPBELL RT, Petrie MC, Jackson CE, Jhund PS, et al
    Which patients with heart failure should receive specialist palliative care?
    Eur J Heart Fail. 2018 Jun 28. doi: 10.1002/ejhf.1240.
    PubMed     Abstract available


  797. COOPER LB, Yap J, Tay WT, Teng TK, et al
    Multi-ethnic comparisons of diabetes in heart failure with reduced ejection fraction: insights from the HF-ACTION trial and the ASIAN-HF registry.
    Eur J Heart Fail. 2018 Jun 26. doi: 10.1002/ejhf.1223.
    PubMed     Abstract available


  798. ANKER MS, von Haehling S, Landmesser U, Coats AJS, et al
    Cancer and heart failure-more than meets the eye: common risk factors and co-morbidities.
    Eur J Heart Fail. 2018 Jun 26. doi: 10.1002/ejhf.1252.
    PubMed    


  799. CUTHBERT JJ, Pellicori P, Rigby A, Pan D, et al
    Low serum chloride in patients with chronic heart failure: clinical associations and prognostic significance.
    Eur J Heart Fail. 2018 Jun 26. doi: 10.1002/ejhf.1247.
    PubMed     Abstract available


  800. SIMONOVIC D, Coiro S, Carluccio E, Girerd N, et al
    Exercise elicits dynamic changes in extravascular lung water and haemodynamic congestion in heart failure patients with preserved ejection fraction.
    Eur J Heart Fail. 2018 Jun 26. doi: 10.1002/ejhf.1228.
    PubMed    


  801. PASCUAL-FIGAL D, Bayes-Genis A
    The misperception of 'stable' heart failure.
    Eur J Heart Fail. 2018 Jun 26. doi: 10.1002/ejhf.1248.
    PubMed    


  802. PATEL RB, Vaduganathan M, Greene SJ, Butler J, et al
    Nomenclature in heart failure: a call for objective, reproducible, and biologically-driven terminology.
    Eur J Heart Fail. 2018 Jun 26. doi: 10.1002/ejhf.1231.
    PubMed    


  803. VACCARO O, Riccardi G, Maggioni AP
    Risk of heart failure in diabetic patients receiving sulfonylureas.
    Eur J Heart Fail. 2018 Jun 22. doi: 10.1002/ejhf.1238.
    PubMed    


  804. AMBROSY AP, Chioncel O
    Combination drug therapy in heart failure: greater than the sum of its parts.
    Eur J Heart Fail. 2018 Jun 22. doi: 10.1002/ejhf.1251.
    PubMed    


  805. KREMER D, Ter Maaten JM, Voors AA
    Bio-adrenomedullin as a potential quick, reliable, and objective marker of congestion in heart failure.
    Eur J Heart Fail. 2018 Jun 22. doi: 10.1002/ejhf.1245.
    PubMed    


  806. OBOKATA M, Borlaug BA
    The strengths and limitations of E/e' in heart failure with preserved ejection fraction.
    Eur J Heart Fail. 2018 Jun 22. doi: 10.1002/ejhf.1250.
    PubMed    


  807. IORIO A, Senni M, Barbati G, Greene SJ, et al
    Prevalence and prognostic impact of non-cardiac co-morbidities in heart failure outpatients with preserved and reduced ejection fraction: a community-based study.
    Eur J Heart Fail. 2018 Jun 19. doi: 10.1002/ejhf.1202.
    PubMed     Abstract available


  808. WOLSK E
    Heart failure and co-morbidity revisited; the elephant in the room.
    Eur J Heart Fail. 2018 Jun 19. doi: 10.1002/ejhf.1225.
    PubMed    


  809. GRODIN JL, Testani JM, Pandey A, Sambandam K, et al
    Perturbations in serum chloride homeostasis in heart failure with preserved ejection fraction: insights from TOPCAT.
    Eur J Heart Fail. 2018 Jun 12. doi: 10.1002/ejhf.1229.
    PubMed     Abstract available


  810. SOKORELI I, Pauws SC, Riistama JM, Cleland JG, et al
    Psychosocial factors and mortality in patients with heart failure: reply.
    Eur J Heart Fail. 2018 Jun 12. doi: 10.1002/ejhf.1224.
    PubMed    


  811. NAGAI M, Dote K, Kato M
    Central command in heart failure: was there effect of hemispheric lateralization in insular cortex activation?
    Eur J Heart Fail. 2018 Jun 11. doi: 10.1002/ejhf.1233.
    PubMed    


  812. PACKER M
    Risk of heart failure in diabetic patients receiving sulfonylureas: reply.
    Eur J Heart Fail. 2018 Jun 11. doi: 10.1002/ejhf.1232.
    PubMed    


  813. BUTLER J, Vijayakumar S, Pitt B
    Need to revisit heart failure treatment guidelines for hyperkalaemia management during the use of mineralocorticoid receptor antagonists.
    Eur J Heart Fail. 2018 Jun 8. doi: 10.1002/ejhf.1217.
    PubMed    


  814. NAUTA JF, Hummel YM, van der Meer P, Lam CSP, et al
    Correlation with invasive left ventricular filling pressures and prognostic relevance of the echocardiographic diastolic parameters used in the 2016 ESC heart failure guidelines and in the 2016 ASE/EACVI recommendations: a systematic review in patient
    Eur J Heart Fail. 2018 Jun 7. doi: 10.1002/ejhf.1220.
    PubMed     Abstract available


  815. METRA M
    June 2018 at a glance: peripartum cardiomyopathy and pathophysiology, prognosis, and device therapy of heart failure.
    Eur J Heart Fail. 2018;20:949-950.
    PubMed    


    May 2018
  816. KONSTAM MA
    Seeking therapeutic precision in heart failure: is ejection fraction really the way? Deconstructing the CHARM of heart failure with mid-range ejection fraction.
    Eur J Heart Fail. 2018 May 31. doi: 10.1002/ejhf.1205.
    PubMed    


  817. ROSSIGNOL P, Ferreira JP, Zannad F
    Fibrosis mechanistic phenotyping and antifibrotic response determination with biomarkers in heart failure: one single biomarker may not fit all settings.
    Eur J Heart Fail. 2018 May 31. doi: 10.1002/ejhf.1214.
    PubMed    


  818. GREENBERG B
    Mineralocorticoid receptor antagonists in heart failure: they work better when patients use them.
    Eur J Heart Fail. 2018 May 31. doi: 10.1002/ejhf.1222.
    PubMed    


  819. LAUFS U, Griese-Mammen N, Krueger K, Wachter A, et al
    PHARMacy-based interdisciplinary program for patients with Chronic Heart Failure (PHARM-CHF): rationale and design of a randomized controlled trial, and results of the pilot study.
    Eur J Heart Fail. 2018 May 30. doi: 10.1002/ejhf.1213.
    PubMed     Abstract available


  820. NAGAI T, Sundaram V, Shoaib A, Shiraishi Y, et al
    Validation of U.S. mortality prediction models for hospitalized heart failure in the United Kingdom and Japan.
    Eur J Heart Fail. 2018 May 30. doi: 10.1002/ejhf.1210.
    PubMed     Abstract available


  821. KOMAJDA M, Bohm M, Borer JS, Ford I, et al
    Incremental benefit of drug therapies for chronic heart failure with reduced ejection fraction: a network meta-analysis.
    Eur J Heart Fail. 2018 May 27. doi: 10.1002/ejhf.1234.
    PubMed     Abstract available


  822. CRESPO-LEIRO MG, Metra M, Lund LH, Milicic D, et al
    Advanced heart failure: a position statement of the Heart Failure Association of the European Society of Cardiology.
    Eur J Heart Fail. 2018 May 27. doi: 10.1002/ejhf.1236.
    PubMed     Abstract available


  823. SHARMA A, Al-Khatib SM, Ezekowitz JA, Cooper LB, et al
    Implantable cardioverter-defibrillators in heart failure patients with reduced ejection fraction and diabetes.
    Eur J Heart Fail. 2018 May 15. doi: 10.1002/ejhf.1192.
    PubMed     Abstract available


  824. KRISTENSEN SL, Rorth R, Jhund PS, Shen L, et al
    Microvascular complications in diabetes patients with heart failure and reduced ejection fraction-insights from the Beta-blocker Evaluation of Survival Trial.
    Eur J Heart Fail. 2018 May 4. doi: 10.1002/ejhf.1201.
    PubMed     Abstract available


  825. KORATALA A
    Metabolic abnormalities in heart failure patients treated with ultrafiltration versus diuretics.
    Eur J Heart Fail. 2018 May 3. doi: 10.1002/ejhf.1207.
    PubMed    



  826. Abstracts of the Heart Failure 2018 and the World Congress on Acute Heart Failure, 26-29 May 2018, Vienna, Austria.
    Eur J Heart Fail. 2018;20 Suppl 1:5-638.
    PubMed    


  827. MARTENS P, Dupont M, Mullens W
    Cardiac iron deficiency-how to refuel the engine out of fuel.
    Eur J Heart Fail. 2018;20:920-922.
    PubMed    


  828. FARMAKIS D, Mantzourani M, Filippatos G
    Anthracycline-induced cardiomyopathy: secrets and lies.
    Eur J Heart Fail. 2018;20:907-909.
    PubMed    


  829. GHIO S
    The need for evaluating right ventricular adaptation and ventriculo-arterial coupling: reply.
    Eur J Heart Fail. 2018;20:944-945.
    PubMed    


  830. PALAZZUOLI A, Ruocco G, Lombardi C
    The need for evaluating right ventricular adaptation and ventriculo-arterial coupling.
    Eur J Heart Fail. 2018;20:943-944.
    PubMed    


  831. PALAZZINI M, Dardi F, Galie N
    Pulmonary vascular disease due to left heart disease: how to achieve a more accurate approach beyond the haemodynamic phenotype: reply.
    Eur J Heart Fail. 2018;20:943.
    PubMed    


  832. GRIGNOLA JC, Trujillo P, Domingo E
    Pulmonary vascular disease due to left heart disease: how to achieve a more accurate approach beyond the haemodynamic phenotype.
    Eur J Heart Fail. 2018;20:942-943.
    PubMed    


  833. METRA M
    May 2018 at a glance: the central role of co-morbidities.
    Eur J Heart Fail. 2018;20:833-834.
    PubMed    


  834. HOES MF, Grote Beverborg N, Kijlstra JD, Kuipers J, et al
    Iron deficiency impairs contractility of human cardiomyocytes through decreased mitochondrial function.
    Eur J Heart Fail. 2018;20:910-919.
    PubMed     Abstract available


  835. GEIJTEMAN ECT
    Denying the inevitability of death.
    Eur J Heart Fail. 2018;20:835-836.
    PubMed    


    April 2018
  836. HARJOLA VP, Parissis J, Brunner-La Rocca HP, Celutkiene J, et al
    Comprehensive in-hospital monitoring in acute heart failure: applications for clinical practice and future directions for research. A statement from the Acute Heart Failure Committee of the Heart Failure Association (HFA) of the European Society of Ca
    Eur J Heart Fail. 2018 Apr 30. doi: 10.1002/ejhf.1204.
    PubMed     Abstract available


  837. RAVASSA S, Trippel T, Bach D, Bachran D, et al
    Biomarker-based phenotyping of myocardial fibrosis identifies patients with heart failure with preserved ejection fraction resistant to the beneficial effects of spironolactone: results from the Aldo-DHF trial.
    Eur J Heart Fail. 2018 Apr 30. doi: 10.1002/ejhf.1194.
    PubMed     Abstract available


  838. KAWADA T
    Psychosocial factors and mortality in patients with heart failure.
    Eur J Heart Fail. 2018 Apr 24. doi: 10.1002/ejhf.1208.
    PubMed    


  839. VAN VELDHUISEN DJ, Rienstra M, van der Meer P
    Value of digoxin in patients with heart failure: new pieces to the puzzle.
    Eur J Heart Fail. 2018 Apr 20. doi: 10.1002/ejhf.1200.
    PubMed    


  840. CERLINSKAITE K, Hollinger A, Mebazaa A, Cinotti R, et al
    Finding the balance between costs and quality in heart failure: a global challenge.
    Eur J Heart Fail. 2018 Apr 19. doi: 10.1002/ejhf.1195.
    PubMed    


  841. ALLA F, Agrinier N, Lavielle M, Rossignol P, et al
    Impact of the interruption of a large heart failure regional disease management programme on hospital admission rates: a population-based study.
    Eur J Heart Fail. 2018 Apr 16. doi: 10.1002/ejhf.1193.
    PubMed    


  842. DOEHNER W, Ural D, Celutkiene J
    Heart-brain interactions in patients with heart failure, including takotsubo syndrome: a need to monitor autonomic sympathetic activity: reply.
    Eur J Heart Fail. 2018 Apr 14. doi: 10.1002/ejhf.1177.
    PubMed    


  843. KLEBER FX, Koln PJ
    Oxygen consumption trajectory flattening-yet another cardiopulmonary exercise testing parameter in chronic heart failure.
    Eur J Heart Fail. 2018 Apr 14. doi: 10.1002/ejhf.1181.
    PubMed    


  844. GRODIN JL, Tang WHW
    I will take my heart failure 'lactate-free' please.
    Eur J Heart Fail. 2018 Apr 10. doi: 10.1002/ejhf.1190.
    PubMed    


  845. NORMAND C, Dickstein K
    Guideline recommendations for cardiac resynchronization therapy evolve but does clinical practice match the pace?
    Eur J Heart Fail. 2018;20:778-779.
    PubMed    


  846. MCMURRAY JJV
    Renin-angiotensin system inhibition-it's been a long but fruitful journey.
    Eur J Heart Fail. 2018;20:687-688.
    PubMed    


  847. VAN DEN BERGH WM, Droogh JM, Damman K
    You do something to me, something deep inside.
    Eur J Heart Fail. 2018;20:801-802.
    PubMed    


  848. HOWLETT JG
    The promise of patient-reported outcomes: one step closer to routine care.
    Eur J Heart Fail. 2018;20:697-699.
    PubMed    


  849. SINAGRA G, Fabris E
    Inflammation in cardiac amyloidosis: prognostic marker or therapeutic target?
    Eur J Heart Fail. 2018;20:758-759.
    PubMed    


  850. METRA M
    April 2018 at a glance: focus on prognostic variables.
    Eur J Heart Fail. 2018;20:625-626.
    PubMed    


  851. ALI N, Patel PA, Lindsay SJ
    Recent developments and controversies in transcatheter aortic valve implantation.
    Eur J Heart Fail. 2018;20:642-650.
    PubMed     Abstract available


  852. LINDE C, Cleland JGF, Gold MR, Claude Daubert J, et al
    The interaction of sex, height, and QRS duration on the effects of cardiac resynchronization therapy on morbidity and mortality: an individual-patient data meta-analysis.
    Eur J Heart Fail. 2018;20:780-791.
    PubMed     Abstract available


  853. CONSOLO F, Sferrazza G, Motolone G, Contri R, et al
    Platelet activation is a preoperative risk factor for the development of thromboembolic complications in patients with continuous-flow left ventricular assist device.
    Eur J Heart Fail. 2018;20:792-800.
    PubMed     Abstract available


  854. SPONGA S, Bagur R, Livi U
    Teleconsultation for left ventricular assist device patients: a new standard of care.
    Eur J Heart Fail. 2018;20:818-821.
    PubMed    


    March 2018
  855. PACKER M
    Augmentation of glucagon-like peptide-1 receptor signalling by neprilysin inhibition: potential implications for patients with heart failure.
    Eur J Heart Fail. 2018 Mar 30. doi: 10.1002/ejhf.1185.
    PubMed     Abstract available


  856. FUDIM M, Mentz RJ
    Early versus late readmission during the vulnerable phase following hospitalization for heart failure: reply.
    Eur J Heart Fail. 2018 Mar 30. doi: 10.1002/ejhf.1189.
    PubMed    


  857. KIMURA M, Kohno T, Yoshikawa T
    Early versus late readmission during the vulnerable phase following hospitalization for heart failure.
    Eur J Heart Fail. 2018 Mar 30. doi: 10.1002/ejhf.1179.
    PubMed    


  858. SLIWA K, Petrie MC, Hilfiker-Kleiner D, Mebazaa A, et al
    Long-term prognosis, subsequent pregnancy, contraception and overall management of peripartum cardiomyopathy: practical guidance paper from the Heart Failure Association of the European Society of Cardiology Study Group on Peripartum Cardiomyopathy.
    Eur J Heart Fail. 2018 Mar 26. doi: 10.1002/ejhf.1178.
    PubMed     Abstract available


  859. SAVARESE G, Carrero JJ, Pitt B, Anker SD, et al
    Factors associated with underuse of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction: an analysis of 11 215 patients from the Swedish Heart Failure Registry.
    Eur J Heart Fail. 2018 Mar 26. doi: 10.1002/ejhf.1182.
    PubMed     Abstract available


  860. PACKER M
    Are the effects of drugs to prevent and to treat heart failure always concordant? The statin paradox and its implications for understanding the actions of antidiabetic medications.
    Eur J Heart Fail. 2018 Mar 22. doi: 10.1002/ejhf.1183.
    PubMed     Abstract available


  861. MAGKOUTIS N, Mantzaraki V, Farmakis D, Spathis A, et al
    Effects of functional electrical stimulation of lower limb muscles on circulating endothelial progenitor cells, CD34+ cells and vascular endothelial growth factor-A in heart failure with reduced ejection fraction.
    Eur J Heart Fail. 2018 Mar 14. doi: 10.1002/ejhf.1176.
    PubMed    


  862. SEFEROVIC PM, Petrie MC, Filippatos GS, Anker SD, et al
    Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology.
    Eur J Heart Fail. 2018 Mar 8. doi: 10.1002/ejhf.1170.
    PubMed     Abstract available


  863. FERRARI R, Bueno H, Chioncel O, Cleland JG, et al
    Acute heart failure: lessons learned, roads ahead.
    Eur J Heart Fail. 2018 Mar 8. doi: 10.1002/ejhf.1169.
    PubMed    


  864. AVOGARO A, Fadini GP
    Insulin treatment in patients with diabetes and heart failure: defendant on the stand.
    Eur J Heart Fail. 2018 Mar 8. doi: 10.1002/ejhf.1161.
    PubMed    


  865. DEMISSEI BG, Voors AA
    Risk stratification in acute heart failure: reply.
    Eur J Heart Fail. 2018 Mar 7. doi: 10.1002/ejhf.1171.
    PubMed    


  866. SILISTE RN, Antohi EL, Pepoyan S, Nakou E, et al
    Anticoagulation in heart failure without atrial fibrillation: gaps and dilemmas in current clinical practice.
    Eur J Heart Fail. 2018 Mar 5. doi: 10.1002/ejhf.1153.
    PubMed     Abstract available


  867. WOLDMAN S
    Heart failure management-time to change our script on prognosis?
    Eur J Heart Fail. 2018 Mar 1. doi: 10.1002/ejhf.1157.
    PubMed    


  868. PACKER M
    Derangements in adrenergic-adipokine signalling establish a neurohormonal basis for obesity-related heart failure with a preserved ejection fraction.
    Eur J Heart Fail. 2018 Mar 1. doi: 10.1002/ejhf.1167.
    PubMed     Abstract available


  869. GRODIN JL, Carter S, Bart BA, Goldsmith SR, et al
    Direct comparison of ultrafiltration to pharmacological decongestion in heart failure: a per-protocol analysis of CARRESS-HF.
    Eur J Heart Fail. 2018 Mar 1. doi: 10.1002/ejhf.1158.
    PubMed     Abstract available


  870. ABDUL-RAHIM AH, Shen L, Rush CJ, Jhund PS, et al
    Effect of digoxin in patients with heart failure and mid-range (borderline) left ventricular ejection fraction.
    Eur J Heart Fail. 2018 Mar 1. doi: 10.1002/ejhf.1160.
    PubMed     Abstract available


  871. LUND LH, Pitt B
    Is hyperkalaemia in heart failure a risk factor or a risk marker? Implications for renin-angiotensin-aldosterone system inhibitor use.
    Eur J Heart Fail. 2018 Mar 1. doi: 10.1002/ejhf.1175.
    PubMed    


  872. BANKE A, Fosbol EL, Moller JE, Gislason GH, et al
    Long-term effect of epirubicin on incidence of heart failure in women with breast cancer: insight from a randomized clinical trial.
    Eur J Heart Fail. 2018 Mar 1. doi: 10.1002/ejhf.1168.
    PubMed     Abstract available


  873. VENTURA HO, Mehra MR
    Blood pressure and goal titration of neurohormonal antagonists: the tortoise wins again?
    Eur J Heart Fail. 2018;20:501-503.
    PubMed    


  874. MASSON S, Latini R
    HOME HF: an honest report of an (apparently) doable study.
    Eur J Heart Fail. 2018;20:481-482.
    PubMed    


  875. BARANDIARAN AIZPURUA A, Franssen FME, van Empel V, Brunner-La Rocca HP, et al
    An old debate still in the beta-phase?
    Eur J Heart Fail. 2018;20:557-559.
    PubMed    


  876. PETRIE MC, Connelly DT, Gardner RS
    Who needs an implantable cardioverter-defibrillator? Controversies and opportunities after DANISH.
    Eur J Heart Fail. 2018;20:413-416.
    PubMed    


  877. IKONOMIDIS I, Andreou I, Parissis J, Iliodromitis E, et al
    Prognostic significance of global longitudinal strain in chronic kidney disease: the evidence is building.
    Eur J Heart Fail. 2018;20:569-571.
    PubMed    


  878. BORIANI G, Malavasi VL
    Extending survival by reducing sudden death with implantable cardioverter-defibrillators: a challenging clinical issue in non-ischaemic and ischaemic cardiomyopathies.
    Eur J Heart Fail. 2018;20:420-426.
    PubMed    


  879. AFZAL A, Vallabhan RC, McCullough PA
    Acute kidney injury in cardiogenic shock: in search of early detection and clinical certainty.
    Eur J Heart Fail. 2018;20:582-584.
    PubMed    


  880. DEFILIPPIS EM, Keller SP, Morrow DA
    De-escalation of support with veno-arterial extracorporeal membrane oxygenation and Impella for cardiogenic shock.
    Eur J Heart Fail. 2018;20:621-622.
    PubMed    


  881. SCHULTE C, Schrage B, Pappalardo F, Westermann D, et al
    De-escalation of support with veno-arterial extracorporeal membrane oxygenation and Impella for cardiogenic shock: reply.
    Eur J Heart Fail. 2018;20:622-623.
    PubMed    


  882. BELLAVIA D, Iacovoni A
    Atrial fibrillation and right ventricular failure: reply.
    Eur J Heart Fail. 2018;20:620-621.
    PubMed    


  883. CURCIO A, De Rosa S, Indolfi C
    Should we rethink the indications for implantable cardioverter-defibrillators in non-ischaemic dilated cardiomyopathy?
    Eur J Heart Fail. 2018;20:417-419.
    PubMed    


  884. CERIT L
    Atrial fibrillation and right ventricular failure.
    Eur J Heart Fail. 2018;20:620.
    PubMed    


  885. TIGGES E, Blankenberg S, von Bardeleben RS, Zurn C, et al
    Implication of pulmonary hypertension in patients undergoing MitraClip therapy: results from the German transcatheter mitral valve interventions (TRAMI) registry.
    Eur J Heart Fail. 2018;20:585-594.
    PubMed     Abstract available


  886. METRA M
    March 2018 at a glance: clinical trials, co-morbidities and treatment of mitral regurgitation.
    Eur J Heart Fail. 2018;20:411-412.
    PubMed    


  887. FRANTZ S, Falcao-Pires I, Balligand JL, Bauersachs J, et al
    The innate immune system in chronic cardiomyopathy: a European Society of Cardiology (ESC) scientific statement from the Working Group on Myocardial Function of the ESC.
    Eur J Heart Fail. 2018;20:445-459.
    PubMed     Abstract available


  888. LUCAS R, Wang SF, Riley J, Pepper J, et al
    Patient experience in clinical trials: results of a survey.
    Eur J Heart Fail. 2018;20:612-614.
    PubMed    


  889. MARTINEZ-PAZ E, Barge-Caballero E, Alvarez-Roy L, Barge-Caballero G, et al
    Paroxysmal bradyarrhythmias are frequent among heart transplant recipients with unexplained syncope: a study based on implantable loop recorders.
    Eur J Heart Fail. 2018;20:616-618.
    PubMed    


  890. MOGENSEN UM, Kober L, Jhund PS, Desai AS, et al
    Sacubitril/valsartan reduces serum uric acid concentration, an independent predictor of adverse outcomes in PARADIGM-HF.
    Eur J Heart Fail. 2018;20:514-522.
    PubMed     Abstract available


  891. TRIPOSKIADIS F, Giamouzis G, Boudoulas KD, Karagiannis G, et al
    Left ventricular geometry as a major determinant of left ventricular ejection fraction: physiological considerations and clinical implications.
    Eur J Heart Fail. 2018;20:436-444.
    PubMed     Abstract available


  892. GEIS NA, Puls M, Lubos E, Zuern CS, et al
    Safety and efficacy of MitraClip therapy in patients with severely impaired left ventricular ejection fraction: results from the German transcatheter mitral valve interventions (TRAMI) registry.
    Eur J Heart Fail. 2018;20:598-608.
    PubMed     Abstract available


    February 2018
  893. COSMI F, Shen L, Magnoli M, Abraham WT, et al
    Treatment with insulin is associated with worse outcome in patients with chronic heart failure and diabetes.
    Eur J Heart Fail. 2018 Feb 28. doi: 10.1002/ejhf.1146.
    PubMed     Abstract available


  894. AMERI P, Canepa M, Anker MS, Belenkov Y, et al
    Cancer diagnosis in patients with heart failure: epidemiology, clinical implications and gaps in knowledge.
    Eur J Heart Fail. 2018 Feb 21. doi: 10.1002/ejhf.1165.
    PubMed     Abstract available


  895. LINDGREN M, Eriksson P, Rosengren A, Robertson J, et al
    Cognitive performance in late adolescence and long-term risk of early heart failure in Swedish men.
    Eur J Heart Fail. 2018 Feb 19. doi: 10.1002/ejhf.1163.
    PubMed     Abstract available


  896. MADIAS JE
    Heart-brain interactions in patients with heart failure, including takotsubo syndrome: a need to monitor autonomic sympathetic activity.
    Eur J Heart Fail. 2018 Feb 12. doi: 10.1002/ejhf.1150.
    PubMed    


  897. LEVY WC, Dardas TF
    Comparison of cardiopulmonary-based risk models with a clinical heart failure risk model.
    Eur J Heart Fail. 2018 Feb 12. doi: 10.1002/ejhf.1164.
    PubMed    


  898. AKIYAMA E, Van Aelst LNL, Arrigo M, Lassus J, et al
    East Asia may have a better 1-year survival following an acute heart failure episode compared with Europe: results from an international observational cohort.
    Eur J Heart Fail. 2018 Feb 12. doi: 10.1002/ejhf.1152.
    PubMed    


  899. ZYMLINSKI R, Biegus J, Sokolski M, Siwolowski P, et al
    Increased blood lactate is prevalent and identifies poor prognosis in patients with acute heart failure without overt peripheral hypoperfusion.
    Eur J Heart Fail. 2018 Feb 12. doi: 10.1002/ejhf.1156.
    PubMed     Abstract available


  900. LUND LH, Claggett B, Liu J, Lam CS, et al
    Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum.
    Eur J Heart Fail. 2018 Feb 12. doi: 10.1002/ejhf.1149.
    PubMed     Abstract available


  901. MOGENSEN UM, Gong J, Jhund PS, Shen L, et al
    Effect of sacubitril/valsartan on recurrent events in the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF).
    Eur J Heart Fail. 2018 Feb 12. doi: 10.1002/ejhf.1139.
    PubMed     Abstract available


  902. COMIN-COLET J, Manito N, Segovia-Cubero J, Delgado J, et al
    Efficacy and safety of intermittent intravenous outpatient administration of levosimendan in patients with advanced heart failure: the LION-HEART multicentre randomised trial.
    Eur J Heart Fail. 2018 Feb 6. doi: 10.1002/ejhf.1145.
    PubMed     Abstract available


  903. ORBAN M, Besler C, Braun D, Nabauer M, et al
    Six-month outcome after transcatheter edge-to-edge repair of severe tricuspid regurgitation in patients with heart failure.
    Eur J Heart Fail. 2018 Feb 6. doi: 10.1002/ejhf.1147.
    PubMed     Abstract available


  904. POPOVIC D, Arena R, Guazzi M
    A flattening oxygen consumption trajectory phenotypes disease severity and poor prognosis in patients with heart failure with reduced, mid-range, and preserved ejection fraction.
    Eur J Heart Fail. 2018 Feb 6. doi: 10.1002/ejhf.1140.
    PubMed     Abstract available


  905. METRA M
    February 2018 at a glance: heart and brain interaction, prognostic variables, and acute heart failure and post-discharge outcomes.
    Eur J Heart Fail. 2018;20:191-192.
    PubMed    


  906. LEON JIMENEZ D, Gomez Huelgas R, Miramontes Gonzalez JP
    The mechanism of action of sodium-glucose co-transporter 2 inhibitors is similar to carbonic anhydrase inhibitors.
    Eur J Heart Fail. 2018;20:409.
    PubMed    


  907. SPIRITO P, Ferrazzi P
    We need more high-volume myectomy centres in Europe.
    Eur J Heart Fail. 2018;20:406-408.
    PubMed    


  908. ROSENKRANZ S, Hoeper MM
    Pulmonary vascular indices and survival in left heart disease: illusion of conclusion?
    Eur J Heart Fail. 2018;20:256-259.
    PubMed    


  909. LUND LH
    Optimizing outcomes after heart transplantation.
    Eur J Heart Fail. 2018;20:395-397.
    PubMed    


  910. STEVENSON LW, Schneiweiss S, Gilstrap L
    Propensity to match or mismatch patients and therapies?
    Eur J Heart Fail. 2018;20:355-358.
    PubMed    


  911. MERLO M, Cannata A, Gobbo M, Stolfo D, et al
    Evolving concepts in dilated cardiomyopathy.
    Eur J Heart Fail. 2018;20:228-239.
    PubMed     Abstract available


  912. CHAMPION S
    Extracorporeal membrane oxygenation in the therapy of cardiogenic shock (ECMO-CS): the need for a better definition of refractory cardiogenic shock.
    Eur J Heart Fail. 2018;20:197-198.
    PubMed    


  913. LOPEZ-SAINZ A, Barge-Caballero E, Barge-Caballero G, Couto-Mallon D, et al
    Late graft failure in heart transplant recipients: incidence, risk factors and clinical outcomes.
    Eur J Heart Fail. 2018;20:385-394.
    PubMed     Abstract available


    January 2018
  914. TROMP J, Voors AA, Lam CSP
    Heart failure with mid-range ejection fraction: causes and consequences.
    Eur J Heart Fail. 2018 Jan 16. doi: 10.1002/ejhf.1134.
    PubMed    


  915. TROMP J, van der Meer P
    Predicting heart failure: one size does not fit all.
    Eur J Heart Fail. 2018 Jan 15. doi: 10.1002/ejhf.1120.
    PubMed    


  916. LUND LH, Vedin O, Savarese G
    Is ejection fraction in heart failure a limitation or an opportunity?
    Eur J Heart Fail. 2018 Jan 15. doi: 10.1002/ejhf.1106.
    PubMed    


  917. TAMPAKAKIS E
    In search of markers of pulmonary vascular remodelling in pulmonary hypertension due to left heart disease.
    Eur J Heart Fail. 2018 Jan 15. doi: 10.1002/ejhf.1137.
    PubMed    


  918. COSTANZO MR
    Uric acid is important, but there is something that matters even more: to deliver sacubitril/valsartan to eligible heart failure patients.
    Eur J Heart Fail. 2018 Jan 12. doi: 10.1002/ejhf.1087.
    PubMed    


  919. ARQUES S
    Myocardial oedema and congestive heart failure: one piece of the puzzle?
    Eur J Heart Fail. 2018 Jan 12. doi: 10.1002/ejhf.1121.
    PubMed    


  920. BEUSEKAMP JC, Tromp J, van der Wal HH, Anker SD, et al
    Potassium and the use of renin-angiotensin-aldosterone system inhibitors in heart failure with reduced ejection fraction: data from BIOSTAT-CHF.
    Eur J Heart Fail. 2018 Jan 12. doi: 10.1002/ejhf.1079.
    PubMed     Abstract available


  921. GORTER TM, de Boer RA
    Myocardial oedema and congestive heart failure: one piece of the puzzle? Reply.
    Eur J Heart Fail. 2018 Jan 10. doi: 10.1002/ejhf.1136.
    PubMed    


  922. DONAL E, Galli E
    Clinical relevance of spectral tissue Doppler-derived E/e' in the diagnosis of heart failure with preserved ejection fraction: reply.
    Eur J Heart Fail. 2018 Jan 8. doi: 10.1002/ejhf.1090.
    PubMed    


  923. LUND LH
    Complex relationships between co-morbidity, outcomes, and treatment effect in heart failure.
    Eur J Heart Fail. 2018 Jan 5. doi: 10.1002/ejhf.1107.
    PubMed    


  924. DE ROSA S, Eposito F, Carella C, Strangio A, et al
    Transcoronary concentration gradients of circulating microRNAs in heart failure.
    Eur J Heart Fail. 2018 Jan 4. doi: 10.1002/ejhf.1119.
    PubMed     Abstract available


  925. MCDONALD K, Troughton R, Dahlstrom U, Dargie H, et al
    Daily home BNP monitoring in heart failure for prediction of impending clinical deterioration: results from the HOME HF study.
    Eur J Heart Fail. 2018 Jan 4. doi: 10.1002/ejhf.1053.
    PubMed     Abstract available


  926. MELE D, Nardozza M, Ferrari R
    Left ventricular ejection fraction and heart failure: an indissoluble marriage?
    Eur J Heart Fail. 2018 Jan 4. doi: 10.1002/ejhf.1071.
    PubMed    


  927. BREIDTHARDT T, Moreno-Weidmann Z, Uthoff H, Sabti Z, et al
    How accurate is clinical assessment of neck veins in the estimation of central venous pressure in acute heart failure? Insights from a prospective study.
    Eur J Heart Fail. 2018 Jan 4. doi: 10.1002/ejhf.1111.
    PubMed    


  928. AMBROSY AP, Fudim M, Chioncel O
    Sudden cardiac death following admission for acute heart failure: adding insult to injury.
    Eur J Heart Fail. 2018 Jan 4. doi: 10.1002/ejhf.1109.
    PubMed    


  929. FERREIRA JP, Duarte K, Pfeffer MA, McMurray JJV, et al
    Association between mean systolic and diastolic blood pressure throughout the follow-up and cardiovascular events in acute myocardial infarction patients with systolic dysfunction and/or heart failure: an analysis from the High-Risk Myocardial Infarct
    Eur J Heart Fail. 2018 Jan 4. doi: 10.1002/ejhf.1131.
    PubMed     Abstract available


  930. SUZUKI H, Matsumoto Y, Ota H, Sugimura K, et al
    Structural brain abnormalities and cardiac dysfunction in patients with chronic heart failure.
    Eur J Heart Fail. 2018 Jan 4. doi: 10.1002/ejhf.1104.
    PubMed    


  931. SOKORELI I, Pauws SC, Steyerberg EW, de Vries GJ, et al
    Prognostic value of psychosocial factors for first and recurrent hospitalizations and mortality in heart failure patients: insights from the OPERA-HF study.
    Eur J Heart Fail. 2018 Jan 4. doi: 10.1002/ejhf.1112.
    PubMed     Abstract available


  932. VADUGANATHAN M, Samman Tahhan A, Greene SJ, Okafor M, et al
    Globalization of heart failure clinical trials: a systematic review of 305 trials conducted over 16 years.
    Eur J Heart Fail. 2018 Jan 4. doi: 10.1002/ejhf.1130.
    PubMed    


  933. PACKER M
    Are physicians neglecting the risk of heart failure in diabetic patients who are receiving sulfonylureas? Lessons from the TOSCA.IT trial.
    Eur J Heart Fail. 2018;20:49-51.
    PubMed    


  934. SWEDBERG K
    Lessons for the monitoring of safety in clinical trials.
    Eur J Heart Fail. 2018;20:148.
    PubMed    


  935. CRESPO-LEIRO MG, Barge-Caballero E
    Heart transplantation and left ventricular assist systems. Not too early, not too late.
    Eur J Heart Fail. 2018;20:161-163.
    PubMed    


  936. BAR C, Thum T
    A long way for microRNAs to become meaningful prognostic biomarkers.
    Eur J Heart Fail. 2018;20:76-77.
    PubMed    


  937. GUSTAFSSON F
    Management of patients with cardiogenic shock on temporary mechanical circulatory support: urgent transplantation or on to the next pump?
    Eur J Heart Fail. 2018;20:187-189.
    PubMed    


  938. METRA M
    January 2018 at a glance: biomarkers, co-morbidities and mechanical circulatory support.
    Eur J Heart Fail. 2018;20:1-2.
    PubMed    


  939. AVOGARO A
    Keeping the right track in the treatment of patients with type 2 diabetes.
    Eur J Heart Fail. 2018;20:52-54.
    PubMed    


  940. NAGUEH SF
    Non-invasive assessment of left ventricular filling pressure.
    Eur J Heart Fail. 2018;20:38-48.
    PubMed     Abstract available


  941. BARGE-CABALLERO E, Almenar-Bonet L, Gonzalez-Vilchez F, Lambert-Rodriguez JL, et al
    Clinical outcomes of temporary mechanical circulatory support as a direct bridge to heart transplantation: a nationwide Spanish registry.
    Eur J Heart Fail. 2018;20:178-186.
    PubMed     Abstract available


    December 2017
  942. TKACZYSZYN M, Jankowska EA
    Iron deficiency and red cell indices in patients with heart failure: reply.
    Eur J Heart Fail. 2017 Dec 27. doi: 10.1002/ejhf.1092.
    PubMed    


  943. DOEHNER W, Ural D, Haeusler KG, Celutkiene J, et al
    Heart and brain interaction in patients with heart failure: overview and proposal for a taxonomy. A position paper from the Study Group on Heart and Brain Interaction of the Heart Failure Association.
    Eur J Heart Fail. 2017 Dec 27. doi: 10.1002/ejhf.1100.
    PubMed     Abstract available


  944. ROSANO GMC, Seferovic P, Farmakis D, Filippatos G, et al
    Renin inhibition in heart failure and diabetes: the real story.
    Eur J Heart Fail. 2017 Dec 22. doi: 10.1002/ejhf.1072.
    PubMed    


  945. XANTHOPOULOS A, Tryposkiadis K, Giamouzis G, Konstantinou D, et al
    Larissa Heart Failure Risk Score: a proposed simple score for risk stratification in chronic heart failure.
    Eur J Heart Fail. 2017 Dec 22. doi: 10.1002/ejhf.1132.
    PubMed    


  946. RAMALHO SHR, Shah AM
    Central sleep apnoea in heart failure with reduced ejection fraction, adaptive servo-ventilation, and left ventricular ejection fraction: the (still) missing link.
    Eur J Heart Fail. 2017 Dec 22. doi: 10.1002/ejhf.1108.
    PubMed    


  947. POKORNEY SD, Al-Khatib SM, Sun JL, Schulte P, et al
    Sudden cardiac death after acute heart failure hospital admission: insights from ASCEND-HF.
    Eur J Heart Fail. 2017 Dec 20. doi: 10.1002/ejhf.1078.
    PubMed     Abstract available


  948. VAN AELST LNL, Arrigo M, Placido R, Akiyama E, et al
    Acutely decompensated heart failure with preserved and reduced ejection fraction present with comparable haemodynamic congestion.
    Eur J Heart Fail. 2017 Dec 18. doi: 10.1002/ejhf.1050.
    PubMed     Abstract available


  949. BISTOLA V, Polyzogopoulou E, Ikonomidis I, Parissis J, et al
    Congestion in acute heart failure with reduced vs. preserved left ventricular ejection fraction: differences, similarities and remaining gaps.
    Eur J Heart Fail. 2017 Dec 18. doi: 10.1002/ejhf.1115.
    PubMed    


  950. EMMENS JE, Jones DJL, Cao TH, Chan DCS, et al
    Proteomic diversity of high-density lipoprotein explains its association with clinical outcome in patients with heart failure.
    Eur J Heart Fail. 2017 Dec 18. doi: 10.1002/ejhf.1101.
    PubMed     Abstract available


  951. LUPON J, Bayes-Genis A
    Left ventricular ejection fraction in heart failure: a clinician's perspective about a dynamic and imperfect parameter, though still convenient and a cornerstone for patient classification and management.
    Eur J Heart Fail. 2017 Dec 18. doi: 10.1002/ejhf.1116.
    PubMed    


  952. DELLES C, Rankin NJ, Boachie C, McConnachie A, et al
    Nuclear magnetic resonance-based metabolomics identifies phenylalanine as a novel predictor of incident heart failure hospitalisation: results from PROSPER and FINRISK 1997.
    Eur J Heart Fail. 2017 Dec 11. doi: 10.1002/ejhf.1076.
    PubMed     Abstract available


  953. BHAMBHANI V, Kizer JR, Lima JAC, van der Harst P, et al
    Predictors and outcomes of heart failure with mid-range ejection fraction.
    Eur J Heart Fail. 2017 Dec 11. doi: 10.1002/ejhf.1091.
    PubMed     Abstract available


  954. VON HAEHLING S
    Co-morbidities in heart failure beginning to sprout-and no end in sight?
    Eur J Heart Fail. 2017;19:1566-1568.
    PubMed    


    November 2017
  955. COWIE MR, Woehrle H, Wegscheider K, Vettorazzi E, et al
    Adaptive servo-ventilation for central sleep apnoea in systolic heart failure: results of the major substudy of SERVE-HF.
    Eur J Heart Fail. 2017 Nov 30. doi: 10.1002/ejhf.1048.
    PubMed     Abstract available


  956. KHERA R, Pandey A
    The heart failure readmission quagmire: taking a deep dive to find solutions.
    Eur J Heart Fail. 2017 Nov 30. doi: 10.1002/ejhf.1082.
    PubMed    


  957. ARQUES S
    Clinical relevance of spectral tissue Doppler-derived E/e' in the diagnosis of heart failure with preserved ejection fraction.
    Eur J Heart Fail. 2017 Nov 30. doi: 10.1002/ejhf.1084.
    PubMed    


  958. WOLSK E, Claggett B, Kober L, Pocock S, et al
    Contribution of cardiac and extra-cardiac disease burden to risk of cardiovascular outcomes varies by ejection fraction in heart failure.
    Eur J Heart Fail. 2017 Nov 30. doi: 10.1002/ejhf.1073.
    PubMed     Abstract available


  959. SENNI M, McMurray JJV, Wachter R, McIntyre HF, et al
    Impact of systolic blood pressure on the safety and tolerability of initiating and up-titrating sacubitril/valsartan in patients with heart failure and reduced ejection fraction: insights from the TITRATION study.
    Eur J Heart Fail. 2017 Nov 22. doi: 10.1002/ejhf.1054.
    PubMed     Abstract available


  960. ROSSING K, Gustafsson F
    Medical and mechanical unloading in advanced heart failure: hope for cardiac recovery?
    Eur J Heart Fail. 2017 Nov 21. doi: 10.1002/ejhf.1081.
    PubMed    


  961. TAVAZZI L
    It's time to move on from counting co-morbidities to curing them: the case of chronic heart failure-chronic obstructive pulmonary disease co-morbidity.
    Eur J Heart Fail. 2017 Nov 21. doi: 10.1002/ejhf.1083.
    PubMed    


  962. GREENE SJ, Felker GM
    Considering the duration of heart failure: using the past to predict the future.
    Eur J Heart Fail. 2017 Nov 21. doi: 10.1002/ejhf.1064.
    PubMed    


  963. FARMAKIS D, Papingiotis G, Parissis J, Filippatos G, et al
    Ups and downs in heart failure: the case of proteomics.
    Eur J Heart Fail. 2017 Nov 21. doi: 10.1002/ejhf.1065.
    PubMed    


  964. SESSA M, Mascolo A, Mortensen RN, Andersen MP, et al
    Relationship between heart failure, concurrent chronic obstructive pulmonary disease and beta-blocker use: a Danish nationwide cohort study.
    Eur J Heart Fail. 2017 Nov 20. doi: 10.1002/ejhf.1045.
    PubMed     Abstract available


  965. RORTH R, Fosbol EL, Mogensen UM, Kragholm K, et al
    Employment status at time of first hospitalization for heart failure is associated with a higher risk of death and rehospitalization for heart failure.
    Eur J Heart Fail. 2017 Nov 16. doi: 10.1002/ejhf.1046.
    PubMed     Abstract available


  966. GO YY, Sugimoto T, Bulluck H, Acharyya S, et al
    Age and ejection fraction modify the impact of atrial fibrillation on acute heart failure outcomes.
    Eur J Heart Fail. 2017 Nov 16. doi: 10.1002/ejhf.1075.
    PubMed    


  967. PALAU P, Dominguez E, Nunez J
    Clinical utility of cardiopulmonary exercise testing in patients with heart failure with preserved ejection fraction.
    Eur J Heart Fail. 2017 Nov 16. doi: 10.1002/ejhf.1066.
    PubMed    


  968. LOURENCO AP, Leite-Moreira AF, Balligand JL, Bauersachs J, et al
    An integrative translational approach to study heart failure with preserved ejection fraction: a position paper from the Working Group on Myocardial Function of the European Society of Cardiology.
    Eur J Heart Fail. 2017 Nov 16. doi: 10.1002/ejhf.1059.
    PubMed     Abstract available


  969. SELVARAJ S, Claggett B, Shah SJ, Anand I, et al
    Systolic blood pressure and cardiovascular outcomes in heart failure with preserved ejection fraction: an analysis of the TOPCAT trial.
    Eur J Heart Fail. 2017 Nov 16. doi: 10.1002/ejhf.1060.
    PubMed     Abstract available


  970. GHIO S, Crimi G, Temporelli PL, Traversi E, et al
    Haemodynamic effects of an acute vasodilator challenge in heart failure patients with reduced ejection fraction and different forms of post-capillary pulmonary hypertension.
    Eur J Heart Fail. 2017 Nov 16. doi: 10.1002/ejhf.1067.
    PubMed     Abstract available


  971. ZENG DX
    Iron deficiency and red cell indices in patients with heart failure.
    Eur J Heart Fail. 2017 Nov 16. doi: 10.1002/ejhf.1052.
    PubMed    


  972. SCHNEIDER D, Flores D, Mueller C
    Risk stratification in acute heart failure.
    Eur J Heart Fail. 2017 Nov 16. doi: 10.1002/ejhf.1057.
    PubMed    


  973. VADUGANATHAN M, Cheema B, Cleveland E, Sankar K, et al
    Plasma renin activity, response to aliskiren, and clinical outcomes in patients hospitalized for heart failure: the ASTRONAUT trial.
    Eur J Heart Fail. 2017 Nov 16. doi: 10.1002.
    PubMed     Abstract available


  974. ARRIGO M, Mebazaa A
    Addressing vulnerability: opening a new door to improved outcomes in acute heart failure.
    Eur J Heart Fail. 2017 Nov 9. doi: 10.1002/ejhf.1063.
    PubMed    


  975. LAL S, Kotchetkova I, Cao J, Jackson D, et al
    Heart failure admissions and poor subsequent outcomes in adults with congenital heart disease.
    Eur J Heart Fail. 2017 Nov 7. doi: 10.1002/ejhf.1051.
    PubMed    


  976. CATINO AB, Ferrin P, Wever-Pinzon J, Horne BD, et al
    Clinical and histopathological effects of heart failure drug therapy in advanced heart failure patients on chronic mechanical circulatory support.
    Eur J Heart Fail. 2017 Nov 1. doi: 10.1002/ejhf.1018.
    PubMed     Abstract available


    October 2017
  977. PACKER M
    Will long-acting glucagon-like peptide-1 analogues recapitulate our agonizing experience with cyclic AMP-dependent positive inotropic agents in heart failure?
    Eur J Heart Fail. 2017 Oct 30. doi: 10.1002/ejhf.1047.
    PubMed    


  978. CHEEMA B, Ambrosy AP, Kaplan RM, Senni M, et al
    Lessons learned in acute heart failure.
    Eur J Heart Fail. 2017 Oct 29. doi: 10.1002/ejhf.1042.
    PubMed     Abstract available


  979. FUDIM M, O'Connor CM, Dunning A, Ambrosy AP, et al
    Aetiology, timing and clinical predictors of early vs. late readmission following index hospitalization for acute heart failure: insights from ASCEND-HF.
    Eur J Heart Fail. 2017 Oct 29. doi: 10.1002/ejhf.1020.
    PubMed     Abstract available


  980. GREENE SJ, Mentz RJ
    Potential advantages of torsemide in patients with heart failure: more than just a 'water pill'?
    Eur J Heart Fail. 2017 Oct 29. doi: 10.1002/ejhf.1024.
    PubMed    


  981. KELLY JP, DeVore AD
    Can walking patients with heart failure and preserved ejection fraction tell us who should walk also to the catheterization laboratory or just walk home?
    Eur J Heart Fail. 2017 Oct 29. doi: 10.1002/ejhf.1041.
    PubMed    


  982. BAJAJ NS, Claggett B, Lewis EF, Desai AS, et al
    Influence of ejection fraction on cause-specific mortality in heart failure with preserved ejection fraction.
    Eur J Heart Fail. 2017 Oct 25. doi: 10.1002/ejhf.1040.
    PubMed    


  983. NAUTA JF, Hummel YM, van Melle JP, van der Meer P, et al
    What have we learned about heart failure with mid-range ejection fraction one year after its introduction?
    Eur J Heart Fail. 2017 Oct 24. doi: 10.1002/ejhf.1058.
    PubMed     Abstract available


  984. PANICO C, Condorelli G
    microRNA-132: a new biomarker of heart failure at last?
    Eur J Heart Fail. 2017 Oct 20. doi: 10.1002/ejhf.1044.
    PubMed    


  985. PACKER M
    Why is the use of digitalis withering? Another reason that we need medical heart failure specialists.
    Eur J Heart Fail. 2017 Oct 19. doi: 10.1002/ejhf.1043.
    PubMed    


  986. STEWART COATS AJ
    Intravenous ferric carboxymaltose for heart failure with iron deficiency.
    Eur J Heart Fail. 2017 Oct 19. doi: 10.1002/ejhf.1027.
    PubMed    


  987. ROY B, Woo M, Kumar R
    Cerebral blood flow in central autonomic network: is there any effect of hemispheric lateralization in patients with heart failure? Reply.
    Eur J Heart Fail. 2017 Oct 18. doi: 10.1002/ejhf.1033.
    PubMed    


  988. GREENE SJ, Butler J, Fonarow GC, Subacius HP, et al
    Pre-discharge and early post-discharge troponin elevation among patients hospitalized for heart failure with reduced ejection fraction: findings from the ASTRONAUT trial.
    Eur J Heart Fail. 2017 Oct 17. doi: 10.1002/ejhf.1019.
    PubMed     Abstract available


  989. DE BUYZERE ML
    Multi-biomarker risk stratification in heart failure: a story of diminished marginal returns after Herculean efforts?
    Eur J Heart Fail. 2017 Oct 17. doi: 10.1002/ejhf.1035.
    PubMed    


  990. GORTER TM, van Veldhuisen DJ, Bauersachs J, Borlaug BA, et al
    Right heart dysfunction and failure in heart failure with preserved ejection fraction: mechanisms and management. Position statement on behalf of the Heart Failure Association of the European Society of Cardiology.
    Eur J Heart Fail. 2017 Oct 16. doi: 10.1002/ejhf.1029.
    PubMed     Abstract available


  991. MAISANO F, Ruschitzka F
    Mitral interventions in heart failure: time to deliver on the promise.
    Eur J Heart Fail. 2017 Oct 16. doi: 10.1002.
    PubMed    


  992. MIRO O, Tost J, Gil V, Martin-Sanchez FJ, et al
    The BRONCH-AHF study: effects on short-term outcome of nebulized bronchodilators in emergency department patients diagnosed with acute heart failure.
    Eur J Heart Fail. 2017 Oct 16. doi: 10.1002/ejhf.1028.
    PubMed    


  993. SHARMA K, Tedford RJ
    Atrial fibrillation in heart failure with preserved ejection fraction: time to address the chicken and the egg.
    Eur J Heart Fail. 2017 Oct 12. doi: 10.1002.
    PubMed    


  994. BOHM M, Komajda M, Borer JS, Ford I, et al
    Duration of chronic heart failure affects outcomes with preserved effects of heart rate reduction with ivabradine: findings from SHIFT.
    Eur J Heart Fail. 2017 Oct 12. doi: 10.1002/ejhf.1021.
    PubMed     Abstract available


  995. LA ROVERE MT, Maestri R, Robbi E, Caporotondi A, et al
    Daytime periodic breathing during short-term laboratory recordings in heart failure patients: the iceberg tip of central sleep apnoea?
    Eur J Heart Fail. 2017 Oct 12. doi: 10.1002/ejhf.1031.
    PubMed    


  996. MASSON S, Batkai S, Beermann J, Bar C, et al
    Circulating microRNA-132 levels improve risk prediction for heart failure hospitalization in patients with chronic heart failure.
    Eur J Heart Fail. 2017 Oct 12. doi: 10.1002.
    PubMed     Abstract available


  997. MORTARA A
    Inotropes and vasopressors in acute heart failure, when the devil dresses as an angel.
    Eur J Heart Fail. 2017 Oct 12. doi: 10.1002/ejhf.1037.
    PubMed    


  998. GREENBERG B
    Jumping down the rabbit hole: unravelling the right ventricle in heart failure.
    Eur J Heart Fail. 2017 Oct 12. doi: 10.1002.
    PubMed    


  999. HANBERG JS, Rao VS, Ahmad T, Chunara Z, et al
    Inflammation and cardio-renal interactions in heart failure: a potential role for interleukin-6.
    Eur J Heart Fail. 2017 Oct 11. doi: 10.1002.
    PubMed    


  1000. KAYE DM, Silvestry FE, Gustafsson F, Cleland JG, et al
    Impact of atrial fibrillation on rest and exercise haemodynamics in heart failure with mid-range and preserved ejection fraction.
    Eur J Heart Fail. 2017 Oct 11. doi: 10.1002.
    PubMed     Abstract available


  1001. AGOSTONI P, Guazzi M
    Exercise ventilatory inefficiency in heart failure: some fresh news into the roadmap of heart failure with preserved ejection fraction phenotyping.
    Eur J Heart Fail. 2017 Oct 9. doi: 10.1002.
    PubMed    


  1002. MEBAZAA A, Motiejunaite J, Gayat E, Crespo-Leiro MG, et al
    Long-term safety of intravenous cardiovascular agents in acute heart failure: results from the European Society of Cardiology Heart Failure Long-Term Registry.
    Eur J Heart Fail. 2017 Oct 8. doi: 10.1002.
    PubMed     Abstract available


  1003. VAN ITERSON EH, Johnson BD, Borlaug BA, Olson TP, et al
    Physiological dead space and arterial carbon dioxide contributions to exercise ventilatory inefficiency in patients with reduced or preserved ejection fraction heart failure.
    Eur J Heart Fail. 2017 Oct 8. doi: 10.1002.
    PubMed     Abstract available


  1004. NUNEZ J, Sanchis J, Bayes-Genis A
    Iron status measurement in routine heart failure assessment: a call for action.
    Eur J Heart Fail. 2017 Oct 8. doi: 10.1002.
    PubMed    


  1005. HUMMEL YM, Liu LCY, Lam CSP, Fonseca-Munoz DF, et al
    Echocardiographic estimation of left ventricular and pulmonary pressures in patients with heart failure and preserved ejection fraction: a study utilizing simultaneous echocardiography and invasive measurements.
    Eur J Heart Fail. 2017 Oct 6. doi: 10.1002.
    PubMed     Abstract available


  1006. SAVARESE G, Lund LH
    Up-titrating angiotensin-converting enzyme inhibitors in heart failure: evidence and challenges.
    Eur J Heart Fail. 2017 Oct 5. doi: 10.1002.
    PubMed    


  1007. LAM PH, Dooley DJ, Fonarow GC, Butler J, et al
    Similar clinical benefits from below-target and target dose enalapril in patients with heart failure in the SOLVD Treatment trial.
    Eur J Heart Fail. 2017 Oct 5. doi: 10.1002.
    PubMed     Abstract available


  1008. STENEMO M, Nowak C, Byberg L, Sundstrom J, et al
    Circulating proteins as predictors of incident heart failure in the elderly.
    Eur J Heart Fail. 2017 Oct 2. doi: 10.1002.
    PubMed     Abstract available


  1009. METRA M
    October 2017 at a glance: phenotyping heart failure, co-morbidities, use of evidence-based therapy and new treatments.
    Eur J Heart Fail. 2017;19:1216-1217.
    PubMed    


  1010. TAVAZZI L
    A brief overview of cardiac resynchronization therapy and its current use in clinical practice.
    Eur J Heart Fail. 2017;19:1280-1283.
    PubMed    


  1011. CHEEMA BS, Sabbah HN, Greene SJ, Gheorghiade M, et al
    Protein turnover in the failing heart: an ever-changing landscape.
    Eur J Heart Fail. 2017;19:1218-1221.
    PubMed    


  1012. SOMMER A, Kronborg MB, Nielsen JC
    Guided left ventricular lead placement for cardiac resynchronization therapy - an opportunity for image integration: reply.
    Eur J Heart Fail. 2017;19:1344.
    PubMed    


    September 2017
  1013. MOTIEJUNAITE J, Celutkiene J, Mebazaa A
    The right ventricle drives the progression of heart failure.
    Eur J Heart Fail. 2017 Sep 29. doi: 10.1002.
    PubMed    


  1014. WELSH P, Kou L, Yu C, Anand I, et al
    Prognostic importance of emerging cardiac, inflammatory, and renal biomarkers in chronic heart failure patients with reduced ejection fraction and anaemia: RED-HF study.
    Eur J Heart Fail. 2017 Sep 27. doi: 10.1002.
    PubMed     Abstract available


  1015. LUND LH, Trochu JN, Meyns B, Caliskan K, et al
    Screening for heart transplantation and left ventricular assist system: results from the ScrEEning for advanced Heart Failure treatment (SEE-HF) study.
    Eur J Heart Fail. 2017 Sep 27. doi: 10.1002.
    PubMed     Abstract available


  1016. LUPON J, Simpson J, McMurray JJV, de Antonio M, et al
    Barcelona Bio-HF Calculator Version 2.0: incorporation of angiotensin II receptor blocker neprilysin inhibitor (ARNI) and risk for heart failure hospitalization.
    Eur J Heart Fail. 2017 Sep 26. doi: 10.1002.
    PubMed    


  1017. AGOSTONI P, Paolillo S, Mapelli M, Gentile P, et al
    Multiparametric prognostic scores in chronic heart failure with reduced ejection fraction: a long-term comparison.
    Eur J Heart Fail. 2017 Sep 26. doi: 10.1002.
    PubMed     Abstract available


  1018. LUND LH, Svennblad B, Dahlstrom U, Stahlberg M, et al
    Effect of expanding evidence and evolving clinical guidelines on the prevalence of indication for cardiac resynchronization therapy in patients with heart failure.
    Eur J Heart Fail. 2017 Sep 26. doi: 10.1002.
    PubMed     Abstract available


  1019. VAN BILSEN M, Patel HC, Bauersachs J, Bohm M, et al
    The autonomic nervous system as a therapeutic target in heart failure: a scientific position statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology.
    Eur J Heart Fail. 2017 Sep 26. doi: 10.1002.
    PubMed     Abstract available


  1020. CANEPA M, Straburzynska-Migaj E, Drozdz J, Fernandez-Vivancos C, et al
    Characteristics, treatments and 1-year prognosis of hospitalized and ambulatory heart failure patients with chronic obstructive pulmonary disease in the European Society of Cardiology Heart Failure Long-Term Registry.
    Eur J Heart Fail. 2017 Sep 26. doi: 10.1002.
    PubMed     Abstract available


  1021. BAYES-GENIS A, Lanfear DE, de Ronde MWJ, Lupon J, et al
    Prognostic value of circulating microRNAs on heart failure-related morbidity and mortality in two large diverse cohorts of general heart failure patients.
    Eur J Heart Fail. 2017 Sep 26. doi: 10.1002.
    PubMed     Abstract available


  1022. HAWKINS NM
    Chronic obstructive pulmonary disease and heart failure in Europe-further evidence of the need for integrated care.
    Eur J Heart Fail. 2017 Sep 26. doi: 10.1002.
    PubMed    


  1023. WOLSK E, Kaye D, Borlaug BA, Burkhoff D, et al
    Resting and exercise haemodynamics in relation to six-minute walk test in patients with heart failure and preserved ejection fraction.
    Eur J Heart Fail. 2017 Sep 26. doi: 10.1002.
    PubMed     Abstract available


  1024. VINEREANU D, Margulescu AD
    The fallacy of resting echocardiographic parameters of cardiac function in heart failure with preserved ejection fraction: reply.
    Eur J Heart Fail. 2017 Sep 25. doi: 10.1002.
    PubMed    


  1025. VAN BOVEN N, Kardys I, van Vark LC, Akkerhuis KM, et al
    Serially measured circulating microRNAs and adverse clinical outcomes in patients with acute heart failure.
    Eur J Heart Fail. 2017 Sep 25. doi: 10.1002.
    PubMed     Abstract available


  1026. KOH AS, Tay WT, Teng THK, Vedin O, et al
    A comprehensive population-based characterization of heart failure with mid-range ejection fraction.
    Eur J Heart Fail. 2017 Sep 25. doi: 10.1002.
    PubMed     Abstract available


  1027. BAYES-GENIS A, Nunez J, Lupon J
    Heart failure with mid-range ejection fraction: a transition phenotype?
    Eur J Heart Fail. 2017 Sep 25. doi: 10.1002.
    PubMed    


  1028. SANDERSON JE, Fang F, Wei YX
    The fallacy of resting echocardiographic parameters of cardiac function in heart failure with preserved ejection fraction.
    Eur J Heart Fail. 2017 Sep 25. doi: 10.1002.
    PubMed    


  1029. WONG LL, Richards AM
    Harnessing the power of microRNAs as prognostic biomarkers in acute heart failure.
    Eur J Heart Fail. 2017 Sep 25. doi: 10.1002.
    PubMed    


  1030. TOMPKINS BA, Rieger AC, Florea V, Banerjee MN, et al
    New insights into cell-based therapy for heart failure from the CHART-1 study.
    Eur J Heart Fail. 2017 Sep 25. doi: 10.1002.
    PubMed    


  1031. KRISTENSEN SL, Mogensen UM, Tarnesby G, Gimpelewicz CR, et al
    Aliskiren alone or in combination with enalapril vs. enalapril among patients with chronic heart failure with and without diabetes: a subgroup analysis from the ATMOSPHERE trial.
    Eur J Heart Fail. 2017 Sep 25. doi: 10.1002.
    PubMed     Abstract available


  1032. MARTENS P, Verbrugge FH, Nijst P, Dupont M, et al
    Limited contractile reserve contributes to poor peak exercise capacity in iron-deficient heart failure.
    Eur J Heart Fail. 2017 Sep 18. doi: 10.1002.
    PubMed    


  1033. CORRA U, Agostoni PG, Anker SD, Coats AJS, et al
    Role of cardiopulmonary exercise testing in clinical stratification in heart failure. A position paper from the Committee on Exercise Physiology and Training of the Heart Failure Association of the European Society of Cardiology.
    Eur J Heart Fail. 2017 Sep 18. doi: 10.1002.
    PubMed     Abstract available


  1034. SQUIRE IB
    Biomarkers and prognostication in heart failure with reduced and preserved ejection fraction: similar but different?
    Eur J Heart Fail. 2017 Sep 18. doi: 10.1002.
    PubMed    


  1035. BUTLER J, Stockbridge N, Gheorghiade M
    Past, present, and future of acute heart failure clinical trials-a high-risk population in search of a strategy.
    Eur J Heart Fail. 2017 Sep 18. doi: 10.1002.
    PubMed    


  1036. NAGAI M, Dote K, Masaya M
    Cerebral blood flow in the central autonomic network: is there any effect of hemispheric lateralization in patients with heart failure?
    Eur J Heart Fail. 2017 Sep 18. doi: 10.1002.
    PubMed    


  1037. GIRERD N, Rossignol P
    Performing lung ultrasound at rest and/or after an exercise stress test to better identify high-risk ambulatory patients with heart failure.
    Eur J Heart Fail. 2017 Sep 18. doi: 10.1002.
    PubMed    


  1038. RAPEZZI C, Milandri A, Lorenzini M
    The complex interplay between systolic and diastolic function at rest and during exercise in heart failure: the case of cardiac amyloidosis.
    Eur J Heart Fail. 2017 Sep 14. doi: 10.1002.
    PubMed    


  1039. PATEL JN, Shah SJ
    Inorganic vs. organic nitrates for heart failure with preserved ejection fraction: it's not all in your head!
    Eur J Heart Fail. 2017 Sep 11. doi: 10.1002.
    PubMed    


  1040. TRIPPEL TD, Van Linthout S, Westermann D, Lindhorst R, et al
    Investigating a biomarker-driven approach to target collagen turnover in diabetic heart failure with preserved ejection fraction patients. Effect of torasemide vs. furosemide on serum C-terminal propeptide of procollagen type I (DROP-PIP trial).
    Eur J Heart Fail. 2017 Sep 11. doi: 10.1002.
    PubMed     Abstract available


  1041. KALOGEROPOULOS AP, Butler J
    Heart rate in heart failure with preserved ejection fraction: target or marker?
    Eur J Heart Fail. 2017 Sep 11. doi: 10.1002.
    PubMed    


  1042. ZHANG Y, Bauersachs J, Langer HF
    Immune mechanisms in heart failure.
    Eur J Heart Fail. 2017 Sep 11. doi: 10.1002.
    PubMed     Abstract available


  1043. STEWART S
    Home is where the heart is when it comes to transitional care in heart failure, but is it the only way to improve health outcomes?
    Eur J Heart Fail. 2017 Sep 10. doi: 10.1002.
    PubMed    


  1044. PACKER M
    How have millions of people with heart failure benefited from our research over the last 10-15 years? The sounds of dead silence.
    Eur J Heart Fail. 2017 Sep 10. doi: 10.1002.
    PubMed    


  1045. INOHARA T, Vemulapalli S
    Percutaneous edge-to-edge leaflet repair: a solution to the risk-treatment paradox of mitral regurgitation complicated by pulmonary hypertension?
    Eur J Heart Fail. 2017 Sep 10. doi: 10.1002.
    PubMed    


  1046. BOSCH L, Carluccio E, Coiro S, Gong L, et al
    Risk stratification of Asian patients with heart failure and reduced ejection fraction: the effectiveness of the Echo Heart Failure Score.
    Eur J Heart Fail. 2017 Sep 7. doi: 10.1002.
    PubMed    


  1047. PLATZ E, Jhund PS, Claggett BL, Pfeffer MA, et al
    Prevalence and prognostic importance of precipitating factors leading to heart failure hospitalization: recurrent hospitalizations and mortality.
    Eur J Heart Fail. 2017 Sep 4. doi: 10.1002.
    PubMed     Abstract available


  1048. BIERING-SORENSEN T, Querejeta Roca G, Hegde SM, Shah AM, et al
    Left ventricular ejection time is an independent predictor of incident heart failure in a community-based cohort.
    Eur J Heart Fail. 2017 Sep 4. doi: 10.1002.
    PubMed     Abstract available


  1049. WAGENAAR KP, Rutten FH, Klompstra L, Bhana Y, et al
    'heartfailurematters.org', an educational website for patients and carers from the Heart Failure Association of the European Society of Cardiology: objectives, use and future directions.
    Eur J Heart Fail. 2017 Sep 4. doi: 10.1002.
    PubMed     Abstract available


  1050. COTTER G, Metra M, Davison BA, Jondeau G, et al
    Systolic blood pressure reduction during the first 24 h in acute heart failure admission: friend or foe?
    Eur J Heart Fail. 2017 Sep 4. doi: 10.1002.
    PubMed     Abstract available


    August 2017
  1051. D'ANGIOLELLA LS, Cortesi PA, Pitotti C, Ritrovato D, et al
    Sacubitril/valsartan in heart failure with reduced ejection fraction: cost and effectiveness in the Italian context.
    Eur J Heart Fail. 2017 Aug 28. doi: 10.1002.
    PubMed    


  1052. GOHAR A, Chong JPC, Liew OW, den Ruijter H, et al
    The prognostic value of highly sensitive cardiac troponin assays for adverse events in men and women with stable heart failure and a preserved vs. reduced ejection fraction.
    Eur J Heart Fail. 2017 Aug 28. doi: 10.1002.
    PubMed     Abstract available


  1053. GAYAT E, Arrigo M, Littnerova S, Sato N, et al
    Heart failure oral therapies at discharge are associated with better outcome in acute heart failure: a propensity-score matched study.
    Eur J Heart Fail. 2017 Aug 28. doi: 10.1002.
    PubMed     Abstract available


  1054. COTTER G, Cohen-Solal A, Davison BA, Mebazaa A, et al
    RELAX-AHF, BLAST-AHF, TRUE-AHF, and other important truths in acute heart failure research.
    Eur J Heart Fail. 2017 Aug 24. doi: 10.1002.
    PubMed    


  1055. ZAMORA E, Lupon J, Bayes-Genis A
    Obesity in heart failure: is it time to rethink the paradox? Reply.
    Eur J Heart Fail. 2017 Aug 24. doi: 10.1002.
    PubMed    


  1056. BUTLER J, Hamo CE, Filippatos G, Pocock SJ, et al
    The potential role and rationale for treatment of heart failure with sodium-glucose co-transporter 2 inhibitors.
    Eur J Heart Fail. 2017 Aug 24. doi: 10.1002.
    PubMed     Abstract available


  1057. GREENBERG B
    Gene therapy for heart failure: time to go back to the drawing board.
    Eur J Heart Fail. 2017 Aug 24. doi: 10.1002.
    PubMed    


  1058. MAGNUSSEN H, Canepa M, Zambito PE, Brusasco V, et al
    What can we learn from pulmonary function testing in heart failure?
    Eur J Heart Fail. 2017 Aug 14. doi: 10.1002.
    PubMed     Abstract available


  1059. PARISSIS J, Bistola V, Ikonomidis I, Triposkiadis F, et al
    Nitroxyl donors for acute heart failure: promising newcomers.
    Eur J Heart Fail. 2017 Aug 14. doi: 10.1002.
    PubMed    


  1060. AMBROSY AP, Gheorghiade M
    Clinical profiles in acute heart failure: one size fits all or not at all?
    Eur J Heart Fail. 2017 Aug 8. doi: 10.1002.
    PubMed    


  1061. AMBROSY AP, Gheorghiade M
    Real-world dosing of evidence-based medications for heart failure: embracing guideline recommendations and clinical judgement.
    Eur J Heart Fail. 2017 Aug 8. doi: 10.1002.
    PubMed    


  1062. METRA M
    August 2017 at a glance: tailored treatment, acute heart failure and cardiac resynchronization.
    Eur J Heart Fail. 2017;19:969-970.
    PubMed    


    July 2017
  1063. COGSWELL RJ, Norby FL, Gottesman RF, Chen LY, et al
    High prevalence of subclinical cerebral infarction in patients with heart failure with preserved ejection fraction.
    Eur J Heart Fail. 2017 Jul 24. doi: 10.1002.
    PubMed     Abstract available


  1064. TITA C, Gilbert EM, Van Bakel AB, Grzybowski J, et al
    A Phase 2a dose-escalation study of the safety, tolerability, pharmacokinetics and haemodynamic effects of BMS-986231 in hospitalized patients with heart failure with reduced ejection fraction.
    Eur J Heart Fail. 2017 Jul 5. doi: 10.1002.
    PubMed     Abstract available


    June 2017
  1065. AMBROSY AP, Butler J, Gheorghiade M
    Clinical trials in acute heart failure: beginning of the end or end of the beginning?
    Eur J Heart Fail. 2017 Jun 28. doi: 10.1002.
    PubMed    


  1066. BURNS KV, Gage RM, Curtin AE, Gorcsan J 3rd, et al
    Left ventricular-only pacing in heart failure patients with normal atrioventricular conduction improves global function and left ventricular regional mechanics compared with biventricular pacing: an adaptive cardiac resynchronization therapy sub-study
    Eur J Heart Fail. 2017 Jun 26. doi: 10.1002.
    PubMed     Abstract available


  1067. SHARMA A, Demissei BG, Tromp J, Hillege HL, et al
    A network analysis to compare biomarker profiles in patients with and without diabetes mellitus in acute heart failure.
    Eur J Heart Fail. 2017 Jun 21. doi: 10.1002.
    PubMed     Abstract available


  1068. STEWART S
    Persistently misunderstood and malignant: the case of heart failure vs. cancer.
    Eur J Heart Fail. 2017 Jun 19. doi: 10.1002.
    PubMed    


  1069. NIKOLOVSKA VUKADINOVIC A, Vukadinovic D, Borer J, Cowie M, et al
    Heart rate and its reduction in chronic heart failure and beyond.
    Eur J Heart Fail. 2017 Jun 19. doi: 10.1002.
    PubMed     Abstract available


  1070. RASTOGI A, Novak E, Platts AE, Mann DL, et al
    Epidemiology, pathophysiology and clinical outcomes for heart failure patients with a mid-range ejection fraction.
    Eur J Heart Fail. 2017 Jun 14. doi: 10.1002.
    PubMed     Abstract available


  1071. ZAMAN S, Zaman SS, Scholtes T, Shun-Shin MJ, et al
    The mortality risk of deferring optimal medical therapy in heart failure: a systematic comparison against norms for surgical consent and patient information leaflets.
    Eur J Heart Fail. 2017 Jun 8. doi: 10.1002.
    PubMed     Abstract available


  1072. BOHM M, Laufs U, Mahfoud F, Schirmer SH, et al
    Primum non nocere: the dangers of deferring heart failure therapy.
    Eur J Heart Fail. 2017 Jun 8. doi: 10.1002.
    PubMed    


  1073. BOSCH L, Lam CSP, Gong L, Chan SP, et al
    Right ventricular dysfunction in left-sided heart failure with preserved versus reduced ejection fraction.
    Eur J Heart Fail. 2017 Jun 8. doi: 10.1002.
    PubMed     Abstract available


  1074. MUELLER C
    Clinical utility of biomarkers in heart failure.
    Eur J Heart Fail. 2017 Jun 5. doi: 10.1002.
    PubMed    


  1075. LASSUS J
    Evaluating pulmonary congestion with lung ultrasound and the need to take the next steps in heart failure.
    Eur J Heart Fail. 2017 Jun 5. doi: 10.1002.
    PubMed    


  1076. DEVORE AD, Hernandez AF
    Improving heart failure health: is there a secret Swedish sauce?
    Eur J Heart Fail. 2017 Jun 5. doi: 10.1002.
    PubMed    


  1077. FERREIRA JP, Rossignol P, Machu JL, Sharma A, et al
    Mineralocorticoid receptor antagonist pattern of use in heart failure with reduced ejection fraction: findings from BIOSTAT-CHF.
    Eur J Heart Fail. 2017 Jun 5. doi: 10.1002.
    PubMed     Abstract available


  1078. HERRERO-PUENTE P, Prieto-Garcia B, Garcia-Garcia M, Llorens P, et al
    The relationship of circulating relaxin-2 concentrations with short-term prognosis in patients with acute heart failure: the RELAHF study.
    Eur J Heart Fail. 2017 Jun 5. doi: 10.1002.
    PubMed     Abstract available


  1079. FILIPPATOS G, Maggioni AP, Lam CSP, Pieske-Kraigher E, et al
    Patient-reported outcomes in the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED ejection fraction (SOCRATES-PRESERVED) study.
    Eur J Heart Fail. 2017;19:782-791.
    PubMed     Abstract available


    May 2017
  1080. TEERLINK JR, Metra M, Filippatos GS, Davison BA, et al
    Benefit of cardiopoietic mesenchymal stem cell therapy on left ventricular remodelling: results from the Congestive Heart Failure Cardiopoietic Regenerative Therapy (CHART-1) study.
    Eur J Heart Fail. 2017 May 31. doi: 10.1002.
    PubMed     Abstract available


  1081. DE CATERINA R
    Aspirin in heart failure: don't throw the baby (aspirin) out with the bathwater.
    Eur J Heart Fail. 2017 May 31. doi: 10.1002.
    PubMed    


  1082. AHMED A, Blackman MR, White M, Anker SD, et al
    Emphasis on abdominal obesity as a modifier of eplerenone effect in heart failure: hypothesis-generating signals from EMPHASIS-HF.
    Eur J Heart Fail. 2017 May 30. doi: 10.1002.
    PubMed    


  1083. ROY B, Woo MA, Wang DJJ, Fonarow GC, et al
    Reduced regional cerebral blood flow in patients with heart failure.
    Eur J Heart Fail. 2017 May 30. doi: 10.1002.
    PubMed     Abstract available


  1084. HARJOLA VP, Mullens W, Banaszewski M, Bauersachs J, et al
    Organ dysfunction, injury and failure in acute heart failure: from pathophysiology to diagnosis and management. A review on behalf of the Acute Heart Failure Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC).
    Eur J Heart Fail. 2017 May 30. doi: 10.1002.
    PubMed     Abstract available


  1085. PLATZ E, Merz AA, Jhund PS, Vazir A, et al
    Dynamic changes and prognostic value of pulmonary congestion by lung ultrasound in acute and chronic heart failure: a systematic review.
    Eur J Heart Fail. 2017 May 30. doi: 10.1002.
    PubMed     Abstract available


  1086. VEGTER EL, van der Meer P, Voors AA
    Associations between volume status and circulating microRNAs in acute heart failure.
    Eur J Heart Fail. 2017 May 25. doi: 10.1002.
    PubMed    


  1087. CHIRINOS JA, Londono-Hoyos F, Zamani P, Beraun M, et al
    Effects of organic and inorganic nitrate on aortic and carotid haemodynamics in heart failure with preserved ejection fraction.
    Eur J Heart Fail. 2017 May 25. doi: 10.1002.
    PubMed     Abstract available


  1088. POPESCU BA, Beladan CC, Popescu AC
    Mechanical dyssynchrony in heart failure with preserved ejection fraction: a treatment target or a dead end?
    Eur J Heart Fail. 2017 May 25. doi: 10.1002.
    PubMed    


  1089. METRA M, Ravera A, Filippatos G
    Understanding worsening heart failure as a therapeutic target: another step forward?
    Eur J Heart Fail. 2017 May 25. doi: 10.1002.
    PubMed    


  1090. PASCUAL-FIGAL DA
    Acute heart failure and biomarkers: time also matters, don't relax.
    Eur J Heart Fail. 2017 May 25. doi: 10.1002.
    PubMed    


  1091. VADUGANATHAN M, Patel RB, Butler J, Metra M, et al
    Integrating electronic health records into the study of heart failure: promises and pitfalls.
    Eur J Heart Fail. 2017 May 25. doi: 10.1002.
    PubMed    


  1092. VAN AELST LNL, Abraham M, Sadoune M, Lefebvre T, et al
    Iron status and inflammatory biomarkers in patients with acutely decompensated heart failure: early in-hospital phase and 30-day follow-up.
    Eur J Heart Fail. 2017 May 17. doi: 10.1002.
    PubMed    


  1093. EDELMANN F, Bobenko A, Gelbrich G, Hasenfuss G, et al
    Exercise training in Diastolic Heart Failure (Ex-DHF): rationale and design of a multicentre, prospective, randomized, controlled, parallel group trial.
    Eur J Heart Fail. 2017 May 17. doi: 10.1002.
    PubMed     Abstract available


  1094. MORBACH C, Marx A, Kaspar M, Guder G, et al
    Prognostic potential of midregional pro-adrenomedullin following decompensation for systolic heart failure: comparison with cardiac natriuretic peptides.
    Eur J Heart Fail. 2017 May 17. doi: 10.1002.
    PubMed     Abstract available


  1095. PINTALHAO M, Castro-Chaves P, Bettencourt P
    Are circulating relaxin levels related to pulmonary hypertension in patients with heart failure? A reply.
    Eur J Heart Fail. 2017 May 4. doi: 10.1002.
    PubMed    


  1096. MAMAS MA, Sperrin M, Watson MC, Coutts A, et al
    Do patients have worse outcomes in heart failure than in cancer? A primary care-based cohort study with 10-year follow-up in Scotland.
    Eur J Heart Fail. 2017 May 3. doi: 10.1002.
    PubMed     Abstract available


  1097. GREENE SJ, Vaduganathan M, Gheorghiade M
    Finding the road to recovery: therapeutic and clinical trial implications of dysfunctional viable myocardium in heart failure with reduced ejection fraction.
    Eur J Heart Fail. 2017 May 2. doi: 10.1002.
    PubMed    


  1098. PALAZZINI M, Dardi F, Manes A, Bacchi Reggiani ML, et al
    Pulmonary hypertension due to left heart disease: analysis of survival according to the haemodynamic classification of the 2015 ESC/ERS guidelines and insights for future changes.
    Eur J Heart Fail. 2017 May 2. doi: 10.1002.
    PubMed     Abstract available



  1099. Abstracts of the Heart Failure 2017 and the 4th World Congress on Acute Heart Failure, Paris, France, 29 April - 2 May 2017.
    Eur J Heart Fail. 2017;19 Suppl 1:5-601.
    PubMed    


  1100. AHMAD T, Testani JM
    What happens to stable heart failure patients when they don't take their medicines?
    Eur J Heart Fail. 2017;19:650-651.
    PubMed    


  1101. NAGELE MP
    Pulmonary artery pressure-based telemedicine in heart failure: ready for Europe?
    Eur J Heart Fail. 2017;19:670-672.
    PubMed    


  1102. LEHLE K, Lubnow M, Philipp A, Foltan M, et al
    Prevalence of hemolysis and metabolic acidosis in patients with circulatory failure supported with extracorporeal life support: a marker for survival?
    Eur J Heart Fail. 2017;19 Suppl 2:110-116.
    PubMed     Abstract available


  1103. ROELEVELD PP
    What is new in pediatric ECMO? 2016, a year in review.
    Eur J Heart Fail. 2017;19 Suppl 2:92-96.
    PubMed     Abstract available


  1104. SOROKIN V, MacLaren G, Vidanapathirana PC, Delnoij T, et al
    Choosing the appropriate configuration and cannulation strategies for extracorporeal membrane oxygenation: the potential dynamic process of organ support and importance of hybrid modes.
    Eur J Heart Fail. 2017;19 Suppl 2:75-83.
    PubMed     Abstract available


  1105. OSTADAL P, Rokyta R, Kruger A, Vondrakova D, et al
    Extra corporeal membrane oxygenation in the therapy of cardiogenic shock (ECMO-CS): rationale and design of the multicenter randomized trial.
    Eur J Heart Fail. 2017;19 Suppl 2:124-127.
    PubMed     Abstract available


  1106. DEN UIL CA, Jewbali LS, Heeren MJ, Constantinescu AA, et al
    Isolated left ventricular failure is a predictor of poor outcome in patients receiving veno-arterial extracorporeal membrane oxygenation.
    Eur J Heart Fail. 2017;19 Suppl 2:104-109.
    PubMed     Abstract available


    April 2017
  1107. KOMAJDA M, Cowie MR, Tavazzi L, Ponikowski P, et al
    Physicians' guideline adherence is associated with better prognosis in outpatients with heart failure with reduced ejection fraction: the QUALIFY international registry.
    Eur J Heart Fail. 2017 Apr 30. doi: 10.1002.
    PubMed     Abstract available


  1108. CHIONCEL O, Mebazaa A, Harjola VP, Coats AJ, et al
    Clinical phenotypes and outcome of patients hospitalized for acute heart failure: the ESC Heart Failure Long-Term Registry.
    Eur J Heart Fail. 2017 Apr 30. doi: 10.1002.
    PubMed     Abstract available


  1109. KOMAJDA M, Isnard R, Cohen-Solal A, Metra M, et al
    Effect of ivabradine in patients with heart failure with preserved ejection fraction: the EDIFY randomized placebo-controlled trial.
    Eur J Heart Fail. 2017 Apr 30. doi: 10.1002.
    PubMed     Abstract available


  1110. TEERLINK JR, Voors AA, Ponikowski P, Pang PS, et al
    Serelaxin in addition to standard therapy in acute heart failure: rationale and design of the RELAX-AHF-2 study.
    Eur J Heart Fail. 2017 Apr 28. doi: 10.1002.
    PubMed     Abstract available


  1111. ANKER SD, Kirwan BA, van Veldhuisen DJ, Filippatos G, et al
    Effects of ferric carboxymaltose on hospitalisations and mortality rates in iron-deficient heart failure patients: an individual patient data meta-analysis.
    Eur J Heart Fail. 2017 Apr 24. doi: 10.1002.
    PubMed     Abstract available


  1112. VINEREANU D, Margulescu AD
    The fallacy of resting echocardiographic parameters of cardiac function in heart failure with preserved ejection fraction: add global longitudinal strain to the list.
    Eur J Heart Fail. 2017 Apr 19. doi: 10.1002.
    PubMed    


  1113. FERREIRA JP, Mentz RJ, Pizard A, Pitt B, et al
    Tailoring mineralocorticoid receptor antagonist therapy in heart failure patients: are we moving towards a personalized approach?
    Eur J Heart Fail. 2017 Apr 12. doi: 10.1002.
    PubMed     Abstract available


  1114. HULOT JS, Salem JE, Redheuil A, Collet JP, et al
    Effect of intracoronary administration of AAV1/SERCA2a on ventricular remodelling in patients with advanced systolic heart failure: results from the AGENT-HF randomized phase 2 trial.
    Eur J Heart Fail. 2017 Apr 10. doi: 10.1002.
    PubMed     Abstract available


  1115. LUPON J, Diez-Lopez C, de Antonio M, Domingo M, et al
    Recovered heart failure with reduced ejection fraction and outcomes: a prospective study.
    Eur J Heart Fail. 2017 Apr 6. doi: 10.1002.
    PubMed     Abstract available


  1116. CHIONCEL O, Lainscak M, Seferovic PM, Anker SD, et al
    Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: an analysis of the ESC Heart Failure Long-Term Registry.
    Eur J Heart Fail. 2017 Apr 6. doi: 10.1002.
    PubMed     Abstract available


  1117. TKACZYSZYN M, Comin-Colet J, Voors AA, van Veldhuisen DJ, et al
    Iron deficiency and red cell indices in patients with heart failure.
    Eur J Heart Fail. 2017 Apr 6. doi: 10.1002.
    PubMed     Abstract available


  1118. VENTURA HO, Messerli FH, Lavie CJ
    Observations on the blood pressure paradox in heart failure.
    Eur J Heart Fail. 2017 Apr 3. doi: 10.1002.
    PubMed    


  1119. LYONS OD, Floras JS, Logan AG, Beanlands R, et al
    Design of the effect of adaptive servo-ventilation on survival and cardiovascular hospital admissions in patients with heart failure and sleep apnoea: the ADVENT-HF trial.
    Eur J Heart Fail. 2017;19:579-587.
    PubMed     Abstract available


  1120. DEFTEREOS S, Giannopoulos G, Panagopoulou V, Filippatos G, et al
    Surrogate endpoints in heart failure: (once again) use with caution.
    Eur J Heart Fail. 2017;19:563-565.
    PubMed    


  1121. PLICHART M, Orvoen G, Jourdain P, Quinquis L, et al
    Brain natriuretic peptide usefulness in very elderly dyspnoeic patients: the BED study.
    Eur J Heart Fail. 2017;19:540-548.
    PubMed     Abstract available


  1122. BRISTOW MR, Sharma K, Assmann SF, Linas S, et al
    Data and Safety Monitoring Board evaluation and management of a renal adverse event signal in TOPCAT.
    Eur J Heart Fail. 2017;19:457-465.
    PubMed     Abstract available


  1123. JANSWEIJER JA, Nieuwhof K, Russo F, Hoorntje ET, et al
    Truncating titin mutations are associated with a mild and treatable form of dilated cardiomyopathy.
    Eur J Heart Fail. 2017;19:512-521.
    PubMed     Abstract available


  1124. ZANNAD F
    Monitoring renal safety in mineralocorticoid receptor antagonist trials.
    Eur J Heart Fail. 2017;19:466-468.
    PubMed    


  1125. BALLIGAND JL
    Cardiac beta3-adrenergic receptors in the clinical arena: the end of the beginning.
    Eur J Heart Fail. 2017;19:576-578.
    PubMed    


  1126. SENNI M, Ferrero P, Iacovoni A
    Prognostic scores: one fits all?
    Eur J Heart Fail. 2017;19:588.
    PubMed    


  1127. VAN LINTHOUT S, Tschope C
    Lost in markers? Time for phenomics and phenomapping in dilated cardiomyopathy.
    Eur J Heart Fail. 2017;19:499-501.
    PubMed    


    March 2017
  1128. ROM O, Aviram M
    High-density lipoprotein-associated paraoxonase 1: a possible prognostic biomarker for heart failure?
    Eur J Heart Fail. 2017 Mar 31. doi: 10.1002.
    PubMed    


  1129. TSUJI K, Sakata Y, Nochioka K, Miura M, et al
    Characterization of heart failure patients with mid-range left ventricular ejection fraction-a report from the CHART-2 Study.
    Eur J Heart Fail. 2017 Mar 31. doi: 10.1002.
    PubMed     Abstract available


  1130. LOFMAN I, Szummer K, Dahlstrom U, Jernberg T, et al
    Associations with and prognostic impact of chronic kidney disease in heart failure with preserved, mid-range, and reduced ejection fraction.
    Eur J Heart Fail. 2017 Mar 29. doi: 10.1002.
    PubMed     Abstract available


  1131. MONTERO D, Flammer AJ
    Exercise intolerance in heart failure with preserved ejection fraction: time to scrutinize diuretic therapy?
    Eur J Heart Fail. 2017 Mar 29. doi: 10.1002.
    PubMed    


  1132. SCHMID FA, Schlager O, Keller P, Seifert B, et al
    Prognostic value of long-term blood pressure changes in patients with chronic heart failure.
    Eur J Heart Fail. 2017 Mar 27. doi: 10.1002.
    PubMed     Abstract available


  1133. COWIE MR, Filippatos GS, Alonso Garcia ML, Anker SD, et al
    New medicinal products for chronic heart failure: advances in clinical trial design and efficacy assessment.
    Eur J Heart Fail. 2017 Mar 27. doi: 10.1002.
    PubMed     Abstract available


  1134. DEVAUX Y, Creemers EE, Boon RA, Werfel S, et al
    Circular RNAs in heart failure.
    Eur J Heart Fail. 2017 Mar 27. doi: 10.1002.
    PubMed     Abstract available


  1135. PIEPOLI MF
    Obesity in heart failure: is it time to rethink the paradox?
    Eur J Heart Fail. 2017 Mar 24. doi: 10.1002.
    PubMed    


  1136. D'ELIA E, Iacovoni A, Vaduganathan M, Lorini FL, et al
    Neprilysin inhibition in heart failure: mechanisms and substrates beyond modulating natriuretic peptides.
    Eur J Heart Fail. 2017 Mar 21. doi: 10.1002.
    PubMed     Abstract available


  1137. BIERING-SORENSEN T, Shah SJ, Anand I, Sweitzer N, et al
    Prognostic importance of left ventricular mechanical dyssynchrony in heart failure with preserved ejection fraction.
    Eur J Heart Fail. 2017 Mar 21. doi: 10.1002.
    PubMed     Abstract available


  1138. MCDONALD K, O'Hanlon R, Savage HO, Khushaba RN, et al
    Sleep-disordered breathing in chronic heart failure is highly variable when measured remotely using a novel non-contact biomotion sensor.
    Eur J Heart Fail. 2017 Mar 21. doi: 10.1002.
    PubMed     Abstract available


  1139. OLIVIER A, Pitt B, Girerd N, Lamiral Z, et al
    Effect of eplerenone in patients with heart failure and reduced ejection fraction: potential effect modification by abdominal obesity: Insight from the EMPHASIS-HF trial.
    Eur J Heart Fail. 2017 Mar 16. doi: 10.1002.
    PubMed     Abstract available


  1140. SHARMA K, Fang JC
    The heart-kidney relationship in heart failure: it's not you, it's me.
    Eur J Heart Fail. 2017 Mar 15. doi: 10.1002.
    PubMed    


  1141. RICKENBACHER P, Kaufmann BA, Maeder MT, Bernheim A, et al
    Heart failure with mid-range ejection fraction: a distinct clinical entity? Insights from the Trial of Intensified versus standard Medical therapy in Elderly patients with Congestive Heart Failure (TIME-CHF).
    Eur J Heart Fail. 2017 Mar 15. doi: 10.1002.
    PubMed     Abstract available


  1142. DOVANCESCU S, Pellicori P, Mabote T, Torabi A, et al
    The effects of short-term omission of daily medication on the pathophysiology of heart failure.
    Eur J Heart Fail. 2017 Mar 15. doi: 10.1002.
    PubMed     Abstract available


  1143. CLELAND JG, Teerlink JR, Davison BA, Shoaib A, et al
    Measurement of troponin and natriuretic peptides shortly after admission in patients with heart failure-does it add useful prognostic information? An analysis of the Value of Endothelin Receptor Inhibition with Tezosentan in Acute heart failure Studie
    Eur J Heart Fail. 2017 Mar 10. doi: 10.1002.
    PubMed     Abstract available


  1144. SLIWA K, Mebazaa A, Hilfiker-Kleiner D, Petrie MC, et al
    Clinical characteristics of patients from the worldwide registry on peripartum cardiomyopathy (PPCM): EURObservational Research Programme in conjunction with the Heart Failure Association of the European Society of Cardiology Study Group on PPCM.
    Eur J Heart Fail. 2017 Mar 8. doi: 10.1002.
    PubMed     Abstract available



  1145. European Society of Cardiology Heart Failure Long-Term Registry (ESC-HF-LT): 1-year follow-up outcomes and differences across regions.
    Eur J Heart Fail. 2017;19:438.
    PubMed    


  1146. DIERCKX R, Inglis SC, Clark RA, Prieto-Merino D, et al
    Telemedicine in heart failure: new insights from the Cochrane meta-analyses.
    Eur J Heart Fail. 2017;19:304-306.
    PubMed    


  1147. PAN A
    The real-world evidence of heart failure co-morbidities.
    Eur J Heart Fail. 2017;19:434.
    PubMed    


  1148. BRISTOW MR
    Genetic variation expressed in the brain may impact heart failure.
    Eur J Heart Fail. 2017;19:324-325.
    PubMed    


  1149. MCDONALD K, Gallagher J
    The practice gap in heart failure-the elephant in the room.
    Eur J Heart Fail. 2017;19:301-303.
    PubMed    


  1150. MAASS AH, DeJongste MJ, van der Meer P
    Neuromodulation for systolic heart failure: more than a placebo effect?
    Eur J Heart Fail. 2017;19:401-403.
    PubMed    



  1151. Body surface area as a prognostic marker in chronic heart failure patients: results from the Heart Failure Registry of the Heart Failure Association of the European Society of Cardiology.
    Eur J Heart Fail. 2017;19:437.
    PubMed    


  1152. DEMISSEI BG, Postmus D, Cleland JG, O'Connor CM, et al
    Plasma biomarkers to predict or rule out early post-discharge events after hospitalization for acute heart failure.
    Eur J Heart Fail. 2017 Mar 1. doi: 10.1002.
    PubMed     Abstract available


  1153. VOORS AA, Ouwerkerk W, Zannad F, van Veldhuisen DJ, et al
    Development and validation of multivariable models to predict mortality and hospitalization in patients with heart failure.
    Eur J Heart Fail. 2017 Mar 1. doi: 10.1002.
    PubMed     Abstract available


  1154. PAPPALARDO F, Schulte C, Pieri M, Schrage B, et al
    Concomitant implantation of Impella(R) on top of veno-arterial extracorporeal membrane oxygenation may improve survival of patients with cardiogenic shock.
    Eur J Heart Fail. 2017;19:404-412.
    PubMed     Abstract available


  1155. BORIANI G, Malavasi VL
    Patient outcome after implant of a cardioverter defibrillator in the 'real world': the key role of co-morbidities.
    Eur J Heart Fail. 2017;19:387-390.
    PubMed    


  1156. BEHAR JM, Rajani R, Rinaldi CA
    Guided left ventricular lead placement for cardiac resynchronization therapy: an opportunity for image integration.
    Eur J Heart Fail. 2017;19:435.
    PubMed    


  1157. LORUSSO R
    Are two crutches better than one? The ongoing dilemma on the effects and need for left ventricular unloading during veno-arterial extracorporeal membrane oxygenation.
    Eur J Heart Fail. 2017;19:413-415.
    PubMed    


    February 2017
  1158. EMMENS JE, Ter Maaten JM, Voors AA
    Are circulating relaxin levels related to pulmonary hypertension in patients with heart failure?
    Eur J Heart Fail. 2017 Feb 28. doi: 10.1002.
    PubMed    


  1159. PELLICORI P, Urbinati A, Shah P, MacNamara A, et al
    What proportion of patients with chronic heart failure are eligible for sacubitril-valsartan?
    Eur J Heart Fail. 2017 Feb 27. doi: 10.1002.
    PubMed     Abstract available


  1160. PAOLILLO S, Mapelli M, Bonomi A, Corra U, et al
    Prognostic role of beta-blocker selectivity and dosage regimens in heart failure patients. Insights from the MECKI score database.
    Eur J Heart Fail. 2017 Feb 24. doi: 10.1002.
    PubMed     Abstract available


  1161. VAN SPALL HG, Rahman T, Mytton O, Ramasundarahettige C, et al
    Comparative effectiveness of transitional care services in patients discharged from the hospital with heart failure: a systematic review and network meta-analysis.
    Eur J Heart Fail. 2017 Feb 24. doi: 10.1002.
    PubMed     Abstract available


  1162. LUND LH, Carrero JJ, Farahmand B, Henriksson KM, et al
    Association between enrolment in a heart failure quality registry and subsequent mortality-a nationwide cohort study.
    Eur J Heart Fail. 2017 Feb 23. doi: 10.1002.
    PubMed     Abstract available


  1163. PARASKEVAIDIS IA, Ikonomidis I, Simitsis P, Parissis J, et al
    Multidimensional contractile reserve predicts adverse outcome in patients with severe systolic heart failure: a 4-year follow-up study.
    Eur J Heart Fail. 2017 Feb 21. doi: 10.1002.
    PubMed     Abstract available


  1164. NAYOR M, Larson MG, Wang N, Santhanakrishnan R, et al
    The association of chronic kidney disease and microalbuminuria with heart failure with preserved vs. reduced ejection fraction.
    Eur J Heart Fail. 2017 Feb 20. doi: 10.1002.
    PubMed     Abstract available


  1165. GUSTAFSSON F, Rogers JG
    Left ventricular assist device therapy in advanced heart failure: patient selection and outcomes.
    Eur J Heart Fail. 2017 Feb 15. doi: 10.1002.
    PubMed     Abstract available


  1166. SCALI MC, Cortigiani L, Simionuc A, Gregori D, et al
    Exercise-induced B-lines identify worse functional and prognostic stage in heart failure patients with depressed left ventricular ejection fraction.
    Eur J Heart Fail. 2017 Feb 15. doi: 10.1002.
    PubMed     Abstract available


  1167. EMDIN M, Aimo A, Passino C, Vergaro G, et al
    Breathing Not Properly in the oldest old. Is brain natriuretic peptide a poor test for the diagnosis of heart failure in the elderly?
    Eur J Heart Fail. 2017 Feb 15. doi: 10.1002.
    PubMed    


  1168. DEVORE AD, McNulty S, Alenezi F, Ersboll M, et al
    Impaired left ventricular global longitudinal strain in patients with heart failure with preserved ejection fraction: insights from the RELAX trial.
    Eur J Heart Fail. 2017 Feb 14. doi: 10.1002.
    PubMed     Abstract available


  1169. HAMMADAH M, Kalogeropoulos AP, Georgiopoulou VV, Weber M, et al
    High-density lipoprotein-associated paraoxonase-1 activity for prediction of adverse outcomes in outpatients with chronic heart failure.
    Eur J Heart Fail. 2017 Feb 7. doi: 10.1002.
    PubMed     Abstract available


  1170. COWIE MR, Simon M, Klein L, Thokala P, et al
    The cost-effectiveness of real-time pulmonary artery pressure monitoring in heart failure patients: a European perspective.
    Eur J Heart Fail. 2017 Feb 7. doi: 10.1002.
    PubMed     Abstract available


  1171. LUND LH, Braunschweig F, Benson L, Stahlberg M, et al
    Association between demographic, organizational, clinical, and socio-economic characteristics and underutilization of cardiac resynchronization therapy: results from the Swedish Heart Failure Registry.
    Eur J Heart Fail. 2017 Feb 7. doi: 10.1002.
    PubMed     Abstract available


  1172. HARJOLA P, Tolonen J, Boyd J, Mattila J, et al
    The role of pre-hospital management in acute heart failure.
    Eur J Heart Fail. 2017;19:287-289.
    PubMed    


  1173. STEWART COATS AJ
    Early abnormalities of cerebral blood flow in mild non-ischaemic heart failure: part of a whole-body response?
    Eur J Heart Fail. 2017;19:269-270.
    PubMed    


  1174. NAAR J, Jaye D, Linde C, Neuzil P, et al
    Spinal cord stimulation in heart failure: effect on disease-associated biomarkers.
    Eur J Heart Fail. 2017;19:283-286.
    PubMed    


  1175. METRA M
    February 2017 at a glance: fibrosis, acute heart failure and neurologic abnormalities.
    Eur J Heart Fail. 2017;19:165-166.
    PubMed    


  1176. AHMAD T, Testani JM
    Haemoconcentration as a treatment goal in heart failure: ready for prime time?
    Eur J Heart Fail. 2017;19:237-240.
    PubMed    


  1177. GYONGYOSI M, Winkler J, Ramos I, Do QT, et al
    Myocardial fibrosis: biomedical research from bench to bedside.
    Eur J Heart Fail. 2017;19:177-191.
    PubMed     Abstract available


  1178. PUYMIRAT E, Fagon JY, Aegerter P, Diehl JL, et al
    Cardiogenic shock in intensive care units: evolution of prevalence, patient profile, management and outcomes, 1997-2012.
    Eur J Heart Fail. 2017;19:192-200.
    PubMed     Abstract available


    January 2017
  1179. DEMISSEI BG, Cotter G, Prescott MF, Felker GM, et al
    A multimarker multi-time point-based risk stratification strategy in acute heart failure: results from the RELAX-AHF trial.
    Eur J Heart Fail. 2017 Jan 30. doi: 10.1002.
    PubMed     Abstract available


  1180. SOKOLSKI M, Zymlinski R, Biegus J, Siwolowski P, et al
    Urinary levels of novel kidney biomarkers and risk of true worsening renal function and mortality in patients with acute heart failure.
    Eur J Heart Fail. 2017 Jan 30. doi: 10.1002.
    PubMed     Abstract available


  1181. PAPADAKI A, Martinez-Gonzalez MA, Alonso-Gomez A, Rekondo J, et al
    Mediterranean diet and risk of heart failure: results from the PREDIMED randomized controlled trial.
    Eur J Heart Fail. 2017 Jan 30. doi: 10.1002.
    PubMed     Abstract available


  1182. GUAZZI M
    Is sildenafil neutral on cardiopulmonary performance in group 2 pulmonary hypertension? More details for interpretation.
    Eur J Heart Fail. 2017 Jan 30. doi: 10.1002.
    PubMed    


  1183. GRUSON D, Pouleur AC, Makris K, Chrysohoou C, et al
    Systematic vitamin D supplementation and monitoring: improving outcomes in heart failure?
    Eur J Heart Fail. 2017 Jan 24. doi: 10.1002.
    PubMed    


  1184. DE KEULENAER GW, Segers VF, Zannad F, Brutsaert DL, et al
    The future of pleiotropic therapy in heart failure. Lessons from the benefits of exercise training on endothelial function.
    Eur J Heart Fail. 2017 Jan 19. doi: 10.1002.
    PubMed     Abstract available


  1185. TER MAATEN JM, Rao VS, Hanberg JS, Perry Wilson F, et al
    Renal tubular resistance is the primary driver for loop diuretic resistance in acute heart failure.
    Eur J Heart Fail. 2017 Jan 19. doi: 10.1002.
    PubMed     Abstract available


  1186. GUAZZI M, van Heerebeek L, Paulus WJ
    Phosphodiesterase-5 inhibition in heart failure with preserved ejection fraction: trading therapy for prevention.
    Eur J Heart Fail. 2017 Jan 19. doi: 10.1002.
    PubMed    


  1187. KOMAJDA M
    Liraglutide in heart failure: caution is needed.
    Eur J Heart Fail. 2017;19:78-79.
    PubMed    


  1188. EZEKOWITZ JA, Armstrong PW
    Diabetes and heart failure in the crosshairs: where is the target?
    Eur J Heart Fail. 2017;19:66-68.
    PubMed    


  1189. GWIZDALA A, Rozwadowska N, Kolanowski TJ, Malcher A, et al
    Safety, feasibility and effectiveness of first in-human administration of muscle-derived stem/progenitor cells modified with connexin-43 gene for treatment of advanced chronic heart failure.
    Eur J Heart Fail. 2017;19:148-157.
    PubMed     Abstract available


  1190. BIERING-SORENSEN T, Santos M, Rivero J, McCullough SD, et al
    Left ventricular deformation at rest predicts exercise-induced elevation in pulmonary artery wedge pressure in patients with unexplained dyspnoea.
    Eur J Heart Fail. 2017;19:101-110.
    PubMed     Abstract available


  1191. NAGELE MP, Steffel J, Robertson M, Singh JP, et al
    Effect of cardiac resynchronization therapy in patients with diabetes randomized in EchoCRT.
    Eur J Heart Fail. 2017;19:80-87.
    PubMed     Abstract available


  1192. TAMPAKAKIS E, Tedford RJ
    Balancing the positives and negatives of the diastolic pulmonary gradient.
    Eur J Heart Fail. 2017;19:98-100.
    PubMed    


  1193. EL-BATTRAWY I, Borggrefe M, Akin I
    Predictors of mortality in Takotsubo cardiomyopathy.
    Eur J Heart Fail. 2017;19:158.
    PubMed    


    December 2016
  1194. KOUDSTAAL S, Pujades-Rodriguez M, Denaxas S, Gho JM, et al
    Prognostic burden of heart failure recorded in primary care, acute hospital admissions, or both: a population-based linked electronic health record cohort study in 2.1 million people.
    Eur J Heart Fail. 2016 Dec 23. doi: 10.1002.
    PubMed     Abstract available


  1195. FARMAKIS D, Triposkiadis F, Lekakis J, Parissis J, et al
    Heart failure in haemoglobinopathies: pathophysiology, clinical phenotypes, and management.
    Eur J Heart Fail. 2016 Dec 20. doi: 10.1002.
    PubMed     Abstract available


  1196. MATYAS C, Nemeth BT, Olah A, Torok M, et al
    Prevention of the development of heart failure with preserved ejection fraction by the phosphodiesterase-5A inhibitor vardenafil in rats with type 2 diabetes.
    Eur J Heart Fail. 2016 Dec 19. doi: 10.1002.
    PubMed     Abstract available


  1197. ANGERMANN CE, Kaspar M, Marx A, Kittel-Schneider S, et al
    A functional variant of the neuropeptide S receptor-1 gene modulates clinical outcomes and healthcare utilization in patients with systolic heart failure: results from the Interdisciplinary Network Heart Failure (INH) Study.
    Eur J Heart Fail. 2016 Dec 18. doi: 10.1002.
    PubMed     Abstract available


  1198. BUNDGAARD H, Axelsson A, Hartvig Thomsen J, Sorgaard M, et al
    The-first-in-man randomized trial of a beta3 adrenoceptor agonist in chronic heart failure: the BEAT-HF trial.
    Eur J Heart Fail. 2016 Dec 18. doi: 10.1002.
    PubMed     Abstract available


  1199. SABBAH HN
    Silent disease progression in clinically stable heart failure.
    Eur J Heart Fail. 2016 Dec 14. doi: 10.1002.
    PubMed     Abstract available


  1200. SILVESTRE OM, Goncalves A, Nadruz W Jr, Claggett B, et al
    Ferritin levels and risk of heart failure-the Atherosclerosis Risk in Communities Study.
    Eur J Heart Fail. 2016 Dec 14. doi: 10.1002.
    PubMed     Abstract available


  1201. CLELAND JG
    Does aspirin detract from the benefits of mineralocorticoid receptor antagonists in patients with heart failure and a reduced left ventricular ejection fraction? Probably!
    Eur J Heart Fail. 2016 Dec 11. doi: 10.1002.
    PubMed    


  1202. BOHM M
    Heart rate: from heart failure to chronic diseases and cancer. Is there a role for supportive care by heart rate reduction?
    Eur J Heart Fail. 2016 Dec 4. doi: 10.1002.
    PubMed    


  1203. VON HAEHLING S, Papp Z, Anker SD
    ESC Heart Failure: a new journal aims to broaden heart failure views.
    Eur J Heart Fail. 2016;18:1415-1419.
    PubMed    


    November 2016
  1204. DUCA F, Zotter-Tufaro C, Kammerlander AA, Panzenbock A, et al
    Cardiac extracellular matrix is associated with adverse outcome in patients with chronic heart failure.
    Eur J Heart Fail. 2016 Nov 27. doi: 10.1002.
    PubMed     Abstract available


  1205. REDDY YN, Borlaug BA
    Sildenafil, unbridled optimism, and heart failure with preserved ejection fraction.
    Eur J Heart Fail. 2016 Nov 21. doi: 10.1002.
    PubMed    


  1206. LIU LC, Hummel YM, van der Meer P, Berger RM, et al
    Effects of sildenafil on cardiac structure and function, cardiopulmonary exercise testing and health-related quality of life measures in heart failure patients with preserved ejection fraction and pulmonary hypertension.
    Eur J Heart Fail. 2016 Nov 21. doi: 10.1002.
    PubMed     Abstract available


  1207. ROSSIGNOL P, Girerd N, Bakris G, Vardeny O, et al
    Impact of eplerenone on cardiovascular outcomes in heart failure patients with hypokalaemia.
    Eur J Heart Fail. 2016 Nov 20. doi: 10.1002.
    PubMed     Abstract available


  1208. CANNON JA, Shen L, Jhund PS, Kristensen SL, et al
    Dementia-related adverse events in PARADIGM-HF and other trials in heart failure with reduced ejection fraction.
    Eur J Heart Fail. 2016 Nov 20. doi: 10.1002.
    PubMed     Abstract available


  1209. GORTER TM, Rienstra M, van Veldhuisen DJ
    Right ventricular dysfunction in heart failure with reduced vs. preserved ejection fraction: non-identical twins?
    Eur J Heart Fail. 2016 Nov 17. doi: 10.1002.
    PubMed    


  1210. GHIO S, Guazzi M, Scardovi AB, Klersy C, et al
    Different correlates but similar prognostic implications for right ventricular dysfunction in heart failure patients with reduced or preserved ejection fraction.
    Eur J Heart Fail. 2016 Nov 17. doi: 10.1002.
    PubMed     Abstract available


  1211. ERKELENS CD, van der Wal HH, de Jong BM, Elting JW, et al
    Dynamics of cerebral blood flow in patients with mild non-ischaemic heart failure.
    Eur J Heart Fail. 2016 Nov 14. doi: 10.1002.
    PubMed     Abstract available


  1212. PACKER M, Holcomb R, Abraham WT, Anker S, et al
    Rationale for and design of the TRUE-AHF trial: the effects of ularitide on the short-term clinical course and long-term mortality of patients with acute heart failure.
    Eur J Heart Fail. 2016 Nov 13. doi: 10.1002.
    PubMed     Abstract available


  1213. HEGGERMONT WA, Papageorgiou AP, Heymans S, van Bilsen M, et al
    Metabolic support for the heart: complementary therapy for heart failure?
    Eur J Heart Fail. 2016 Nov 4. doi: 10.1002.
    PubMed     Abstract available


  1214. PARISSIS J, Nikolaou M, Mebazaa A
    The Model for End-stage Liver Disease score in acute heart failure: hepatorenal dysfunction hides behind.
    Eur J Heart Fail. 2016 Nov 4. doi: 10.1002.
    PubMed    


  1215. KAJIMOTO K, Takano T
    Role of functional mitral regurgitation in heart failure with preserved ejection fraction: an unrecognized protagonist?: reply.
    Eur J Heart Fail. 2016 Nov 4. doi: 10.1002.
    PubMed    


  1216. TRIPOSKIADIS F, Pieske B, Butler J, Parissis J, et al
    Global left atrial failure in heart failure.
    Eur J Heart Fail. 2016;18:1307-1320.
    PubMed     Abstract available


  1217. JHUND PS
    Geographic variation in heart failure-a matter of celebration or condemnation?
    Eur J Heart Fail. 2016;18:1329-1330.
    PubMed    


  1218. METRA M
    November 2016 at a glance: the left atrium, screening for heart failure, multimodality imaging for cardiac resynchronization therapy.
    Eur J Heart Fail. 2016;18:1305-1306.
    PubMed    


  1219. MEIJERS WC, de Boer RA, Ho JE
    Biomarkers to identify and prevent new-onset heart failure in the community.
    Eur J Heart Fail. 2016;18:1351-1352.
    PubMed    


  1220. YANG H, Negishi K, Wang Y, Nolan M, et al
    Echocardiographic screening for non-ischaemic stage B heart failure in the community.
    Eur J Heart Fail. 2016;18:1331-1339.
    PubMed     Abstract available


  1221. HAUGAA KH, Edvardsen T
    Global longitudinal strain: the best biomarker for predicting prognosis in heart failure?
    Eur J Heart Fail. 2016;18:1340-1341.
    PubMed    


    October 2016
  1222. ARRIGO M, Gayat E, Parenica J, Ishihara S, et al
    Precipitating factors and 90-day outcome of acute heart failure: a report from the intercontinental GREAT registry.
    Eur J Heart Fail. 2016 Oct 28. doi: 10.1002.
    PubMed     Abstract available


  1223. TARGHER G, Dauriz M, Laroche C, Temporelli PL, et al
    In-hospital and 1-year mortality associated with diabetes in patients with acute heart failure: results from the ESC-HFA Heart Failure Long-Term Registry.
    Eur J Heart Fail. 2016 Oct 28. doi: 10.1002.
    PubMed     Abstract available


  1224. JORSAL A, Kistorp C, Holmager P, Tougaard RS, et al
    Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre, double-blind, randomised, placebo-controlled trial.
    Eur J Heart Fail. 2016 Oct 28. doi: 10.1002.
    PubMed     Abstract available


  1225. COIRO S, Girerd N, Rossignol P, Ferreira JP, et al
    Association of beta-blocker treatment with mortality following myocardial infarction in patients with chronic obstructive pulmonary disease and heart failure or left ventricular dysfunction: a propensity matched-cohort analysis from the High-Risk Myoc
    Eur J Heart Fail. 2016 Oct 24. doi: 10.1002.
    PubMed     Abstract available


  1226. DIEZ J
    Chronic heart failure as a state of reduced effectiveness of the natriuretic peptide system: implications for therapy.
    Eur J Heart Fail. 2016 Oct 21. doi: 10.1002.
    PubMed     Abstract available


  1227. MEIJERS WC, van der Velde AR, Muller Kobold AC, Dijck-Brouwer J, et al
    Variability of biomarkers in patients with chronic heart failure and healthy controls.
    Eur J Heart Fail. 2016 Oct 21. doi: 10.1002.
    PubMed     Abstract available


  1228. KLIP IT, Voors AA, Swinkels DW, Bakker SJ, et al
    Serum ferritin and risk for new-onset heart failure and cardiovascular events in the community.
    Eur J Heart Fail. 2016 Oct 19. doi: 10.1002.
    PubMed     Abstract available


  1229. BREIDTHARDT T, Weidmann ZM, Twerenbold R, Gantenbein C, et al
    Impact of haemoconcentration during acute heart failure therapy on mortality and its relationship with worsening renal function.
    Eur J Heart Fail. 2016 Oct 19. doi: 10.1002.
    PubMed     Abstract available


  1230. GREENE SJ, Fonarow GC, Solomon SD, Subacius HP, et al
    Influence of atrial fibrillation on post-discharge natriuretic peptide trajectory and clinical outcomes among patients hospitalized for heart failure: insights from the ASTRONAUT trial.
    Eur J Heart Fail. 2016 Oct 17. doi: 10.1002.
    PubMed     Abstract available


  1231. NAGY AI, Venkateshvaran A, Merkely B, Lund LH, et al
    Determinants and prognostic implications of the negative diastolic pulmonary pressure gradient in patients with pulmonary hypertension due to left heart disease.
    Eur J Heart Fail. 2016 Oct 17. doi: 10.1002.
    PubMed     Abstract available


  1232. OBOKATA M, Borlaug BA
    Right ventricular dysfunction and pulmonary hypertension in heart failure with preserved ejection fraction.
    Eur J Heart Fail. 2016 Oct 13. doi: 10.1002.
    PubMed    


  1233. BIEGUS J, Zymlinski R, Sokolski M, Siwolowski P, et al
    Impaired hepato-renal function defined by the MELD XI score as prognosticator in acute heart failure.
    Eur J Heart Fail. 2016 Oct 6. doi: 10.1002.
    PubMed     Abstract available


  1234. METRA M
    October 2016 at a glance: treatment of heart failure.
    Eur J Heart Fail. 2016;18:1209-1210.
    PubMed    


  1235. VADUGANATHAN M, Patel RB, Yancy CW
    Stroke prevention in heart failure and sinus rhythm: where do we go from here?
    Eur J Heart Fail. 2016;18:1267-1269.
    PubMed    


  1236. CHAGGAR PS, Williams SG, Yonan N, Fildes J, et al
    Myocardial recovery with mechanical circulatory support.
    Eur J Heart Fail. 2016;18:1220-1227.
    PubMed     Abstract available


  1237. REGOLI F, Bongiorni MG, Rordorf R, Santamaria M, et al
    High recurrence of device-related adverse events following transvenous lead extraction procedure in patients with cardiac resynchronization devices.
    Eur J Heart Fail. 2016;18:1270-1277.
    PubMed     Abstract available


    September 2016
  1238. FITCHETT DH, Udell JA, Inzucchi SE
    Heart failure outcomes in clinical trials of glucose-lowering agents in patients with diabetes.
    Eur J Heart Fail. 2016 Sep 21. doi: 10.1002.
    PubMed     Abstract available


  1239. GORTER TM, Hoendermis ES, van Veldhuisen DJ, Voors AA, et al
    Right ventricular dysfunction in heart failure with preserved ejection fraction: a systematic review and meta-analysis.
    Eur J Heart Fail. 2016 Sep 20. doi: 10.1002.
    PubMed     Abstract available


  1240. NIEWINSKI P, Janczak D, Rucinski A, Tubek S, et al
    Carotid body resection for sympathetic modulation in systolic heart failure: results from first-in-man study.
    Eur J Heart Fail. 2016 Sep 20. doi: 10.1002.
    PubMed     Abstract available


  1241. DINI FL, Carluccio E, Simioniuc A, Biagioli P, et al
    Right ventricular recovery during follow-up is associated with improved survival in patients with chronic heart failure with reduced ejection fraction.
    Eur J Heart Fail. 2016 Sep 20. doi: 10.1002.
    PubMed     Abstract available


  1242. ADAMO L, Nassif ME, Novak E, LaRue SJ, et al
    Prevalence of lactic acidaemia in patients with advanced heart failure and depressed cardiac output.
    Eur J Heart Fail. 2016 Sep 20. doi: 10.1002.
    PubMed     Abstract available


  1243. MARTINSON M, Bharmi R, Dalal N, Abraham WT, et al
    Pulmonary artery pressure-guided heart failure management: US cost-effectiveness analyses using the results of the CHAMPION clinical trial.
    Eur J Heart Fail. 2016 Sep 19. doi: 10.1002.
    PubMed     Abstract available


  1244. MELENOVSKY V, Petrak J, Mracek T, Benes J, et al
    Myocardial iron content and mitochondrial function in human heart failure: a direct tissue analysis.
    Eur J Heart Fail. 2016 Sep 19. doi: 10.1002.
    PubMed     Abstract available


  1245. SANTAS E, Nunez E, Nunez J
    Role of functional mitral regurgitation in heart failure with preserved ejection fraction: an unrecognized protagonist?
    Eur J Heart Fail. 2016 Sep 19. doi: 10.1002.
    PubMed    


  1246. ADAMSON PB, Ginn G, Anker SD, Bourge RC, et al
    Remote haemodynamic-guided care for patients with chronic heart failure: a meta-analysis of completed trials.
    Eur J Heart Fail. 2016 Sep 16. doi: 10.1002.
    PubMed     Abstract available


  1247. KITAI T, Grodin JL, Mentz RJ, Hernandez AF, et al
    Insufficient reduction in heart rate during hospitalization despite beta-blocker treatment in acute decompensated heart failure: insights from the ASCEND-HF trial.
    Eur J Heart Fail. 2016 Sep 16. doi: 10.1002.
    PubMed     Abstract available


  1248. IBRAHIM I, Kuan WS, Frampton C, Troughton R, et al
    Superior performance of N-terminal pro brain natriuretic peptide for diagnosis of acute decompensated heart failure in an Asian compared with a Western setting.
    Eur J Heart Fail. 2016 Sep 13. doi: 10.1002.
    PubMed     Abstract available


  1249. ADELBORG K, Horvath-Puho E, Ording A, Pedersen L, et al
    Heart failure and risk of dementia: a Danish nationwide population-based cohort study.
    Eur J Heart Fail. 2016 Sep 9. doi: 10.1002.
    PubMed     Abstract available


  1250. OMERSA D, Farkas J, Erzen I, Lainscak M, et al
    National trends in heart failure hospitalization rates in Slovenia 2004-2012.
    Eur J Heart Fail. 2016 Sep 9. doi: 10.1002.
    PubMed     Abstract available


  1251. KONSTANTINIDES SV
    Trends in pregnancy outcomes in patients with pulmonary hypertension: still a long way to go.
    Eur J Heart Fail. 2016;18:1129-31.
    PubMed    


    July 2016
  1252. SLIWA K, van Hagen IM, Budts W, Swan L, et al
    Pulmonary hypertension and pregnancy outcomes: data from the Registry Of Pregnancy and Cardiac Disease (ROPAC) of the European Society of Cardiology.
    Eur J Heart Fail. 2016 Jul 7. doi: 10.1002.
    PubMed     Abstract available


    February 2016
  1253. METRA M
    February 2016 at a glance. Focus issue on cardiac regeneration, medical treatment and cardiac devices.
    Eur J Heart Fail. 2016;18:127.
    PubMed    


  1254. VADUGANATHAN M, Prasad V
    Cardiovascular risk assessment in oncological clinical trials: is there a role for centralized events adjudication?
    Eur J Heart Fail. 2016;18:128-32.
    PubMed    


  1255. STOLFO D, Tonet E, Merlo M, Barbati G, et al
    Early right ventricular response to cardiac resynchronization therapy: impact on clinical outcomes.
    Eur J Heart Fail. 2016;18:205-13.
    PubMed     Abstract available


  1256. BATTY JA, Lima JA Jr, Kunadian V
    Direct cellular reprogramming for cardiac repair and regeneration.
    Eur J Heart Fail. 2016;18:145-56.
    PubMed     Abstract available


  1257. SCHUSSLER-LENZ M, Beuneu C, Menezes-Ferreira M, Jekerle V, et al
    Cell-based therapies for cardiac repair: a meeting report on scientific observations and European regulatory viewpoints.
    Eur J Heart Fail. 2016;18:133-41.
    PubMed     Abstract available


  1258. VADUGANATHAN M, Goldsmith SR, Senni M, Butler J, et al
    Contrasting acute and chronic effects of tolvaptan on serum osmolality in the EVEREST trial.
    Eur J Heart Fail. 2016;18:185-91.
    PubMed     Abstract available


    January 2016
  1259. BRAMLAGE P, Swift SL, Thoenes M, Minguet J, et al
    Non-steroidal mineralocorticoid receptor antagonism for the treatment of cardiovascular and renal disease.
    Eur J Heart Fail. 2016;18:28-37.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Chronic Heart Failure is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: